Document:

exv10w5

EXHIBIT 10.5

FOURTH AMENDMENT TO LEASE

     This FOURTH AMENDMENT TO LEASE (“Fourth Amendment”) is dated for reference purposes May 7,
2008 (“Fourth Amendment Date”), by and between ARI COMMERCIAL PROPERTIES, INC., a California
corporation, in its capacity as agent for the tenant-in-common owners of the Building (“Landlord”),
and REVA MEDICAL, INC., a California corporation (“Tenant”), with reference to the facts set forth
in the Recitals below.

RECITALS

     A. Landlord, as successor-in-interest to FSP Telecom Business Center Limited Partnership, and
Tenant, formerly known as MD3 Inc., are parties to a Telecom Business Center NNN Lease dated as of
December 18, 2001, as amended by the First Amendment to Lease dated as of January 3, 2005, the
Second Amendment to Lease dated as of February 18, 2006, and the Third Amendment to Lease dated as
of December 14, 2006 (collectively, “Lease”) for certain premises consisting of approximately
12,799 square feet of rentable area within Suite B (“Original Premises”) of the building located at
5751 Copley Drive, San Diego, California (“Building”), as more specifically described in the Lease.

     B. Landlord and Tenant have agreed to make certain modifications to the Lease, including,
among other things, (i) expanding the Original Premises, (ii) extending the term of the Lease,
(iii) increasing the number of parking spaces provided to Tenant, and (iv) providing for certain
improvements to be made to the Original Premises and the Expansion Premises (as defined below).

AMENDMENT

     NOW, THEREFORE, in consideration of the Recitals above, the mutual covenants and conditions
below, and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties agree as follows:

     1. Expansion of the Original Premises. Effective as of the date (“Expansion
Commencement Date”) of Substantial Completion of the Improvement Work (as defined in the Work
Letter attached as Exhibit “A”), Tenant shall lease approximately 4,219 additional square feet of
rentable area located in Suite E of the Building (“Expansion Premises”). The Expansion Premises
are depicted on the Space Plan attached to the Work Letter as Exhibit “A-l”. The lease term for
the Expansion Premises shall begin on the Expansion Commencement Date and end on the date that is
thirty-six (36) months following the Expansion Commencement Date (“Fourth Amendment Expiration
Date”), on all of the same terms and conditions of the Lease, except as specifically set forth in
this Fourth Amendment. The estimated Expansion Commencement Date is July 1, 2008. Promptly after
the determination of the Expansion Commencement Date, Tenant shall execute an Expansion
Commencement Certificate in the form of the attached Exhibit “B”. Notwithstanding any provision of
the Lease to the contrary, beginning on the Expansion Commencement Date (a) the “Premises” shall
mean the Original Premises and the Expansion
Premises collectively, and (b) the Premises shall consist of a total of 17,018 square feet of
rentable area.

Page 1

 

     2. Extension of Term of the Original Premises. Beginning upon the expiration of the
Third Extension Term (i.e., beginning on March 1, 2010), the term of the Lease shall be extended
until the Fourth Amendment Expiration Date on all of the same terms and conditions of the Lease,
except as specifically modified by this Fourth Amendment.

     3. Rent.

          (a) Base Rent for the Expansion Premises. Beginning on the Expansion Commencement
Date, and continuing through and until the Fourth Amendment Expiration Date, Tenant shall pay
monthly Base Rent for the Expansion Premises pursuant to the following schedule:

	 	 	 	 	 	 	 	 	 
	 	 	Amount of Base Rent	 	 
	 	 	Payable Per Month	 	 
	 	 	Per Rentable Square	 	Amount of Total Base Rent
	Months*	 	Foot**	 	Payable Per Month
	1-12
	 	$	1.60	 	 	$	6,750.40	 
	13-24
	 	$	1.66	 	 	$	6,986.66	 
	25-36 (i.e., the Fourth Amendment Expiration Date)
	 	$	1.71	 	 	$	7,231.20	 

 

			
	*	 	For the purposes of this Section 3(a), the reference to “Months” shall mean the number of
months following the Expansion Commencement Date. For example, “12” shall mean the twelfth
(12th) month following the Expansion Commencement Date.
	 
	**	 	An approximation based on rounding the result of the “Amount of Total Base Rent Payable Per
Month” divided by the total rentable square footage of the Expansion Premises.

          (b) Base Rent for the Original Premises. Monthly Base Rent for the Original Premises
shall be payable pursuant to the Lease until February 28, 2010. Beginning on March 1, 2010, and
continuing through and until the Fourth Amendment Expiration Date, Tenant shall pay monthly Base
Rent for the Original Premises pursuant to the following schedule:

	 	 	 	 	 	 	 	 	 
	 	 	Amount of Base Rent	 	 
	 	 	Payable Per Month	 	Amount of Total Base Rent
	Months	 	Per Rentable Square Foot*	 	Payable Per Month
	3/1/2010 – 2/28/2001
	 	$	1.63	 	 	$	20,800.01	 
	3/1/2011 – the Fourth Amendment Expiration Date
	 	$	1.68	 	 	$	21,528.01	 

 

			
	*	 	An approximation based on rounding the result of the “Amount of Total Base Rent Payable Per
Month” divided by the total rentable square footage of the Expansion Premises.

          (c) First Month’s Base Rent for the Expansion Premises. Concurrently with Tenant’s
execution of this Fourth Amendment, Tenant shall pay to Landlord in immediately available funds
(i) the sum of Six Thousand Seven Hundred Fifty and 40/100 Dollars
($6,750.40), which Landlord shall credit against the first monthly installment of Base Rent
for the Expansion Premises; and (ii) an amount equal to the first monthly installment of Tenant’s
Percentage Share for the Expansion Premises.

Page 2

 

          (d) Security Deposit. Upon execution of this Fourth Amendment, Tenant shall deposit
with Landlord Six Thousand Seven Hundred Fifty and 40/100 Dollars ($6,750.40), which Landlord shall
hold as security for the Premises in accordance with this Section. Tenant and Landlord acknowledge
that immediately prior to the Fourth Amendment Date Landlord is not holding a security deposit.
Effective as of the Fourth Amendment Date, Section 16.4.10 of the Telecom Business Center NNN Lease
is deleted.

          (e) Tenant’s Percentage Share. Beginning on the Expansion Commencement Date,
“Tenant’s Percentage Share” shall mean 16.73% with respect to the Premises. To the extent
necessary to calculate Tenant’s Percentage Share with respect to the Original Premises or the
Expansion Premises separately, the term “Tenant’s Percentage Share” shall mean 12.58% with respect
to the Original Premises, and the term “Tenant’s Percentage Share” shall mean 4.15% with respect to
the Expansion Premises.

     4. Improvements. Within five (5) days after the full execution of this Fourth
Amendment by Landlord and Tenant and the delivery by Tenant of the amounts required under
Sections 3(c) and 3(d) above, Landlord shall deliver the Expansion Premises to Tenant in its “as
is” condition with no representations and warranties, express or implied, as to the suitability,
quality or condition of any of the existing improvements or any fixtures or equipment contained
therein or otherwise serving the Expansion Premises and with no obligation on the part of the
Landlord to undertake or pay for any work with regard to the Expansion Premises, except as
specifically set forth in this Fourth Amendment and except for those maintenance and/or repair
obligations of Landlord contained in the Lease. Upon delivery of the Expansion Premises to Tenant,
Tenant shall have the right to construct the Improvement Work (as defined in the Work Letter)
pursuant to the terms of the Work Letter attached hereto as Exhibit “A”.

     5. Parking. Commencing as of the Expansion Commencement Date, Tenant shall have the
right to use fourteen (14) additional unreserved parking spaces pursuant to the terms and
conditions of the Lease. Landlord acknowledges that immediately prior to the Expansion
Commencement Date, Tenant has been utilizing forty-two (42) unreserved parking spaces.

     6. Brokers. Tenant represents and warrants to Landlord that Tenant is represented by
Irving Hughes (“Tenant’s Broker”) and that no party is entitled to a commission or fee in
connection with this Fourth Amendment other than Tenant’s Broker and Landlord’s broker, CB Richard
Ellis, Inc., each of whom shall be paid by Landlord pursuant to a separate written agreement.
Tenant shall defend, indemnify and hold Landlord harmless from and against any claims for liability
arising out of any claim by anyone other than Tenant’s Broker or Landlord’s broker and claiming by
or through Tenant.

     7. Defined Terms. Unless otherwise specifically defined in this Fourth Amendment,
terms with initial capital letters in this Fourth Amendment shall have the same meaning as such
terms have in the Lease.

     8. No Construction Against Party Drafting Amendment. Landlord and Tenant acknowledge
and agree that each of them, and their respective professional advisors, have reviewed this Fourth
Amendment and that the provisions of this Fourth Amendment shall not be construed against either
party. The rule of construction that ambiguities are to be construed

Page 3

 

against the party drafting
the agreement shall not apply to the interpretation of this Fourth Amendment and is waived.

     9. Counterpart Execution. This Fourth Amendment may be executed in multiple
counterparts, each of which when so executed and delivered shall be deemed to be an original and
all of which together shall constitute one instrument.

     10. Continued Effect. Except as specifically modified by this Fourth Amendment, all
of the terms, conditions and provisions of the Lease shall remain in full force and effect.

     IN WITNESS WHEREOF, the parties have executed this Fourth Amendment to Lease.

LANDLORD: ARI Commercial Properties, Inc., a California corporation, in its capacity as agent for
the tenant-in-common owners of the Building

	 	 	 	 	 	 	 

	By:

	 	/s/ David Ho
 

David Ho, Senior Vice President
	 	 	 	Date:  5/18/08 

	 	 	 	 	 	 	 

	TENANT: Reva Medical, Inc., a California corporation	 	 
	 
	 	 	 	 	 	 
	By: 

	 	/s/ Robert K. Schultz
 

Name: Robert K. Schultz
	 	 	 	Date:  5-8-08 
	

	 	 Title:   President	 	 	 	 

Page 4

 

EXHIBIT “A”

Work Letter

     1. Tenant Improvements. The improvements (collectively, “Improvement Work”) to be
constructed on and within the Original Premises and the Expansion Premises shall consist of those
improvements depicted on the drawings attached to this Work Letter as Exhibit “A-l”, which drawings
are incorporated herein by this reference (“Space Plan”). Construction of the Improvement Work
shall be by or at the direction of Tenant, subject to Landlord’s supervision, at Tenant’s sole cost
and expense (including all hard construction costs, planning and design costs and permits fees),
except for payment of the Allowance (as defined below) in the manner set forth in this Work Letter.
Such construction shall be completed subject to the terms of this Work Letter, using building
standard methods, materials and finishes; provided, however, that Tenant shall be able to elect to
use above building standard methods, materials and finishes, subject to Landlord’s reasonable
approval.

     2. Tenant’s Representative. Tenant hereby designates Joe Dipari (telephone no.
858-430-0720) as Tenant’s representative, and he is authorized to receive notices, approve
submittals and issue requests for changes. Landlord shall be entitled to rely upon authorizations
and directives of such person, as if given directly by Tenant. Tenant may amend the designation of
its construction representative at any time upon delivery of written notice to Landlord.

     3. Construction Drawings. Prior to construction of the Improvement Work, Tenant shall
cause, at Tenant’s sole cost and expense, the preparation of working drawings for the Improvement
Work (“Construction Drawings”) based on the Space Plan and shall submit the Construction Drawings
to Landlord for review and approval, which shall not be unreasonably withheld or delayed beyond
five (5) business days after delivery thereof to Landlord. Notwithstanding the foregoing, however,
if the Construction Drawings do not accurately depict the Improvement Work shown on the Space Plan
(as reasonably determined by Landlord’s construction manager), it shall not be unreasonable for
Landlord to delay its approval of the Construction Drawings until the same are appropriately
revised by Tenant (as reasonably determined by Landlord’s construction manager). Tenant shall be
responsible for submitting the Construction Drawings to the City of San Diego for review and
approval. Any changes to the Space Plan or the Construction Drawings after approval by Landlord,
whether such change is requested by the City of San Diego or otherwise, shall be submitted to
Landlord for Landlord’s review and approval, which shall not be unreasonably withheld or delayed.
No portion of the Improvement Work shall be undertaken by Tenant until the Construction Drawings
have been finally approved by Landlord. Any and all cost related to either the illegality or
malfunctioning of any item or aspect of any of the Improvement Work, whether arising from the
design, plans, specifications, working drawings or otherwise, shall be borne solely by Tenant,
notwithstanding Landlord’s approval of the same.

     4. Permits. Tenant shall be responsible, at Tenant’s sole cost and expense, for
obtaining all permits and approvals required by any governmental agency or regulatory body in
connection with Tenant’s installation and construction of the Improvement Work, including without
limitation, all permits that may be required by the California Environmental Protection

A-1

 

Agency, the Regional Air Quality Management District, and/or the California Department of
Health Services. Tenant shall use its due diligence in procuring all such permits and approvals.

     5. Construction; Compliance with Laws and Landlord Requirements. The Improvement Work
shall be constructed and/or installed by contractors and subcontractors selected by Tenant, and
approved by Landlord, which approval shall not be unreasonably withheld, conditioned or delayed.
Tenant shall enter into a direct contract for the construction and/or installation of the
Improvement Work with such contractors and subcontractors. (If the general contractor will be
selecting and entering into contracts directly with the subcontractors, then Landlord shall have
the right to approve of such subcontractors, which approval shall not be unreasonably withheld,
conditioned or delayed.) Tenant shall construct and install the Improvement Work, or shall cause
the Improvement Work to be constructed and/or installed: (i) with due diligence, in a good and
workmanlike manner, using materials that are new and of a quality equal to or greater than those as
specified in the Building standards; (ii) in compliance with the Construction Drawings; (iii) in
accordance with all applicable building codes, ordinances, laws or regulations governing the
Improvement Work; (iv) in compliance with the construction rules and regulations promulgated by
Landlord from time to time; and (v) subject to all conditions which Landlord may, in Landlord’s
reasonable discretion, impose, including requirements for Tenant to provide payment or performance
bonds or additional insurance if reasonably required (from Tenant or Tenant’s contractors,
subcontractors or design professionals). Any material deviation from the approved Construction
Drawings will require Landlord’s prior written approval. Landlord shall have the right to post a
notice of non-responsibility at a prominent location within the Expansion Premises and the Original
Premises. Tenant acknowledges that Landlord shall not be obligated to remove any cabling currently
located in the Expansion Premises. Landlord’s approval of the Space Plans, the Construction
Drawings and/or any revisions thereto, or Landlord’s supervision or performance of any work for or
on behalf of Tenant, shall not be deemed to be a representation by Landlord that the Space Plans,
the Construction Drawings and/or any revisions thereto comply with applicable insurance
requirements, building codes, ordinances, laws or regulations or that the improvements constructed
in accordance with the Space Plans and/or the Construction Drawings or any revisions thereto comply
with applicable insurance requirements, building codes, ordinances, laws or regulations or will be
adequate for Tenant’s use.

     6. Entry to Expansion Premises to Construct Improvement Work. Any entry into the
Expansion Premises by Tenant, its contractors and/or subcontractors prior to the Expansion
Commencement Date shall be in a manner and upon terms and conditions and at times satisfactory to
Landlord. Tenant, its contractors and subcontractors shall comply with all requirements imposed by
Landlord on third party contractors, including without limitation the maintenance by Tenant and its
contractors and subcontractors of workers’ compensation and public liability and property damage
insurance in amounts and with companies and on forms satisfactory to Landlord, with certificates of
such insurance being furnished to Landlord at least twenty-four (24) hours prior to proceeding with
any such entry, with all such certificates naming Landlord and its property manager as additional
insureds on a separate endorsement. Tenant, its contractors and subcontractors shall not have the
right to construct and install the Improvement Work until at least twenty-four (24) hours after the
delivery to Landlord of reasonable written evidence that the City of San Diego has approved the
Construction Drawings and issued the appropriate building permits. Notwithstanding the foregoing,
Tenant shall have the right to enter

A-2

 

the Expansion Premises prior to the issuance of such building permits to commence ordinary
pre-construction activities for which a permit is not required. The entry shall be deemed to be
under ail of the provisions of the Lease except as to the covenants to pay Base Rent and Tenant’s
Percentage Share. A violation of Landlord’s rules, regulations, and requirements established by
Landlord pursuant to this Work Letter shall constitute a default of the Lease. Landlord shall not
be liable in any way for any injury, loss or damage that may occur to or as a result of any such
work being performed by Tenant, the same being solely at Tenant’s risk.

     7. Expansion Premises “As-Is”. Tenant accepts the Expansion Premises in their “as-is”
condition and configuration, and Tenant agrees that Landlord shall not be required to perform any
work or incur any costs in connection with the construction or demolition of any improvements in
the Original Premises or the Expansion Premises, except as provided below with respect to the
Allowance. Notwithstanding the foregoing, Landlord represents that all plumbing, mechanical, HVAC,
and electrical systems located within the Expansion Premises shall in be good working order as of
the date that this Fourth Amendment is fully executed and delivered. If any work outside the
Expansion Premises or the Original Premises, or any work on or adjustment to any of the Building
systems, is required in connection with or as a result of the Improvement Work, such work shall be
performed at Tenant’s expense by contractors designated by Landlord. Tenant taking possession of
the Expansion Premises shall be deemed conclusive evidence that, as of the date of taking
possession, the Expansion Premises are in good order and satisfactory condition.

     8. No Rent Abatement. Tenant acknowledges that the work to be performed by Tenant
pursuant to this Work Letter shall be performed while Tenant is occupying the Original Premises,
that Tenant shall be entitled to (but shall not be obligated to) conduct business throughout the
course of construction of such renovations and that Tenant shall not be entitled to any abatement
of rent, nor shall Tenant be deemed to be constructively evicted from the Original Premises, as a
result of the construction of such renovations.

     9. Assignment of Warranties. Tenant shall assign to Landlord on a non-exclusive basis
all contractor and subcontractor warranties and guaranties relating to the Improvement Work, to the
extent assignable.

     10. Substantial Completion. “Substantial Completion of the Improvement Work” shall
mean the earlier of (i) the date on which (1) all of the Improvement Work has been completed in
accordance with this Work Letter subject to “punch list” items, and (2) all approvals required by
the City of San Diego for occupancy of the Expansion Premises have been issued; (ii) the date that
Tenant commences its normal business operations from the Expansion Premises; or (iii) August 31,
2008. If Substantial Completion of the Improvement Work is delayed by any Tenant Delay (as defined
below), then the Expansion Commencement Date and the payment of Base Rent and additional rent for
the Expansion Premises shall be accelerated by the number of days of such Tenant Delay on a
day-for-day basis. Landlord shall give Tenant written notice within a reasonable time of any
circumstance that Landlord believes constitutes a Tenant Delay. A “Tenant Delay” shall include,
but shall not be limited to, any delay caused by or resulting from any one or more of the
following:

A-3

 

          (a) Tenant’s failure to timely review and reasonably approve any preliminary or final layout,
drawings and/or plans;

          (b) Tenant’s request for or use of special materials, finishes or installations that are not
readily available;

          (c) Tenant’s failure to obtain any necessary governmental approvals or permits for the
Improvement Work;

          (d) Any change requested by Tenant, including any changes requested by Tenant to the Space
Plan or the Construction Drawings after they have been approved; and

          (e) Tenant’s, or any of Tenant’s contractor’s or subcontractor’s, failure to provide any
certificate of insurance, as required under Paragraph 6 above.

     11. Tenant Improvement Allowance. Tenant shall construct and install the Improvement
Work at Tenant’s sole cost and expense; provided, however, that if Tenant is not in default under
the Lease on the Expansion Commencement Date, then Landlord shall contribute an improvement
allowance equal to (i) Ten and 00/100 Dollars ($10.00) per rentable square foot for the Improvement
Work in the Expansion Premises (i.e., $42,190.00) (“Expansion Premises Allowance”), and (ii) One
and 50/100 Dollars ($1.50) per rentable square foot for the Improvement Work in the Original
Premises (i.e., $19,198.50) (“Original Premises Allowance”), for a total allowance of Sixty-One
Thousand Three Hundred Eighty-Eight and 50/100 Dollars ($61,388.50) (collectively, “Fourth
Amendment Allowance”). The Expansion Premises Allowance shall be used only for Improvement Work in
the Expansion Premises and the Original Premises Allowance shall be used only for Improvement Work
in the Original Premises. In addition, Tenant has an unused tenant improvement allowance pursuant
to the Third Amendment to Lease in the amount of up to Thirty-Eight Thousand Three Hundred
Ninety-Seven ($38,397.00) (“Third Amendment Allowance”). The Third Amendment Allowance may be used
only for Improvement Work in the Original Premises. Notwithstanding the foregoing, Tenant may use
the Third Amendment Allowance to pay for improvements that Tenant has made to the Original Premises
prior to the Fourth Amendment Date (“Third Amendment Improvement Work”); provided, however, that in
seeking reimbursement for the cost of the Third Amendment Improvement Work Tenant complies with all
requirements regarding the reimbursement of the costs for the Improvement Work set forth in this
Work Letter. The Fourth Amendment Allowance and the Third Amendment Allowance (collectively,
“Allowance”) shall not be used for any rent credit or for the purchase or installation of any of
Tenant’s furniture, fixtures, equipment, personal property, cabling or communications systems. The
Allowance shall be paid to Tenant within thirty (30) days following receipt by Landlord of
(a) payment receipts covering all labor and materials expended and used in the construction and
installation of the Improvement Work; (b) copies of lien waivers from all contractors and
materialmen in statutory form; (c) a sworn contractor’s affidavit from the general contractor and a
request to disburse from Tenant containing an approval by Tenant of the Improvement Work as
completed; (d) as-built plans of the Improvement Work; (e) the written certification of Tenant and
its architect that the Improvement Work has been constructed and installed in a good and
workmanlike manner in accordance with the Construction Drawings and applicable building codes,
ordinances, laws or regulations; (f) a duly issued, written certificate of occupancy and/or

A-4

 

equivalent final inspection by the governmental agency having jurisdiction relative to
occupancy of the Expansion Premises and the completion of the Improvement Work; (g) reasonable
written evidence that all permit and approval fees relating to the construction and installation of
the Improvement Work have been paid by Tenant; and (h) copies of all construction warranties and
guarantees relating to construction of the Improvement Work, if any, and an assignment to Landlord
on a non-exclusive basis of all of such warranties and guaranties, to the extent assignable. The
Expansion Premises Allowance shall be disbursed in the amount reflected on the payment receipts for
the Improvement Work in the Expansion Premises that meet the requirements above. The Original
Premises Allowance shall be disbursed in the amount reflected on the payment receipts for the
Improvement Work in the Original Premises that meet the requirements above. The Third Amendment
Allowance shall be disbursed in the amount reflected on the payment receipts for the Improvement
Work in the Original Premises and the Third Amendment Improvement Work that meet the requirements
above. Notwithstanding any provision of the Lease to the contrary, Landlord shall not be obligated
to disburse any portion of the Allowance during the continuance of an uncured default under the
Lease, and Landlord’s obligation to disburse shall resume only when and if such default is cured.
In the event that the Expansion Premises Allowance is not sufficient to pay for the entire cost to
complete the Improvement Work in the Expansion Premises, then Tenant shall pay any and all excess
costs related to such Improvement Work. Tenant acknowledges that neither the Original Premises
Allowance nor the Third Amendment Allowance can be applied to any such excess costs for the
Improvement Work in the Expansion Premises. In the event that the Original Premises Allowance and
the Third Amendment Allowance are not sufficient to pay for the entire cost to complete the
Improvement Work in the Original Premises, then Tenant shall pay any and all excess costs related
to such Improvement Work. Tenant acknowledges that the Expansion Premises Allowance cannot be
applied to any such excess costs for the Improvement Work in the Original Premises. In the event
that the Expansion Premises Allowance exceeds the cost of the Improvement Work in the Expansion
Premises, or if the full Expansion Premises Allowance amount is not applied to the cost of the
Improvement Work in the Expansion Premises within twelve (12) months after the Expansion
Commencement Date, then any remaining portion of the Expansion Premises Allowance shall accrue to
the sole benefit of Landlord, it being agreed that Tenant shall not be entitled to any credit,
offset, abatement or payment with respect thereto. In the event that the Original Premises
Allowance exceeds the cost of the Improvement Work in the Original Premises, or if the full
Original Premises Allowance amount is not applied to the cost of the Improvement Work in the
Original Premises within twelve (12) months after the Expansion Commencement Date, then any
remaining portion of the Original Premises Allowance shall accrue to the sole benefit of Landlord,
it being agreed that Tenant shall not be entitled to any credit, offset, abatement or payment with
respect thereto. In the event that the Third Amendment Allowance exceeds the cost of the
Improvement Work in the Original Premises and the Third Amendment Improvement Work, or the full
Third Amendment Allowance is not applied to the cost of the Improvement Work in the Original
Premises or the Third Amendment Improvement Work within twelve (12) months after the Expansion
Commencement Date, then any remaining portion of the Third Amendment Allowance shall accrue to the
sole benefit of Landlord, it being agreed that Tenant shall not be entitled to any credit, offset,
abatement or payment with respect thereto. Landlord shall be entitled to deduct from the Fourth
Amendment Allowance a construction management fee for Landlord’s oversight and supervision of the
Improvement Work in an amount equal to two percent (2%) of the disbursed portion of the Fourth
Amendment

A-5

 

Allowance. Pursuant to the Third Amendment, Landlord shall be entitled to deduct from the
Third Amendment Allowance a construction management fee for Landlord’s oversight and supervision of
the Improvement Work and the Third Amendment Improvement Work in an amount equal to three percent
(3%) of the disbursed portion of the Third Amendment Allowance.

     12. Indemnification. Tenant shall indemnify and defend (with counsel chosen by
Landlord) Landlord and its members, agents, employees, partners, and their respective employees,
partners, officers, directors, agents, representatives, successors and assigns and hold them
harmless from and against any and all suits, claims, liens, actions, losses, costs, liabilities or
expenses (including attorneys’ fees and claims for workers’ compensation) arising out of or in
connection with the Improvement Work (including, but not limited to, claims for breach of warranty,
personal injury or property damage). Landlord shall have the right, in Landlord’s sole and
exclusive discretion, to settle, compromise, or otherwise dispose of any and all suits, claims, and
actions against any of the indemnified parties arising out of or in connection with the Improvement
Work.

     13. Applicable Only to the Expansion Alterations. This Work Letter shall not be
deemed applicable to any additional space added to the Original Premises or the Expansion Premises
at any time or from time to time, unless expressly so provided in the Lease or any amendment or
supplement to the Lease.

A-6

 

EXHIBIT “B”

Expansion Commencement Certificate

     This Expansion Commencement Certificate (“Certificate”) is given by REVA MEDICAL, INC., a
California corporation (“Tenant”), to ARI COMMERCIAL PROPERTIES, INC., a California corporation, in
its capacity as agent for the tenant-in-common owners of the Building (“Landlord”), with respect to
that certain Fourth Amendment to Lease dated May 7, 2008 (“Fourth Amendment”), under which Tenant
has leased from Landlord certain premises known as Suite E (“Expansion Premises”) in the building
located at 5751 Copley Drive, San Diego, California (“Building”).

     In consideration of the mutual covenants and agreements stated in the Fourth Amendment, and
intending that this Certificate may be relied upon by Landlord and any prospective purchaser or
present or prospective mortgagee, deed of trust beneficiary or ground lessor of all or a portion of
the Building, Tenant certifies as follows:

     a. Except for those terms expressly defined in this Certificate, all initially capitalized
terms have the meanings stated for such terms in the Lease.

     b. The Expansion Commencement Date occurred on                     , 2008.

     c. The Fourth Amendment Expiration Date (which is the lease expiration date for both the
Original Premises and the Expansion Premises) is                     , 2011.

     d. The dates on which Base Rent for the Expansion Premises increases are:                     , 2009,
and                     , 2010.

TENANT: Reva Medical, Inc., a California corporation

	 	 	 	 	 	 	 	 	 	 	 

	By:

	 	 	 	 	 	Date:	 	 	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Name:
	 	 	 	 	 	 	 	 	 	 
	 

	 	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Title:
	 	 	 	 	 	 	 	 	 	 
	 

	 	 

	 	 	 	 	 	 	 	 

B-1exv10w6

EXHIBIT 10.6

Agreement and Plan of Merger

     This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of
October 13, 2004 (the “Agreement Date”), by and among (i) Boston Scientific Corporation, a
Delaware corporation (the “Parent”), (ii) RMI Acquisition Corp., a California corporation
and a wholly owned Subsidiary of Scimed Life Systems, Inc. (which is a wholly owned Subsidiary of
Parent) (“Merger Sub”), (iii) REVA Medical, Inc., a California corporation (the
“Company”), and (iv) Robert Stockman, Gordon Nye and Brian Dovey, acting in each case in
his capacity as a member of the Stockholder Representative Committee referred to herein.
Capitalized terms used herein without definition shall have the respective meanings set forth in
Section 10.2 hereof.

     Whereas, Parent and the Company have entered into a Securities Purchase Agreement,
dated as of the date hereof (the “Securities Purchase Agreement”);

     Whereas, at the Closing referred to in the Securities Purchase Agreement, upon the
terms and subject to the conditions set forth in the Securities Purchase Agreement, Parent may
purchase 1,014,199 shares of Series G-1 Preferred Stock, no par value per share, of the Company
(the “Series G-1 Preferred Stock”) for an aggregate purchase price of approximately
$10,000,000;

     Whereas, subject to and upon the terms and conditions set forth in the Securities
Purchase Agreement, Parent may elect to make certain Loans (as defined in the Securities Purchase
Agreement) to the Company, upon the Company’s request, such Loans to be evidenced by Notes (as
defined in the Securities Purchase Agreement);

     Whereas, Parent may, in its sole discretion, deliver a Merger Election Notice (as
such term is defined below) to cause Merger Sub to merge with and into the Company (the
“Merger”), following which the Company shall continue as the surviving corporation (the
surviving corporation is referred to herein as the “Surviving Corporation”), upon the terms
and subject to the conditions set forth in this Agreement and in accordance with the provisions of
California Law (as defined herein);

     Whereas, the board of directors of the Company (the “Company Board”) has
approved and adopted the form of this Agreement and the consummation of the transactions
contemplated hereby, and has determined to submit the execution and delivery of this Agreement, the
Securities Purchase Agreement, the Amended and Restated Articles of Incorporation of the Company in
the form attached as Exhibit A to the Securities Purchase Agreement (the
“Restated Articles”), and the performance of the transactions contemplated hereby and
thereby to the holders (the “Company Stockholders”) of the shares of the Company’s Common
Stock, no par value per share (the “Common Stock”), and Preferred Stock, no par value per
share (the “Company Preferred Stock”), for their approval by majority written consent in
accordance with California Law; and

     Whereas, the Company Board has carefully considered the terms of this Agreement and
has determined that the terms and conditions of the transactions contemplated hereby, including the
Merger, are fair and in the best interests of, and are advisable to, the Company and the Company
Stockholders, and the Company Board recommends that the Company Stockholders vote for the approval
of this Agreement and the transactions contemplated hereby.

     Now, Therefore, in consideration of the foregoing and the mutual covenants and
agreements herein contained and intending to be legally bound hereby, Parent, Merger Sub, the
Company and the members of the Stockholder Representative Committee hereby agree as follows:

 

 

ARTICLE 1

THE MERGER

     1.1 The Merger. Subject to the other terms and conditions of this Agreement,
including those set forth in Article 7 hereof, the Merger may be consummated under the following
circumstances:

          (a) Disclosure Schedules. Attached hereto is a schedule of disclosures and exceptions
to the representations and warranties made by the Company in Article 3 hereof (the “Company
Disclosure Schedule”). At any time and from time to time during the Option Period and in
accordance with Section 1 of the Securities Purchase Agreement, Parent may, upon notice to the
Company (a “Disclosure Schedule Request”), require the Company to prepare an updated
schedule of disclosures and exceptions to the representations and warranties of the Company
contained in Article 3 hereof (each such update, an “Updated Company Disclosure Schedule”),
as if such representations and warranties were made as of the date of such Updated Company
Disclosure Schedule, except to the extent any such representations and warranties refer expressly
to an earlier date, provided, that in no event shall Parent be entitled to deliver a
Disclosure Schedule Request after the Option Price Adjustment Date or, if later, the Option
Expiration Date. The Company shall prepare and deliver to Parent an Updated Company Disclosure
Schedule within thirty (30) days of receipt of a Disclosure Schedule Request. Pursuant to the
Securities Purchase Agreement, the Company may, at its election, also provide Updated Company
Disclosure Schedule(s) in connection with the Loans. Any Updated Company Disclosure Schedule
delivered pursuant to this Section 1.1(a) shall refer only to (i) disclosures of actual facts
contained in the Company Disclosure Schedule attached to this Agreement, and (ii) disclosures of
actual facts in existence on the date of such Updated Company Disclosure Schedule that have
occurred or been discovered since the Agreement Date, and the Updated Company Disclosure Schedule
shall not otherwise limit or modify any of the representations and warranties made in this
Agreement. No disclosure of a fact or event on any Updated Company Disclosure Schedule shall be
deemed to cure any failure to disclose such fact or event on any previously delivered Company
Disclosure Schedule or Updated Company Disclosure Schedule, or otherwise amend any previously
delivered Company Disclosure Schedule or Updated Company Disclosure Schedule.

          (b) Election by Parent to Cause The Merger.

               (i) Notwithstanding any termination or scheduled expiration of the Option Period following
delivery of a Disclosure Schedule Request, Parent shall have the right at any time after delivery
of a Disclosure Schedule Request and prior to the earlier of (A) the thirtieth (30th)
day following receipt of any Updated Company Disclosure Schedule, or (B) the fiftieth
(50th) day following delivery of such Disclosure Schedule Request to elect, in its sole
discretion, to cause the Company and Merger Sub to close the Merger by delivery to the Company of a
written notice of such election (a “Merger Election Notice”) in the form of Exhibit
A hereto. The Merger Election Notice shall also set forth the proposed closing date of the
Merger (which shall be no more than ninety (90) days after the date of the Merger Election Notice).
In the event that the Company does not deliver an Updated Company Disclosure Schedule to Parent
within the time period specified in Section 1.1(a), the most recent Updated Company Disclosure
Schedule delivered by the Company to Parent or, if none, the Company Disclosure Schedule originally
attached hereto, shall be deemed to be the final Company Disclosure Schedule for all purposes of
this Agreement and all references to the Company Disclosure Schedule and any Updated Company
Disclosure Schedule in Article 3 hereof shall be deemed to refer to such original (or most recent
Updated) Company Disclosure Schedule. No later than five (5) business days prior to the proposed
closing date set forth in the Merger Election Notice, the Company shall deliver to Parent an
agreement of merger, substantially in the form attached hereto as Exhibit B (the
“Merger Certificate”), executed by appropriate officers of the Company. The Merger
Certificate shall be executed by Parent and retained by Parent and filed upon the closing of the
Merger.

-2-

 

               (ii) After execution and delivery of the Merger Election Notice and the Merger Certificate,
upon the terms hereof and subject to the conditions set forth herein, and in accordance with
California Law, at the Effective Time (as defined in Section 1.1(c)), Merger Sub shall be merged
with and into the Company and, as a result of the Merger, the separate corporate existence of
Merger Sub shall cease, and the Company shall continue as the surviving corporation.

               (iii) Notwithstanding anything to the contrary in this Agreement, (A) none of the parties
hereto shall have any obligation to consummate the Merger unless and until Parent delivers a Merger
Election Notice and (B) Parent is under no obligation to deliver any Merger Election Notice or any
Disclosure Schedule Request at any time.

          (c) Consummation of the Merger; Effective Time. Subject to the fulfillment or waiver
of all of the conditions contained in Article 7, as soon as is reasonably practicable on or after
the closing date specified in the Merger Election Notice, a closing (the “Closing”) will be
held at the offices of Bingham McCutchen LLP in Boston, Massachusetts (or such other place as the
parties may agree). The date on which the Closing is actually held is referred to herein as the
“Closing Date.” On the Closing Date, Parent, Merger Sub and the Company shall cause the
Merger to be consummated by filing the Merger Certificate, with such changes that are not
inconsistent with the other terms of this Agreement as may be requested by the California Secretary
of State, with the California Secretary of State. The term “Effective Time” means the date
and time of the filing of the Merger Certificate with the California Secretary of State (or such
later time as may be agreed by each of the parties hereto and specified in the Merger Certificate
in accordance with California Law). In the event of a conflict between this Agreement and the
Merger Certificate, this Agreement shall govern.

          (d) Deposit. Parent may deliver to the Stockholder Representative Committee, for the
benefit of the Company Stockholders (other than any Disqualified Stockholder) a deposit (the
“Deposit”) in an amount equal to Forty Million Dollars ($40,000,000) in cash on or prior to
the Option Price Adjustment Date, unless Parent has previously elected to terminate the Option
Period by delivering written notice (the “Termination Notice”) to the Company prior to the
Option Price Adjustment Date. The Stockholder Representative Committee shall transfer the Deposit,
if paid, on a pro rata basis to the holders of the (i) Company Common Stock, (ii) Company Preferred
Stock, (iii) Company Options and (iv) Company Warrants, determined as of the Option Price
Adjustment Date and assuming the exercise in full of all Company Options and Company Warrants
(whether or not exercisable, whether or not vested, and whether or not performance-based), and in
each case excluding any shares of Company Common Stock, Company Preferred Stock, Company Options or
Company Warrants held by the Company, any Subsidiaries of the Company or any Disqualified
Stockholder. The proportionate share of any Deposit to be paid to any Company Stockholder or any
holder of Company Options or Company Warrants (collectively, the “Company Securityholders”)
shall be determined by dividing (A) the sum of (i) the number of shares of Company Common Stock,
excluding any shares of Company Common Stock held by the Company, any subsidiary of the Company or
any Disqualified Stockholder, (ii) the number of shares of Company Preferred Stock (calculated as
if all shares of Company Preferred Stock had been converted into Company Common Stock as of the
Option Price Adjustment Date, excluding any shares of Company Preferred Stock held by the Company,
any subsidiary of the Company or any Disqualified Stockholder) and (iii) the number of shares of
Company Common Stock issuable upon exercise of the Company Options and Company Warrants (or upon
conversion of any shares of Company Preferred Stock issuable upon exercise of any Company Warrants)
but without deducting or making any adjustment to the number of shares of Company Common Stock or
Company Preferred Stock issuable upon exercise of such Company Options or Company Warrants for any
exercise price otherwise payable to acquire such underlying shares of Company Common Stock held by
such Company Securityholder as of the Option Price Adjustment Date, excluding any shares of Company
Common Stock held by the Company, any subsidiary of the Company or any Disqualified Stockholder, by
(B) the total number of shares of Company Common Stock and Company Preferred Stock outstanding on
such date (calculated as if all

-3-

 

shares of Company Preferred Stock had been converted into Company Common Stock and all Company
Options and Company Warrants had been exercised in full as of the Option Price Adjustment Date,
excluding any shares of Company Common Stock, Company Preferred Stock, Company Options and Company
Warrants held by the Company, any subsidiary of the Company or any Disqualified Stockholder). The
Deposit, if paid, shall be non-refundable, and Parent irrevocably waives any right to recover or
receive a refund of any portion of the Deposit. The Company irrevocably waives any right to
receive any portion of the Deposit, if paid, and any rights in the Deposit. The parties agree to
treat the Deposit as option consideration transferred directly by Parent to the Company
Stockholders related to the right to consummate the Merger in accordance with the terms of this
Agreement. In the event that Parent shall for any reason (or for no reason) fail to pay the
Deposit by the Option Price Adjustment Date, then the members of the Stockholder Representative
Committee may, in their discretion, deliver an Option Period Termination Notice to Parent of their
intention to terminate the Option Period. Unless Parent shall pay the Deposit within ten (10) days
after receipt of the Option Period Termination Notice, the Option Period shall terminate on the
date that is eleven (11) days following the date on which the Stockholder Representative Committee
delivers the Option Period Termination Notice to Parent. The parties agree that Parent is not
obligated to pay the Deposit and the sole recourse of the Company, the Stockholder Representative
Committee and the Participating Rights Holders with respect to Parent’s election not to pay the
Deposit as aforesaid shall be the delivery by the Stockholder Representative Committee of an Option
Period Termination Notice and Parent shall not be liable for any damages, or subject to any
equitable remedy, for any failure to pay the Deposit.

     1.2 Effect of the Merger. At the Effective Time, the effect of the Merger shall be as
provided in the Merger Certificate and as provided by the applicable provisions of California Law.
Without limiting the generality of the foregoing, and subject thereto, upon the consummation of the
Merger, all the property (including, but not limited to, Intellectual Property and licenses to
Intellectual Property), rights, privileges, powers and franchises of the Company and the Merger Sub
shall vest in the Surviving Corporation, and all debts, liabilities, obligations, restrictions,
disabilities and duties of each of those corporations shall become the debts, liabilities,
obligations, restrictions, disabilities and duties of the Surviving Corporation.

     1.3 Charter; Bylaws.

          (a) At the Effective Time, the Articles of Incorporation of the Surviving Corporation (the
“Surviving Corporation Charter”) shall be the Articles of Incorporation of the Company, as
amended by the Merger Certificate.

          (b) At the Effective Time, the bylaws of the Surviving Corporation shall be the bylaws of
Merger Sub, as in effect immediately prior to the Effective Time, until thereafter amended as
provided by California Law, the Surviving Corporation Charter and such bylaws.

     1.4 Directors and Officers. The directors of Merger Sub immediately prior to the
Effective Time shall be the initial directors of the Surviving Corporation, each to hold office in
accordance with the Surviving Corporation Charter and the bylaws of the Surviving Corporation, and
until their respective successors are duly elected and qualified or until their earlier death,
disability, resignation or removal. The officers of Merger Sub immediately prior to the Effective
Time shall be the initial officers of the Surviving Corporation, in each case until their
respective successors are duly elected or appointed and qualified or until their earlier death,
disability, resignation or removal.

     1.5 Closing Date Consideration; Initial Escrow Amount; Committee Reimbursement Amount.

          (a) The aggregate consideration to be paid by Parent to the Participating Rights Holders at
the Closing in connection with the Merger shall be the Closing Payment. At the Closing,

-4-

 

Parent shall also pay in full (i) to the holders thereof the amounts owing under the
Stockholder Debt outstanding immediately prior to the Effective Time, but only to the extent of the
amounts thereof set forth on the Capitalization and Fee Certificate, and (ii) to the parties owed
the amounts due under the Merger-Triggered Fees, but only to the extent of the amounts thereof set
forth on the Capitalization and Fee Certificate.

          (b) Notwithstanding the foregoing, a portion of the Closing Payment otherwise payable to the
Participating Rights Holders with respect to their shares of Company Common Stock, Company Options
or Company Warrants that are exercisable for Company Common Stock, equal in amount to ten percent
(10%) of the aggregate Closing Payment determined prior to any deductions under this paragraph (b)
or paragraph (c) below (the “Initial Escrow Amount”), shall not be paid at the Closing to
Participating Rights Holders with respect to such shares of Company Common Stock, Company Options
or Company Warrants that are exercisable for Company Common Stock, but shall instead be deposited
with The Bank of New York or such other escrow agent as shall be mutually agreed-upon by Parent and
the Company (the “Escrow Agent”), to be held by the Escrow Agent on behalf of the
Participating Rights Holders pursuant to an Escrow Agreement, substantially in the form of the
attached Exhibit C (the “Escrow Agreement”), and distributed in accordance
therewith. To the extent that Parent elects to pay some or all of the Closing Payment through the
issuance of shares of Parent Common Stock in accordance with Section 1.8, the escrowed portion of
the Closing Payment shall consist entirely of cash to the extent cash is included in the Closing
Payment, and in the event that there is not sufficient cash included in the Closing Payment to fund
such escrow obligation in its entirety, the balance of such escrowed consideration shall be
composed of shares of Parent Common Stock valued at the Reference Market Value used to determine
the number of shares of Parent Common Stock included in the Closing Payment. At the Closing,
Parent, Merger Sub, the Company, the Stockholder Representative Committee and the Escrow Agent will
execute and deliver the Escrow Agreement.

          (c) In addition, a portion of the Closing Payment in cash otherwise payable to the
Participating Rights Holders with respect to their shares of Company Common Stock, Company Options
or Company Warrants that are exercisable for Company Common Stock, equal to $100,000 (together with
any additional amounts deposited with the Stockholder Representative Committee pursuant to Section
1.8(c), the “Committee Reimbursement Amount”), shall not be paid at the Closing to the
Participating Rights Holders with respect to such shares of Company Common Stock, Company Options
or Company Warrants that are exercisable for Company Common Stock, but shall instead be deposited
with the Stockholder Representative Committee, to be held by the Stockholder Representative
Committee for the payment of expenses incurred by the Stockholder Representative Committee in
performing its duties pursuant to this Agreement. The portion of the Committee Reimbursement
Amount contributed on behalf of each Participating Rights Holder shall be proportionate to the
portion of the Closing Payment which such Participating Rights Holder would otherwise be entitled
to receive with respect to such Participating Rights Holder’s shares of Company Common Stock,
Company Options or Company Warrants that are exercisable for Company Common Stock,. Any of the
Committee Reimbursement Amount originally deposited with the Stockholder Representative Committee
at the Closing that has not been consumed by the Stockholder Representative Committee pursuant to
the terms of this Agreement on or prior to the end of the period in which Parent, the Surviving
Corporation and their Affiliates may make claims for indemnification pursuant to Section 9.2 or, if
later, the date on which all indemnification claims of Parent, the Surviving Corporation or any of
their Affiliates outstanding at the end of such period have been discharged in full, shall be
distributed by the Stockholder Representative Committee to the Participating Rights Holders pro
rata based on their respective rights to participate in the Closing Payment with respect to their
shares of Company Common Stock, Company Options or Company Warrants that are exercisable for
Company Common Stock. The Committee Reimbursement Amount shall be subject to increase from time to
time as provided in Section 2.5.

     1.6 Additional Payments.

-5-

 

          (a) In the event that the Merger is consummated, as additional consideration for the Merger,
and subject to the set-off rights of Parent and the Surviving Corporation pursuant to Section
1.9(h) and Article 9 hereof, after the Effective Time, Parent shall make certain contingent
payments (collectively, the “Contingent Payments”) on the terms provided in this Section
1.6, to the Participating Rights Holders in accordance with the provisions of this Section 1.6 and
Sections 1.9 and 2.1, and subject to the limitation on such contingent payments set forth in
Section 1.7 hereof and the provisions of Section 2.5. The Contingent Payments shall include the
Sales Contingent Payments and Milestone Contingent Payments described below.

          (b) Parent shall make a Contingent Payment with respect to the sale of Contingent Payment
Products for each Contingent Payment Year (collectively, the “Sales Contingent Payments”).
The consideration to be paid by Parent to the Participating Rights Holders at the time specified in
Section 1.9 in connection with such Sales Contingent Payment shall be that portion of the amount of
the Sales Contingent Payment Amount allocated to each of such Participating Rights Holders pursuant
to Section 2.1.

          (c) In the event that the First Milestone is completed following the Effective Time and the
Closing Payment Amount has not otherwise been increased in accordance with the definition thereof
as a result of the achievement of such First Milestone, Parent shall make a Contingent Payment (the
“First Milestone Contingent Payment”) equal to that portion of the First Milestone Amount
allocated to each of the Participating Rights Holders pursuant to Section 2.1. The First Milestone
Contingent Payment shall be paid by Parent together with the Sales Contingent Payment payable under
Section 1.6(b) for the Contingent Payment Year in which the First Milestone is completed,
provided, that if there is no Sales Contingent Payment payable with respect to such
Contingent Payment Year, then the First Milestone Contingent Payment shall be paid within sixty
(60) days following the last day of such Contingent Payment Year, and provided,
further, that if the Contingent Payment Commencement Date has not occurred prior to the
completion of the First Milestone, the First Milestone Contingent Payment shall be made within
sixty (60) days of the completion of the First Milestone.

          (d) In the event that the Second Milestone is completed following the Effective Time and the
Closing Payment Amount has not otherwise been increased in accordance with the definition thereof
as a result of the achievement of such Second Milestone, Parent shall make a Contingent Payment
(the “Second Milestone Contingent Payment”) equal to that portion of the Second Milestone
Amount allocated to each of the Participating Rights Holders pursuant to Section 2.1. The Second
Milestone Contingent Payment shall be paid by Parent together with the Sales Contingent Payment
payable under Section 1.6(b) for the Contingent Payment Year in which the Second Milestone is
completed, provided, that if there is no Sales Contingent Payment payable with respect to
such Contingent Payment Year, then the Second Milestone Contingent Payment shall be paid within
sixty (60) days following the last day of such Contingent Payment Year, and provided,
further, if the Contingent Payment Commencement Date has not occurred prior to the
completion of the Second Milestone, the Second Milestone Contingent Payment shall be made within
sixty (60) days of the completion of the Second Milestone.

          (e) In the event that the Fourth Milestone is completed following the Effective Time and the
Closing Payment Amount has not otherwise been increased in accordance with the definition thereof
as a result of the achievement of such Fourth Milestone, Parent shall make a Contingent Payment
(the “Fourth Milestone Contingent Payment”) equal to that portion of the Fourth Milestone
Amount allocated to each of the Participating Rights Holders pursuant to Section 2.1. The Fourth
Milestone Contingent Payment shall be paid by Parent within sixty (60) days following completion of
the Fourth Milestone.

          (f) Each of Parent and the Company hereby acknowledge that the amount of Worldwide Net Sales,
if any, that Parent and its Affiliates may generate during any Contingent Payment Year is uncertain
and that (i) Parent and its Affiliates may not generate any Worldwide Net Sales in any

-6-

 

Contingent Payment Year, and (ii) it is therefore not assured that Parent will be required to
make any Sales Contingent Payments for any particular Contingent Payment Year, or at all.

          (g) Parent shall have sole discretion over all matters relating to the Contingent Payment
Products after the Effective Time, including, but not limited to, any development, manufacturing,
marketing and sales decisions relating to any Contingent Payment Product.

     1.7 Maximum Aggregate Contingent Payments. Subject to the further rights of Parent
and the Surviving Corporation to reduce the Contingent Payments pursuant to Section 1.9 and Article
9 hereof, Parent shall not be required to make any Contingent Payments once Parent has made
Contingent Payments based on Contingent Payment Amounts equal to the amount of (i) $1,250,000,000,
minus (ii) the Closing Payment Amount, minus (iii) the Deposit if Parent has
delivered the Deposit pursuant to Section 1.1(d), minus (iv) the original principal amount
of the Third Loan, if any (the “Maximum Contingent Amount”). Upon distributing Contingent
Payments based on Contingent Payment Amounts equal to the Maximum Contingent Amount, Parent’s
obligation to make any additional or future Contingent Payments pursuant to Section 1.6 shall
cease, and the rights of the Participating Rights Holders to receive Contingent Payments shall
terminate. To the extent that any provision of Section 1.6 would otherwise require Parent to make
a Contingent Payment resulting in Parent paying Contingent Payments based on Contingent Payment
Amounts that, in the aggregate, exceed the Maximum Contingent Amount, Parent shall be entitled to
reduce such Contingent Payment such that the Maximum Contingent Amount is not exceeded, and no
further Contingent Payment shall be due or payable thereafter. For purposes of this Section 1.7,
any amounts offset by Parent against any Contingent Payments made pursuant to Section 1.9(h),
Section 2.1, Section 2.5(e), Section 9.4 or otherwise, shall be deemed to have been paid by Parent
pursuant to this Section 1.7. Notwithstanding anything herein to the contrary, no additional
Contingent Payments shall accrue or become payable after the Contingent Period Termination Date;
provided, however, that Parent shall remain obligated after the Contingent Period
Termination Date to make any Contingent Payments that are due and payable but unpaid as of the
Contingent Period Termination Date.

     1.8 Form of Consideration Payable by Parent.

          (a) Parent Common Stock. Subject to the provisions of Section 1.8(b) below, at the
sole discretion of Parent, any portion or all of the Closing Payment (other than that portion which
constitutes the Committee Reimbursement Amount) and any portion or all of any Contingent Payment
may be satisfied by (i) the issuance to the Participating Rights Holders of that number of shares
of Parent Common Stock equal to the quotient obtained by dividing (x) the amount of the Closing
Payment or Contingent Payment that Parent has elected to satisfy through the issuance of whole
shares of Parent Common Stock, by (y) the Reference Market Value on the date of payment, with any
fraction of a share of Parent Common Stock being treated as provided in Section 1.8(c) below, (ii)
payment of such amount in cash, or (iii) a combination of the forms of consideration referred to in
the foregoing clauses (i) and (ii).

          (b) Conditions. The right of Parent to pay all or any portion of the Closing Payment
or any Contingent Payment through the issuance of shares of Parent Common Stock shall, upon the
date such shares are issued to the Participating Rights Holders, be subject to the satisfaction of
all of the following conditions:

               (i) any and all such shares shall either be registered under the Securities Act or shall be
saleable, subject to any restrictions that would be imposed as a result of such Participating
Rights Holder’s individual circumstance (i.e., any volume limitations imposed pursuant to Rules 144
or 145 under the Securities Act), on the date of delivery, without requiring further registration
under the Securities Act and without any further holding period being imposed by the Securities
Act;

               (ii) Parent shall have caused any shares of Parent Common Stock issued pursuant to this
Agreement to be listed on each securities exchange on which similar securities, including

-7-

 

as to class and series, issued by Parent are then listed and, if not so listed, to be listed
on the Nasdaq National Stock Market, subject only to notice of issuance; and

               (iii) any and all such shares shall have been duly authorized and reserved for issuance, and
upon issuance thereof in accordance with this Agreement, be validly issued, fully paid and
nonassessable.

          (c) No Fractional Shares. In the event that all or any portion of the Closing Payment
or any Contingent Payment is paid in the form of shares of Parent Common Stock, no certificates or
scrip representing fractional shares of Parent Common Stock shall be issued, but an amount in cash
equal to the aggregate Reference Market Value of all such fractional shares shall instead be
deposited with the Stockholder Representative Committee by Parent as additional Committee
Reimbursement Amount.

          (d) Legend. Any certificate issued to any Participating Rights Holders representing
shares of Parent Common Stock that have not been registered under the Securities Act shall be
imprinted with the following legend (or the substantial equivalent thereof):

          “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933 AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF, IN WHOLE OR IN
PART, OTHER THAN PURSUANT TO REGISTRATION UNDER SAID ACT OR IN
CONFORMITY WITH THE LIMITATIONS OF RULE 144 OR OTHER SIMILAR RULE OR
EXEMPTION AS THEN IN EFFECT, WITHOUT FIRST OBTAINING (I) IF
REASONABLY REQUIRED BY THE COMPANY, A WRITTEN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY, WHICH MAY BE COUNSEL TO THE COMPANY, TO
THE EFFECT THAT THE CONTEMPLATED SALE OR OTHER DISPOSITION WILL NOT
BE IN VIOLATION OF SAID ACT, OR (II) A ‘NO-ACTION’ OR INTERPRETIVE
LETTER FROM THE STAFF OF THE SECURITIES AND EXCHANGE COMMISSION TO
THE EFFECT THAT SUCH STAFF WILL TAKE NO ACTION IN RESPECT OF THE
CONTEMPLATED SALE OR OTHER DISPOSITION.”

          In the event that any certificate issued to any Participating Rights Holders representing
shares of Parent Common Stock is imprinted with the foregoing legend (or a similar legend), Parent
shall cause such legends to be removed in connection with any resale of such shares of Parent
Common Stock that is made in compliance with, or pursuant to a valid exemption from, the
registration provisions of the Securities Act.

     1.9 Payment of Contingent Payments.

          (a) Contingent Payment Certificates. On or prior to the sixtieth (60th)
day following the last day of each Contingent Payment Year, Parent shall deliver to the Stockholder
Representative Committee a certificate (each, a “Contingent Payment Certificate”), setting
forth Parent’s determination of the Sales Contingent Payment Amount for such Contingent Payment
Year and the amount of Worldwide Net Sales used to determine such Sales Contingent Payment Amount.
In addition, on or prior to the thirtieth (30th) day following the achievement of any
Milestone, Parent shall deliver to the Stockholder Representative Committee notice of the
achievement of such Milestone.

          (b) Stockholder Representative Committee Audit Rights. Parent hereby grants the
Stockholder Representative Committee and its representatives, at the Stockholder Representative
Committee’s sole expense, the right, exercisable no more than once during each ninety (90) day
period following delivery to the Stockholder Representative Committee of a Contingent Payment
Certificate, and

-8-

 

subject to the execution of, and compliance with, Parent’s standard form of confidentiality
agreement, to examine its books of account and records of Worldwide Net Sales for the Contingent
Payment Year with respect to which the most recent Contingent Payment Certificate has been
delivered, at the location of such records on prior written notice (the “Audit Notice”) of
at least twenty (20) days, for the purpose of verifying the amount of Worldwide Net Sales for the
Contingent Payment Year with respect to which the most recent Contingent Payment Certificate has
been delivered (each, a “Contingent Payment Audit”). For the purpose of conducting a
Contingent Payment Audit, the Stockholder Representative Committee may hire, at its expense, an
auditor and/or attorney of its choosing to assist in such examination, provided, that such
auditor or attorney has entered into Parent’s standard form of confidentiality agreement. The
Stockholder Representative Committee shall have access to such books and records for a thirty (30)
day period commencing on the date on which access to such books and records is made available to
the Stockholder Representative Committee; provided, that any review of such books and
records conducted on Parent’s premises shall be completed within ten (10) business days from such
date. Nothing in this Section 1.9(b) shall be deemed to require Parent to keep any books of
account or records other than those which it maintains in the ordinary course of business in its
usual and customary practice, to retain any such books of account or records for any period in
excess of the period for which Parent retains such records in the ordinary course of business in
its usual and customary practice, or to provide access to any books and records of Parent other
than that specified above.

          (c) Dispute Notice. In the event that the Stockholder Representative Committee does
not agree with the Sales Contingent Payment Amount set forth on any Contingent Payment Certificate,
the Stockholder Representative Committee shall be entitled, within sixty (60) days of the later of
(i) delivery of such Contingent Payment Certificate or (ii) the completion of a Contingent Payment
Audit commenced in connection with the delivery of such Contingent Payment Certificate (the
“Dispute Period”), to give Parent written notice (a “Dispute Notice”) of such
disagreement.

          (d) Agreed Contingent Payment Amount. In the event that the Stockholder
Representative Committee delivers a Dispute Notice within the Dispute Period, the Stockholder
Representative Committee and Parent shall, for a period of not less than thirty (30) days after
delivery of the Dispute Notice, attempt to resolve the Sales Contingent Payment Amount (the
“Disputed Contingent Payment Amount”) in dispute and mutually determine any adjustments to
such Sales Contingent Payment Amount (the “Agreed Contingent Payment Amount”). Parent and
the Stockholder Representative Committee shall, subject to execution of a confidentiality agreement
in form and substance satisfactory to the delivering party, provide each other with such
information, records and material kept in the ordinary course of business in such party’s
possession and which such party may disclose without violating confidentiality obligations to third
parties, as is reasonably necessary and appropriate in attempting to resolve such Disputed
Contingent Payment Amount, including the delivery of a copy to the Stockholder Representative
Committee of any such information, records and material that is used to calculate the amount of
Worldwide Net Sales set forth on each Contingent Payment Certificate.

          (e) Arbitration of Disputes. In the event that no agreement can be reached by the
Stockholder Representative Committee and Parent as to the calculation of the Disputed Contingent
Payment Amount within ninety (90) days after delivery of the Dispute Notice, then either party
shall have the right to submit the Disputed Contingent Payment Amount to arbitration by the New
York, New York office of one (1) of the following entities or their respective successors, so long
as such entity or its successors is not the principal regularly-engaged outside accountant to
Parent or the Company: Deloitte & Touche LLP, KPMG LLP, Ernst & Young LLP and
PricewaterhouseCoopers LLP (collectively, the “Accountants”); provided,
however, that the engagement and charge of the Accountants shall be limited to determining
the Worldwide Net Sales of any identified product or products for the Contingent Payment Year used
to calculate the Disputed Contingent Payment Amount, and, that the Accountants shall not be
entitled to determine whether any products sold by Parent are Contingent Payment Products for
purposes of this Agreement. The Stockholder Representative Committee and Parent shall jointly
select which of

-9-

 

the Accountants will perform the calculation within thirty (30) days after the Stockholder
Representative Committee and Parent determine that they are unable to settle the amount
independently. The partner selected from one of the Accountants in accordance with this Agreement
to be responsible for the determination of the Disputed Contingent Payment Amount, who shall be
mutually agreeable to Parent and the Stockholder Representative Committee, shall be referred to
herein as the “Appraiser.” The Appraiser shall determine the Disputed Contingent Payment
Amount based on the final Worldwide Net Sales for the Contingent Payment Year subject to the
Dispute Notice within ninety (90) days after the date of such Appraiser’s engagement. The fees and
expenses of the Appraiser shall be paid by the Stockholder Representative Committee;
provided, that if the final Sales Contingent Payment Amount determined after calculation of
the amount of Worldwide Net Sales by the Appraiser in any examination conducted pursuant to this
Section 1.9(e) is more than $250,000 greater than the Sales Contingent Payment Amount set forth in
the relevant Contingent Payment Certificate, Parent shall pay the fees and expenses of the
Appraiser.

          (f) Final Calculation and Payment of Contingent Payment. With respect to any Sales
Contingent Payment Amount:

               (i) In the event that the Stockholder Representative Committee does not deliver a Dispute
Notice with respect to such Sales Contingent Payment Amount within the Dispute Period, the Sales
Contingent Payment Amount set forth in the relevant Contingent Payment Certificate shall be deemed
to be the final Sales Contingent Payment Amount for such Contingent Payment Year and for all
purposes of this Agreement, absent fraud or intentional misconduct, and Parent shall, within
fifteen (15) days after the expiration of the Dispute Period, pay the amount specified in Section
1.6 in respect of the applicable Contingent Payment Year to the Stockholder Representative
Committee (for the benefit of the Participating Rights Holders) in a form of consideration selected
by Parent in accordance with Section 1.8 and subject to Section 1.9(h).

               (ii) In the event that the Stockholder Representative Committee delivers a Dispute Notice
pursuant to Section 1.9(c) with respect to a Sales Contingent Payment Amount, and Parent and the
Stockholder Representative Committee shall mutually determine the Agreed Contingent Payment Amount,
then the Agreed Contingent Payment Amount shall be deemed to be the final such Sales Contingent
Payment Amount for all purposes of this Agreement, absent fraud or intentional misconduct, and
Parent shall, within fifteen (15) days after such Agreed Contingent Payment Amount is mutually
determined, pay the amount specified in Section 1.6 in respect of the applicable Contingent Payment
Year based on the Agreed Contingent Payment Amount to the Stockholder Representative Committee (for
the benefit of the Participating Rights Holders) in a form of consideration selected by Parent in
accordance with Section 1.8 and subject to Section 1.9(h).

               (iii) In the event that an Appraiser shall determine the Disputed Contingent Payment Amount
pursuant to Section 1.9(e), then the Sales Contingent Payment Amount determined by the Appraiser
pursuant to Section 1.9(e) shall be deemed to be the final such Sales Contingent Payment Amount for
such Contingent Payment Year for all purposes of this Agreement, absent fraud or intentional
misconduct, and Parent shall, within fifteen (15) days after such final determination by the
Appraiser, pay the amount specified in Section 1.6 in respect of the applicable Contingent Payment
Year based on the final Sales Contingent Payment Amount determined by the Appraiser to the
Stockholder Representative Committee (for the benefit of the Participating Rights Holders) in a
form of consideration selected by Parent in accordance with Section 1.8 and subject to Section
1.9(h).

               (iv) The determination of any Sales Contingent Payment Amount pursuant to Sections 1.9(f)(i),
1.9(f)(ii) or 1.9(f)(iii) shall, in the absence of fraud or intentional misconduct, be conclusive
for all purposes of this Agreement, and Parent, Stockholder Representative Committee and Appraiser
shall each be free from any and all liability resultant from such determination.

-10-

 

          (g) Termination of Audit and Arbitration Rights. Notwithstanding anything to the
contrary herein, in the event that two (2) or more examinations by an Appraiser have been commenced
by the Stockholder Representative Committee pursuant to Section 1.9(e) hereof, and in two (2) such
examinations the aggregate amount of the Sales Contingent Payment Amounts finally determined by the
Appraiser in such examinations is less than one percent (1%) greater than the aggregate Sales
Contingent Payment Amounts set forth on the Contingent Payment Certificates originally delivered by
Parent with respect to such Contingent Payment Years, then the Stockholder Representative Committee
shall no longer be permitted to deliver an Audit Notice or Dispute Notice to Parent, or submit any
additional disputed Sales Contingent Payment Amounts to a determination by an Accountant in
accordance with this Section 1.9 for such Contingent Payment Year or any other Contingent Payment
Years.

          (h) Unilateral Right of Set-Off; Payment Upon Resolution. Notwithstanding anything to
the contrary in this Agreement, the obligation of Parent and the Surviving Corporation to make any
Contingent Payment shall be qualified in its entirety by the right of Parent and the Surviving
Corporation to reduce the amount of any Contingent Payment, to the extent Parent would otherwise be
entitled to be indemnified therefore, by the amount of any Damages incurred or suffered, or
reasonably likely to be incurred or suffered, by Parent or the Surviving Corporation, as determined
by Parent in good faith and subject only to the express limitations on indemnification set forth in
Article 9 hereof. In the event that Parent reduces the amount of any Contingent Payment by the
amount of any Damages that have not been, at the time the Contingent Payment is made, incurred by
Parent, and it is finally determined that such Damages will not be incurred by Parent, then Parent
shall promptly upon such determination and whether before or following the Contingent Period
Termination Date pay to the Participating Rights Holders such amounts as have been withheld plus
interest thereon which shall accrue from the date such Contingent Payment was reduced at the “Prime
Rate” as announced from time to time by Bank of America, N.A., in Boston, Massachusetts, or its
successor, plus one percent (1%).

          (i) Dissenting Shares. The provisions of this Section 1.9 shall also apply to
Dissenting Shares that lose their status as such, except that the obligations of Parent under this
Section 1.9 shall commence on the date of loss of such status and the holder of such shares shall
be entitled to receive in exchange for such shares the payments to which such holder would
otherwise have been entitled pursuant to Section 2.1 hereof had such shares of Company capital
stock not been Dissenting Shares at the Effective Time.

ARTICLE 2

CONVERSION OF SECURITIES; EXCHANGE OF CERTIFICATES; PAYMENTS

     2.1 Conversion of Securities.

          (a) Common Stock. Each share of the Company Common Stock issued and outstanding
immediately prior to the Effective Time and held by Participating Rights Holders will be converted
at the Effective Time into the right to receive from Parent, in the form of consideration
determined by Parent in accordance with Section 1.8, (i) an amount equal to the Per Share Common
Closing Payment, plus (ii) an amount equal to the Per Share Common Contingent Payment
associated with each Contingent Payment when such payments, if any, are made pursuant to Sections
1.6 and 1.9 hereof. All such shares of Company Common Stock, when so converted, shall no longer be
outstanding and shall automatically be cancelled and retired and shall cease to exist, and each
holder of a certificate representing any such shares of Company Common Stock shall cease to have
any rights with respect thereto, except the right to receive the Per Share Common Closing Payment
and the Per Share Common Contingent Payment associated with each Contingent Payment, if any, upon
the surrender of such certificate in accordance with Section 2.2 and this Section 2.1.
Notwithstanding the foregoing, portions of the Closing Payment attributable to the Company Common
Stock shall be deposited in escrow or paid to the Stockholder Representative Committee as Committee
Reimbursement Amount in accordance with

-11-

 

Section 1.5, and a portion of any Contingent Payment otherwise attributable to the Company
Common Stock may be deducted from such Contingent Payment and paid to the Stockholder
Representative Committee as additional Committee Reimbursement Amount in accordance with Section
2.5.

          (b) Preferred Stock. Each share of each series, if any, of Company Preferred Stock
issued and outstanding immediately prior to the Effective Time and held by Participating Rights
Holders will be converted at the Effective Time into the right to receive, in the form of
consideration determined by Parent in accordance with Section 1.8, an amount equal to the Per Share
Preferred Closing Payment associated with such series of Company Preferred Stock; provided,
however, that in no event shall any amount be paid pursuant to this Section 2.1(b) with respect to
any share of Company Preferred Stock in excess of the maximum amount that is distributable with
respect to such share upon a liquidation of the Company, or any other event deemed to be a
liquidation of the Company, pursuant to the Company’s Restated Articles as in effect immediately
prior to the Effective Time. All shares of Company Preferred Stock, when so converted, shall no
longer be outstanding and shall automatically be cancelled and retired and shall cease to exist,
and each holder of a certificate representing any such shares of Company Preferred Stock shall
cease to have any rights with respect thereto, except the right to receive the Per Share Preferred
Closing Payment associated with the applicable series of Company Preferred Stock upon the surrender
of such certificate in accordance with Section 2.2 and this Section 2.1.

          (c) Disposition of Options. All options to purchase Company Common Stock issued under
the Company’s 2001 Stock Option/Stock Issuance Plan (the “Company Option Plan”) or
otherwise listed in Section 3.2(c) of the Company Disclosure Schedule, whether or not exercisable,
whether or not vested, and whether or not performance-based, which are outstanding immediately
prior to the Effective Time (each a “Company Option”), shall not be assumed by the
Surviving Corporation or Parent, but shall instead be converted at the Effective Time into the
right to receive from Parent, in the form of consideration determined by Parent in accordance with
Section 1.8, and subject to Section 1.5, (i) payment as of the Closing of an amount equal to the
excess, if any, of the aggregate Per Share Common Closing Payment that would be payable with
respect to all shares of Company Common Stock that would be issuable upon exercise of such Company
Option (the “Option Shares”) over the aggregate exercise price otherwise payable by the
holder to acquire such Option Shares; plus (ii) payment out of each Contingent Payment of
an amount equal to the excess of the aggregate Per Share Common Contingent Payment that would be
payable with respect to such Option Shares in connection with each Contingent Payment over any
exercise price otherwise payable by the holder to acquire such Option Shares, in each case to the
extent such exercise price has not previously been deducted from any Per Share Common Closing
Payment or other Per Share Common Contingent Payment, when such payments, if any, are made pursuant
to Sections 1.6 and 1.9 hereof. Notwithstanding the foregoing, portions of the Closing Payment
attributable to the Company Options shall be deposited in escrow or paid to the Stockholder
Representative Committee as Committee Reimbursement Amount in accordance with Section 1.5, and
portions of any Contingent Payment otherwise attributable to the Company Options may be deducted
from such Contingent Payment and paid to the Stockholder Representative Committee as additional
Committee Reimbursement Amount in accordance with Section 2.5.

          (d) Disposition of Warrants. All unexercised rights, warrants or options not subject
to the Company Option Plan or otherwise listed in Section 3.2(c) of the Company Disclosure Schedule
to purchase shares of Company Preferred Stock and/or Company Common Stock outstanding immediately
prior to the Effective Time (each a “Company Warrant”), shall not be assumed by the
Surviving Corporation or Parent, but shall instead be converted at the Effective Time into the
right to receive from Parent, in the form of consideration provided in Section 1.8, and subject to
Section 1.5, (x) payment as of the Closing of an amount equal to the excess, if any, of the
aggregate Per Share Preferred Closing Payment or Per Share Common Closing Payment, as applicable,
that would be payable with respect to all shares of Company Preferred Stock and/or Company Common
Stock that would be issuable upon exercise of such Company Warrant (“Warrant Shares”) over
the aggregate exercise price otherwise

-12-

 

payable by the holder to acquire such Warrant Shares; plus (y) payment out of each
Contingent Payment of an amount equal to the excess of the aggregate Per Share Common Contingent
Payment that would be payable with respect to such Warrant Shares in connection with each
Contingent Payment over any exercise price otherwise payable by the holder to acquire such Warrant
Shares, in each case to the extent such exercise price has not previously been deducted from any
Per Share Preferred Closing Payment or Per Share Common Closing Payment, as applicable, or, if
applicable, other Per Share Common Contingent Payment, when such payments, if any, are made
pursuant to Sections 1.6 and 1.9 hereof. Notwithstanding the foregoing, a portion of the Closing
Payment attributable to Company Warrants that are exercisable for shares of Company Common Stock
shall be deposited in escrow or paid to the Stockholder Representative Committee as Committee
Reimbursement Amount in accordance with Section 1.5, and a portion of any Contingent Payment
otherwise attributable to Company Warrants that are exercisable for shares of Company Common Stock
may be deducted from such Contingent Payment and paid to the Stockholder Representative Committee
as additional Committee Reimbursement Amount in accordance with Section 2.5.

          (e) Treasury Stock. Each share of Company Common Stock or Company Preferred Stock
held in the treasury of the Company or held by any Subsidiary of the Company immediately prior to
the Effective Time shall be cancelled and extinguished at the Effective Time without any conversion
thereof and no payment shall be made with respect thereto.

          (f) Stock Held by Parent. Each share of Company Common Stock or Company Preferred
Stock held by any Disqualified Stockholder shall be cancelled and extinguished at the Effective
Time without any conversion thereof and no payment shall be made with respect thereto.

          (g) Stock of Merger Sub. Each share of common stock of Merger Sub issued and
outstanding immediately prior to the Effective Time shall be converted into one (1) validly issued
fully paid and nonassessable share of common stock of the Surviving Corporation.

          (h) Fractional Shares. No holder of Company Common Stock, Company Preferred Stock,
Company Options or Company Warrants, after aggregation of all of the Parent Common Stock issuable
to such holder at the Effective Time, shall be entitled to a fractional share of Parent Common
Stock, but instead, any such fractional shares shall be treated as set forth in Section 1.8(c).

     2.2 Exchange of Certificates and Instruments for Closing Payment.

          (a) Exchange Procedures.

               (i) Within a reasonable period of time prior to the Closing, Parent will deliver to the
Company forms of the transmittal materials which Parent or its transfer agent will reasonably
require from those Participating Rights Holders entitled to receive at the Closing a portion of the
Closing Payment in respect of their shares of Company Common Stock or Company Preferred Stock, or
in respect of their Company Options or Company Warrants, which materials may include any
certifications Parent may request with respect to compliance with any withholding obligations of
Parent or the Surviving Corporation under the Code. The Company will distribute such materials to
eligible Participating Rights Holders. As promptly as practicable following the Effective Time,
Parent will deliver to each Participating Rights Holder who has completed such transmittal
materials and returned them to Parent at or prior to the Closing, together with the certificate or
certificates representing outstanding shares of Company Common Stock or Company Preferred Stock
(the “Certificates”) or certificates or instruments representing outstanding Company
Options or Company Warrants (“Derivative Instruments”) or a signed affidavit in a form
reasonably acceptable to Parent that such Certificate or Derivative Instrument has been lost
(“Affidavits”), (A) a check (or, at Parent’s election, a wire transfer to the extent that
the aggregate amount owed to any such holder at the Closing is in excess of $5,000,000)
representing that portion of the Closing Payment to which such Participating Rights Holder is
entitled that Parent has elected to satisfy in cash; provided, that such payment made by
Parent by check may be made

-13-

 

by delivering such checks on the Closing Date to the Stockholder Representative Committee,
which, in turn, shall distribute such checks to the appropriate Participating Rights Holders, or
(B) a certificate representing any shares of Parent Common Stock issued in respect of such Company
Common Stock, Company Preferred Stock, Company Options or Company Warrants. The delivery of such
checks (or wire transfers, as applicable) and certificates by Parent to the Stockholder
Representative Committee shall be deemed, for all purposes, to have satisfied in full Parent’s
Closing Payment obligations to such Participating Rights Holders and Parent shall have no further
obligation for such payments. Parent shall not be required to pay any amount of the Closing
Payment or any Contingent Payment to any Participating Rights Holder until receipt from such
Participating Rights Holder of properly completed and executed transmittal materials in the form
prepared by Parent and the applicable Certificate, Derivative Instruments or Affidavits.

               (ii) As promptly as practicable after the Effective Time, Parent or its transfer agent will
send to each Participating Rights Holder who does not submit completed transmittal materials to
Parent at or before the Closing, as permitted by Section 2.2(a)(i) above, transmittal materials for
use in exchanging his, her or its Certificates or Derivative Instruments for the applicable portion
of the Closing Payment into which such shares of Company Common Stock or Company Preferred Stock
(other than any Dissenting Shares) or Company Options or Company Warrants, have been converted.
Until surrendered or delivery of an Affidavit as contemplated by this Section 2.2, each Certificate
or Derivative Instrument shall be deemed at any time after the Effective Time to represent only the
right to receive upon such surrender the applicable amounts of Merger Consideration payable
pursuant to Section 2.1. Upon receipt of the completed transmittal materials and the applicable
Certificates, Derivative Instruments or Affidavits, Parent will issue to the Participating Rights
Holder a certificate representing shares of Parent Common Stock or deliver to the Participating
Rights Holder a check (or, at Parent’s election, a wire transfer, to the extent that the aggregate
amount owed to such Participating Rights Holder as of the Closing is in excess of $5,000,000)
representing that portion of the Closing Payment to which such Participating Rights Holder is
entitled that Parent has elected to satisfy in cash.

               (iii) Parent shall be entitled to rely entirely on the information contained in the
Capitalization and Fee Certificate and any transmittal materials delivered hereunder for purposes
of satisfying Parent’s obligation to deliver the Closing Payment and any Contingent Payment
hereunder.

          (b) No Further Rights in Certificates or Derivative Instruments. After the Effective
Time, holders of Company Common Stock, Company Preferred Stock, Company Options or Company Warrants
outstanding immediately prior to the Effective Time will cease to be, and will have no rights as,
stockholders or rightholders of the Company or the Surviving Corporation, other than (i) in the
case of Company Common Stock and Company Preferred Stock (other than Dissenting Shares), and
Company Options and Company Warrants, the rights to receive the applicable portions of the Merger
Consideration to be issued at Closing and of the Contingent Payments; (ii) in the case of
Dissenting Shares, the rights afforded to the holders thereof under California Law, and (iii)
rights under this Agreement and the Escrow Agreement.

          (c) No Liability. Neither Parent, the Surviving Corporation nor the Company shall be
liable to any holder of Company Common Stock, Company Preferred Stock, Company Options or Company
Warrants for any portion of the Merger Consideration delivered to an appropriate public official
pursuant to any abandoned property, escheat or similar law.

          (d) Withholding Rights. Each of the Surviving Corporation, Parent and Escrow Agent
shall be entitled to deduct and withhold from the consideration otherwise payable pursuant to this
Agreement (including, without limitation, the Deposit) to any holder of Company Common Stock,
Company Preferred Stock, Company Options or Company Warrants such amounts as it is required to
deduct and withhold with respect to the making of such payment under the Code, or any provision of
state, local or foreign Tax law, regardless of the form of consideration that Parent elects to
issue in

-14-

 

accordance with Section 1.8. To the extent that amounts are so withheld by the Surviving
Corporation, Parent or Escrow Agent, as the case may be, such withheld amounts shall be treated for
all purposes of this Agreement as having been paid to such holder in respect of which such
deduction and withholding was made by the Surviving Corporation, Parent or Escrow Agent, as the
case may be.

     2.3 Stock Transfer Books. At the Effective Time, the stock transfer books of the
Company shall be closed and there shall be no further registration of transfers of Company Common
Stock or Company Preferred Stock thereafter on the records of the Company. From and after the
Effective Time, the holders of certificates representing such shares outstanding immediately prior
to the Effective Time shall cease to have any rights with respect to such shares except as
otherwise provided herein or by any applicable laws.

     2.4 Dissenting Shares.

          (a) Notwithstanding any provision of this Agreement to the contrary, Dissenting Shares shall
not be converted into or represent the right to receive any portion of the amounts to be paid
pursuant to Section 2.1, but the holders thereof shall only be entitled to such rights as are
granted by California Law. All Dissenting Shares held by stockholders who shall have failed to
perfect or who effectively shall have withdrawn or lost their dissenters’ rights shall thereupon be
deemed to have been converted into and to have become exchangeable for, as of the later of the
Effective Time or the occurrence of such event, the right to receive an appropriate portion of the
amounts to be paid pursuant to Section 2.1, without any interest thereon, upon surrender, in the
manner provided in Section 2.2, of the Certificates that formerly evidenced such shares.

          (b) The Company shall give Parent (i) prompt notice of any demands for fair value of shares of
Company Common Stock or Company Preferred Stock received by the Company, withdrawals of such
demands, and any other instruments served pursuant to California Law, if any, and received by the
Company, and (ii) the opportunity to direct, at its expense, all negotiations and proceedings with
respect to demands for fair value under California Law, if any. The Company shall not, except with
the prior written consent of Parent, make any payment with respect to any demands for the fair
value of shares of Company Common Stock or Company Preferred Stock or settle or offer to settle any
such demands other than by operation of law or pursuant to a final order of a court of competent
jurisdiction.

     2.5 Stockholder Representative Committee.

          (i) Appointment of Stockholder Representative Committee. Each of Robert Stockman,
Gordon Nye and Brian Dovey are hereby appointed, effective from and after the Effective Time of the
Merger, to act as the Stockholder Representative Committee under this Agreement in accordance with
the terms of this Section 2.5 and the Escrow Agreement. The members of the Stockholder
Representative Committee shall designate (and notify Parent of such designation) a single member of
the Stockholder Representative Committee as its designated representative (the “Designated
Representative”), who shall have full power and authority to take all actions on behalf of the
Stockholder Representative Committee and upon whose instruction Parent and the Surviving
Corporation shall be entitled to rely, without any investigation or inquiry, as having been taken
or not taken upon the authority of the Stockholder Representative Committee. Robert Stockman shall
initially be the Designated Representative. The Designated Representative may be changed from time
to time by the written consent of the then existing member or members of the Stockholder
Representative Committee. In the event that one (1) or two (2) members of the Stockholder
Representative Committee cease to be members as a result of death, resignation, incapacity or
removal, then the remaining member(s) of the Stockholder Representative Committee shall appoint the
successor member(s) as soon as practicable. In the event that there are no members of the
Stockholder Representative Committee at any time from and after the Effective Time as a result of
death, resignation, incapacity or removal, then Robert Schultz and Katrina Thompson shall be
automatically deemed to be appointed as successor members of the Stockholder

-15-

 

Representative Committee and Parent shall be entitled to rely, without any investigation or
inquiry, on the instruction of such individuals.

          (b) Authority After the Effective Time. From and after the Effective Time, the
Stockholder Representative Committee shall be authorized to:

               (i) take all actions required by, and exercise all rights granted to, the Stockholder
Representative Committee in this Agreement or the Escrow Agreement;

               (ii) receive all notices or other documents given or to be given to the Stockholder
Representative Committee by Parent pursuant to this Agreement or the Escrow Agreement;

               (iii) negotiate, undertake, compromise, defend, resolve and settle any suit, proceeding or
dispute under this Agreement or the Escrow Agreement;

               (iv) execute and deliver all agreements, certificates and documents required or deemed
appropriate by the Stockholder Representative Committee in connection with any of the transactions
contemplated by this Agreement (including executing and delivering the Escrow Agreement);

               (v) engage special counsel, accountants and other advisors and incur such other expenses in
connection with any of the transactions contemplated by this Agreement or the Escrow Agreement;

               (vi) apply the Committee Reimbursement Amount to the payment of (or reimbursement of the
Stockholder Representative Committee for) expenses and liabilities which the Stockholder
Representative Committee may incur pursuant to this Section 2.5;

               (vii) approve of and execute amendments to this Agreement in accordance with Section 10.12;
and

               (viii) take such other action as the Stockholder Representative Committee may deem
appropriate, including:

                    (A) agreeing to any modification or amendment of this Agreement or the Escrow Agreement and
executing and delivering an agreement of such modification or amendment;

                    (B) taking any actions required or permitted under the Escrow Agreement; and

                    (C) all such other matters as the Stockholder Representative Committee may deem necessary or
appropriate to carry out the intents and purposes of this Agreement and the Escrow Agreement.

          (c) Reimbursement of Expenses. The members of the Stockholder Representative
Committee shall be entitled to receive reimbursement from any Committee Reimbursement Amounts
retained on behalf of the Stockholder Representative Committee and then, immediately prior to its
distribution to the Participating Rights Holders, against the consideration held pursuant to the
Escrow Agreement, for any and all expenses, charges and liabilities, including reasonable
attorneys’ fees, incurred by the Stockholder Representative Committee in the performance or
discharge of its rights and obligations under this Agreement (the “SRC Expenses”). The
Committee Reimbursement Amount shall only be used for the payment of the SRC Expenses or as
otherwise required by this Agreement.

          (d) Release from Liability; Indemnification; Authority of Stockholder Representative
Committee. Each Participating Rights Holder hereby releases the Stockholder Representative
Committee, and each of its members, from, and each Participating Rights Holder agrees to indemnify
the Stockholder Representative Committee, and each of its members, against, liability for any
action taken or not taken by him, her or it in his, her or its capacity as such agent, except for
the liability of the Stockholder

-16-

 

Representative Committee, or any member thereof, to a Participating Rights Holder for loss
which such holder may suffer from the willful misconduct or gross negligence of the Stockholder
Representative Committee or such member in carrying out his, her or its duties hereunder. By
virtue of the adoption of this Agreement and the approval of the Merger by the stockholders of the
Company, each Participating Rights Holder (regardless of whether or not such Participating Rights
Holder votes in favor of the adoption of the Agreement and the approval of the Merger, whether at a
meeting or by written consent in lieu thereof) appoints, as of the date of this Agreement, the
Stockholder Representative Committee as his, her or its true and lawful agent and attorney-in-fact
to enter into any agreement in connection with the transactions contemplated by this Agreement, to
exercise all or any of the powers, authority and discretion conferred on him, her or it under any
such agreement, to give and receive notices on their behalf and to be his, her or its exclusive
representative with respect to any matter, suit, claim, action or proceeding arising with respect
to any transaction contemplated by any such agreement, including, without limitation, the defense,
settlement or compromise of any claim, action or proceeding for which Parent or the Surviving
Corporation may be entitled to indemnification and, by virtue of its approval of the Agreement, the
Stockholder Representative Committee agrees to act as, and to undertake the duties and
responsibilities of, such agent and attorney-in-fact. This power of attorney is coupled with an
interest and is irrevocable. All actions, decisions and instructions of the Stockholder
Representative Committee shall be conclusive and binding upon all of the Participating Rights
Holders.

          (e) Reduction of Contingent Payments to Replenish Committee Reimbursement Amount and
Escrowed Funds. The Stockholder Representative Committee, upon written notice delivered to
Parent no less than twenty (20) business days prior to the making of any Contingent Payment, shall
be entitled to cause Parent to deduct amounts from that portion of such Contingent Payment payable
to Participating Rights Holders with respect to their shares of Company Common Stock, Company
Options and Company Warrants exercisable for Company Common Stock that is not subject to reduction
in accordance with Sections 1.9(h), 2.1(a), 2.1(c), 2.1(d) and 9.4 for purposes of (i) replenishing
the Committee Reimbursement Amount hereunder (which Committee Reimbursement Amount may be increased
from time to time in the discretion of the Stockholder Representative Committee, but not above
$100,000 at any one time), or (ii) reimbursing the members of the Stockholder Representative
Committee for the amount of any SRC Expenses previously paid by the Stockholder Representative
Committee and not discharged out of the Committee Reimbursement Amount or any consideration held
pursuant to the Escrow Agreement. In addition, (x) to the extent that, at the time Parent is
required to make any Contingent Payment, the Committee Reimbursement Amount then maintained by the
Stockholder Representative Committee is less than $100,000, the Stockholder Representative
Committee shall be required to instruct the Parent to deduct such amounts from such Contingent
Payments as may be required to maintain $100,000 in the Committee Reimbursement Amount at all
times, and (y) in the event that the amount of any fees payable by the Stockholder Representative
Committee to the Escrow Agent in accordance with the terms of the Escrow Agreement have been
deducted from the consideration held pursuant to the Escrow Agreement in accordance therewith, the
Stockholder Representative Committee shall be required to instruct Parent to deduct such amounts
from such Contingent Payments and to redeposit such amounts with the Escrow Agent as Escrowed Funds
under the Escrow Agreement. Any reduction from the consideration held pursuant to the Escrow
Agreement or any offset against any Contingent Payment shall be made against the amounts to be
distributed to the Participating Rights Holders pro rata based on the aggregate amounts of such
escrowed consideration or Contingent Payment otherwise to be received by such Participating Rights
Holders. In connection with any such offsets by Parent pursuant to this Section 2.5(e), the
Stockholder Representative Committee hereby releases Parent from, and agrees to indemnify Parent
against, liability for any action taken by Parent at the direction of the Stockholder
Representative Committee in accordance with this Section 2.5(e). Any of the Committee
Reimbursement Amount originally deposited with the Stockholder Representative Committee pursuant to
this Section 2.5(e) that has not been consumed by the Stockholder Representative Committee pursuant
to the terms of this Agreement on or prior to the end of the period in which Parent, the Surviving

-17-

 

Corporation and their Affiliates may make claims for indemnification pursuant to Section 9.2
or, if later, the date on which all indemnification claims of Parent, the Surviving Corporation or
any of their Affiliates outstanding at the end of such period have been discharged in full, shall
be distributed by the Stockholder Representative Committee to the Participating Rights Holders pro
rata based on their respective rights to participate in the Contingent Payments, if any, from which
such amounts were originally deducted.

ARTICLE 3

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

     The Company hereby represents and warrants to Parent as follows as of each of (a) the date
hereof and (b) the Closing Date, except as specifically contemplated by this Agreement;
provided, that the representations and warranties made as of the date hereof shall be
qualified by the Company Disclosure Schedule, and the representations and warranties as of the
Closing Date shall be qualified by the Updated Company Disclosure Schedule delivered by the Company
most recently prior to the delivery of the Merger Election Notice by Parent, and the references
below to the Company Disclosure Schedule shall be deemed, for purposes of determining the accuracy
of such representations and warranties as of the Closing Date, to be references to such Updated
Company Disclosure Schedule. Except as may be specifically set forth herein, each representation
and warranty contained in this Article 3 shall be deemed to be made as of each date on which
representations and warranties are deemed to be made in accordance with this paragraph.
Notwithstanding any other provision of this Agreement or such Company Disclosure Schedule, each
exception set forth in the Company Disclosure Schedule or any Updated Company Disclosure Schedule
will be deemed to qualify only each representation and warranty set forth in this Agreement (i)
that is specifically identified (by cross-reference or otherwise) in the Company Disclosure
Schedule or such Updated Company Disclosure Schedule as being qualified by such exception, or (ii)
with respect to which the relevance of such exception is readily apparent on the face of the
disclosure of such exception set forth in the Company Disclosure Schedule or such Updated Company
Disclosure Schedule.

     3.1 Organization, Good Standing and Qualification. The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of California and has
all requisite corporate power and authority to carry on its business as now conducted. The Company
is duly qualified or licensed to transact business and is in good standing in each jurisdiction in
which the failure to so qualify would have a Material Adverse Effect. The Company has all
requisite corporate power and authority to own and operate its properties and assets, to execute
and deliver this Agreement and the Related Agreements to which it is a party, to issue the
Purchased Shares and the Conversion Shares, and to perform its obligations under, and carry out the
provisions of, this Agreement and the Related Agreements, and to carry on its business as presently
conducted and as presently contemplated to be conducted.

     3.2 Capitalization and Voting Rights.

          (a) The authorized capital of the Company consists of (except as otherwise disclosed in the
Company Disclosure Schedule):

               (i) Preferred Stock. 10,276,918 shares of Company Preferred Stock, of which 1,814,558
shares have been designated Series A Preferred Stock, 833,333 shares have been designated Series B
Preferred Stock, 558,374 shares have been designated Series C Preferred Stock, 819,673 shares have
been designated Series D Preferred Stock, 2,550,980 shares have been designated Series E Preferred
Stock, 1,000,000 shares have been designated Series F Preferred Stock, 2,100,000 shares have been
designated Series G-1 Preferred Stock and 600,000 shares have been designated Series G-2 Preferred
Stock. The respective rights, restrictions, privileges and preferences of the Company Preferred
Stock are as stated in the form of the Restated Articles.

-18-

 

               (ii) Common Stock. 20,000,000 shares of Common Stock and 130,000 shares of Non-Voting
Common Stock.

          (b) The number of shares of each series of Company Preferred Stock and of Company Common Stock
issued and outstanding is set forth on Section 3.2(b) of the Company Disclosure Schedule.

          (c) Except as set forth in Section 3.2(c) of the Company Disclosure Schedule or as expressly
contemplated by this Agreement and the Related Agreements, there are not outstanding any options,
warrants, instruments, rights (including conversion or preemptive rights and rights of first
refusal), proxy or stockholder agreements, or other agreements or instruments of any kind,
including convertible debt instruments, for the purchase or acquisition from the Company of any of
its Securities. The Company is not a party or subject to any agreement or understanding and, to
the Company’s knowledge, there is no agreement or understanding between any other persons, that
affects or relates to the voting or giving of written consents with respect to any security or by a
director of the Company. The Company Stockholders collectively currently own, beneficially and of
record, a sufficient number of shares of each class of the Securities outstanding on the date
hereof required to approve the transactions contemplated by this Agreement and the Related
Agreements, including the Merger.

          (d) All of the issued and outstanding shares of the Company Common Stock and Company Preferred
Stock (i) have been duly authorized and validly issued and are fully paid and nonassessable, and
(ii) were issued in compliance with all applicable state and federal laws concerning the issuance
of securities.

          (e) Each series of Company Preferred Stock is presently convertible into Company Common Stock
on a one-for-one basis and the consummation of the transactions contemplated hereunder (including
the issuance of the Purchased Shares and the Conversion Shares) will not result in any
anti-dilution adjustment or other similar adjustment to the outstanding shares of Company Preferred
Stock. The Purchased Shares and the Conversion Shares have been duly and validly reserved for
issuance. When issued in compliance with the provisions of the Securities Purchase Agreement and
the Restated Articles, the Purchased Shares and the Conversion Shares will be validly issued, fully
paid and nonassessable, and will be free of any liens or encumbrances.

          (f) Section 3.2(f) of the Company Disclosure Schedule sets forth the name and address of each
Securityholder and the Securities owned beneficially and of record by each Securityholder, and, in
the case of options, warrants, instruments and other rights to acquire capital stock of the
Company, (i) the per-share exercise price payable therefor, (ii) the number of shares of the
Company’s capital stock each option, warrant, instrument or other right is vested or exercisable
for as of the Agreement Date or the Closing Date, as applicable, (iii) whether the holder of such
option, warrant, instrument or other right is an employee of the Company, (iv) whether the vesting
of such option, warrant, instrument or other right shall be accelerated by a change of control of
the Company, including as a result of the Merger, and (v) whether or not any such options,
warrants, instruments or other rights are intended to be “incentive stock options” as such term is
defined in the Code.

     3.3 Subsidiaries. The Company does not presently own or control, directly or
indirectly, any interest in any other corporation, association, partnership, limited liability
company or other business entity. The Company is not a participant in any joint venture or similar
arrangement.

     3.4 Authorization; Binding Obligations; Governmental Consents.

          (a) All corporate action on the part of the Company, its officers, directors and stockholders
necessary for the authorization, execution and delivery of this Agreement and the Related
Agreements to which it is a party, the performance of all obligations of the Company hereunder and
thereunder, including the authorization, issuance (or reservation for issuance) and delivery of the
Purchased Shares and the Conversion Shares pursuant thereto in accordance with the terms thereof,
have

-19-

 

been taken prior to the Agreement Date, except for the Initial Stockholder Approval. This
Agreement and the Related Agreements to which it is a party will be valid and legally binding
obligations of the Company, enforceable against the Company in accordance with their respective
terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and
other laws of general application affecting enforcement of creditors’ rights, and (ii) as limited
by laws relating to the availability of specific performance, injunctive relief, or other equitable
remedies. The issuances of the Purchased Shares and the Conversion Shares are not and will not be
subject to any preemptive rights or rights of first refusal that have not been properly waived or
complied with.

          (b) No consent, approval, permit, order or authorization of, or registration, qualification,
designation, declaration or filing with, any federal, state or local governmental authority or any
other person on the part of the Company is required in connection with the execution and delivery
of this Agreement or the Related Agreements to which it is a party and the consummation of the
transactions contemplated hereby or thereby, except (i) the filing of merger documents with the
California Secretary of State; and (ii) such filings as may be required under the HSR Act or any
applicable state or foreign anti-takeover and similar laws.

     3.5 Financial Statements.

          (a) The Company has made available to Parent, and included in the Company Disclosure Schedule
are, the Financial Statements. The Financial Statements are complete and correct in all material
respects and have been prepared in accordance with GAAP applied on a basis consistent with prior
periods, except that the unaudited financial statements do not contain footnotes. The Financial
Statements fairly present the financial condition of the Company on a consolidated basis as of the
dates and during the periods indicated therein, subject, in the case of the unaudited financial
statements, to normal year-end audit adjustments which are neither individually nor in the
aggregate material in amount. The Company maintains and will continue to maintain a standard
system of accounting established and administered in accordance with GAAP applied on a basis
consistent with prior periods.

          (b) Except for Indebtedness reflected in the Financial Statements or Indebtedness (other than
Indebtedness for borrowed money) incurred in the ordinary course of business and not individually
or in the aggregate in excess of $250,000, the Company Disclosure Schedule, the Company has no
Indebtedness outstanding. The Company is not in default with respect to any outstanding
Indebtedness or any instrument relating thereto, nor, to the Company’s knowledge, is there any
event which, with the passage of time or giving of notice, or both, would result in a default, and
no such Indebtedness or any instrument or agreement relating thereto purports to limit the issuance
of any Securities by the Company or the operation of the business of the Company. Complete and
correct copies of all instruments (including all amendments, supplements, waivers and consents)
relating to any Indebtedness of the Company have been furnished to Parent or counsel to Parent.

     3.6 Liabilities. The Company and its Subsidiaries have no material liabilities and
the Company knows of no material contingent liabilities required to be disclosed in the Financial
Statements that are not so disclosed, except current liabilities incurred in the ordinary course of
business consistent with past practice subsequent to the date of the Financial Statements.

     3.7 Offering Valid. Subject in part to the truth and accuracy of Parent’s
representations in this Agreement and in the Securities Purchase Agreement, the offer, sale and
issuance of the Purchased Shares and the Conversion Shares, as contemplated by the Securities
Purchase Agreement, will be exempt from the registration requirements of the Securities Act and
will have been registered or qualified (or exempt from registration and qualification) under the
registration, permit or qualification requirements of all applicable state securities laws, and
neither the Company nor any authorized agent acting on its behalf will take any action hereafter
that would cause the loss of such exemption.

-20-

 

     3.8 Litigation. There is no action, suit, proceeding or investigation pending or, to
the knowledge of the Company, currently threatened against the Company and its Subsidiaries or any
of its officers or directors. The foregoing includes, without limitation, actions, suits,
proceedings or investigations pending or, to the knowledge of the Company, threatened involving the
prior employment of any of the Company’s employees, their use in connection with the Company’s
business of any information or techniques allegedly proprietary to any of their former employers,
or their obligations under any agreements with prior employers. The Company and its Subsidiaries
are not a party or subject to the provisions of any order, writ, injunction, judgment or decree of
any court or government agency or instrumentality. There is no action, suit, proceeding or
investigation by the Company or any of its Subsidiaries currently pending or that the Company or
any of its Subsidiaries intends to initiate.

     3.9 Intellectual Property.

          (a) Section 3.9(a) of the Company Disclosure Schedule sets forth a complete and accurate list
of (i) all Intellectual Property owned, licensed or used by the Company or any of its Subsidiaries,
all applications therefor, and all licenses, assignments and other agreements relating thereto to
which the Company is a party, and (ii) all written agreements relating to technology, know-how and
processes which the Company or any of its Subsidiaries has licensed or authorized for use by
others.

          (b) The operation of the business of the Company and its Subsidiaries as currently conducted
or as currently contemplated by the Company and its Subsidiaries to be conducted does not interfere
with, conflict with, infringe upon, misappropriate or otherwise violate the Intellectual Property
rights of any third party, and no action or claim is pending or, to the knowledge of the Company,
threatened alleging that the operation of such business interferes with, conflicts with, infringes
upon, misappropriates or otherwise violates the Intellectual Property rights of any third party.

          (c) The Company has the full right, title and interest in and to, or has a valid license or
other legal right under, the Company Owned Intellectual Property and the Company Licensed
Intellectual Property used in or necessary to the operation of its business as presently conducted
or as currently contemplated by the Company to be conducted, subject to the terms of the license
agreements governing the Company Licensed Intellectual Property.

          (d) Except as set forth in Section 3.9(d) of the Company Disclosure Schedule, there are no
outstanding options, licenses, or agreements of any kind relating to the Company Owned Intellectual
Property, nor is the Company or any of its Subsidiaries bound by or a party to any options,
licenses or agreements of any kind with respect to the Intellectual Property of any other person
(other than generally available off the shelf software and other standard products).

          (e) The Company has no present knowledge from which it should reasonably conclude that the
Company Owned Intellectual Property and any Intellectual Property licensed to the Company under the
Company Licensed Intellectual Property, are invalid or unenforceable, and the same have not been
adjudged invalid or unenforceable in whole or in part. The Company Owned Intellectual Property and
the Company Licensed Intellectual Property constitute all of the Intellectual Property necessary
for the operation of the business of the Company and its Subsidiaries as currently conducted or as
currently contemplated by the Company to be conducted. The Company has complied with all of its
obligations of confidentiality in respect of the claimed trade secrets or proprietary information
of others and knows of no violation of such obligations of confidentiality as are owed to it.

          (f) No claims or actions have been asserted, are pending or, to the knowledge of the Company,
threatened against the Company or any of its Subsidiaries (i) based upon or challenging or seeking
to deny or restrict the ownership by or license rights of the Company or any of its Subsidiaries of
any of the Company Owned Intellectual Property or Company Licensed Intellectual Property, (ii)
alleging that any services provided by, processes used by, or products manufactured or sold by the
Company or any of its Subsidiaries infringe or misappropriate any Intellectual Property right of
any third party, or (iii)

-21-

 

alleging that the Company Licensed Intellectual Property is being licensed or sublicensed in
conflict with the terms of any license or other agreement, and, to the knowledge of the Company,
there is no basis for such a claim.

          (g) To the knowledge of the Company and without conducting any specific investigation, no
person is engaging in any activity that infringes or misappropriates the Company Owned Intellectual
Property or Company Licensed Intellectual Property. Except as set forth in Section 3.9(g) of the
Company Disclosure Schedule, neither the Company nor any of its Subsidiaries has granted any
license or other right to any third party with respect to the Company Owned Intellectual Property
or Company Licensed Intellectual Property. The execution, delivery and performance of this
Agreement and the consummation of the transactions contemplated by this Agreement by the Company
will not breach, violate or conflict with any instrument or agreement concerning the Company Owned
Intellectual Property, will not cause the forfeiture or termination or give rise to a right of
forfeiture or termination of any of the Company Owned Intellectual Property or materially impair
the right of Surviving Corporation to license or dispose of, or to bring any action for the
infringement of, any material Company Owned Intellectual Property.

          (h) The Company has delivered or made available to Parent or counsel to Parent correct and
complete copies of all the licenses of the Company Licensed Intellectual Property, other than
licenses of commercial off-the-shelf computer software or other generally available standard
products. With respect to each such license:

               (i) such license is valid and binding and in full force and effect and represents the entire
agreement between the respective licensor and licensee with respect to the subject matter of such
license;

               (ii) such license will not cease to be valid and binding and in full force and effect on terms
identical in all material respects to those currently in effect as a result of the consummation of
the transactions contemplated by this Agreement, nor will the consummation of the transactions
contemplated by this Agreement constitute a material breach or default under such license or
otherwise so as to give the licensor or any other person a right to terminate such license;

               (iii) neither the Company nor any of its Subsidiaries has (A) received any notice of
termination or cancellation under such license, (B) received any notice of breach or default under
such license, which breach has not been cured, or (C) granted to any other third party any rights,
adverse or otherwise, under such license that would constitute a material breach of such license;
and

               (iv) neither the Company nor, to the knowledge of the Company, any other party to such license
(including any Subsidiaries of the Company) is in material breach or default thereof, and, to the
knowledge of the Company, no event has occurred that, with notice or lapse of time, would
constitute such a material breach or default or permit termination, modification or acceleration
under such license.

          (i) Except as set forth in Section 3.9(i) of the Company Disclosure Schedule, neither the
Company nor any of its Subsidiaries is aware that any of its respective employees, officers,
directors, agents or consultants (i) has breached or violated confidentiality restrictions in favor
of any third person the breach or violation of which could subject the Company or any of its
Subsidiaries to any material liability, or (ii) is obligated, to the Company’s knowledge, under any
contract (including licenses, covenants or commitments of any nature) or other agreement, or
subject to any judgment, decree or order of any court or administrative agency, that would
interfere with their duties to the Company or any of its Subsidiaries, as applicable, or that would
conflict with the Company’s or any of its Subsidiaries’ business as presently conducted. Each
employee and officer of and consultant to the Company and any of the Subsidiaries of the Company
has executed a proprietary information and inventions agreement, a confidentiality agreement, or a
mutual confidentiality agreement in the form of Exhibits D-1, D-2, or
D-3

-22-

 

attached hereto. No current or former employee or officer of or consultant to the Company or
any of its Subsidiaries has excluded works or inventions made prior to his or her employment or
relationship with the Company or any of its Subsidiaries from his or her assignment of inventions
pursuant to such employee’s, officer’s or consultant’s proprietary information and inventions
agreement.

          (j) Each of the Company and each of its Subsidiaries has taken reasonable steps in accordance
with normal industry practice to maintain the confidentiality of its trade secrets and other
confidential Company Owned Intellectual Property. To the knowledge of the Company, (i) there has
been no misappropriation of any material trade secrets or other material confidential Company Owned
Intellectual Property by any person; (ii) no employee, independent contractor or agent of the
Company or any of its Subsidiaries has misappropriated any trade secrets of any other person in the
course of such performance as an employee, independent contractor or agent; and (iii) no employee,
independent contractor or agent of the Company or any of its Subsidiaries is in material default or
breach of any term of any employment agreement, non-disclosure agreement, assignment of invention
agreement or similar agreement or contract relating in any way to the protection, ownership,
development, use or transfer of Company Owned Intellectual Property.

          (k) Neither the execution nor delivery of this Agreement or any of the Related Agreements, nor
the carrying on of the Company’s or any of its Subsidiaries’ business by the employees of and
consultants to the Company or any of its Subsidiaries, as the case may be, nor the conduct of the
Company’s or any of its Subsidiaries’ business as presently conducted or as currently proposed by
the Company to be conducted, will, to the knowledge of the Company, conflict with or result in a
breach of the terms, conditions or provisions of, or constitute a default under, any contract,
covenant or instrument under which any of such employees is now obligated. Except to the extent
already assigned to the Company or any of its Subsidiaries, neither the Company nor any of its
Subsidiaries believes that it is or will be necessary to utilize any inventions or proprietary
information of any of its respective employees (or people it currently intends to hire) made prior
to their employment by the Company or any of its Subsidiaries, as the case may be.

     3.10 Compliance with Other Instruments. Neither the Company nor any of its
Subsidiaries are in violation or default of any provision of its Articles of Incorporation or
bylaws, or of any material mortgage, indenture, contract, agreement, instrument, judgment, order,
writ or decree to which it is a party or by which it is bound or, to the Company’s knowledge, of
any provision of any federal or state statute, rule or regulation applicable to the Company or any
of its Subsidiaries. The execution, delivery and performance of this Agreement and the Related
Agreements to which the Company is a party, and the issuance of the Purchased Shares and the
Conversion Shares, will not result in any such violation or be in conflict with or constitute, with
or without the passage of time or giving of notice, a default under any such provision, instrument,
judgment, order, writ or decree, or result in the creation of any material mortgage, pledge, lien,
charge or encumbrance upon any of the properties or assets of the Company or any of its
Subsidiaries or the suspension, revocation, impairment, forfeiture, or nonrenewal of any material
permit, license, authorization or approval applicable to the business, operations or any of the
assets or properties of the Company or any of its Subsidiaries.

     3.11 Agreements; Actions.

          (a) Except as set forth in Section 3.11(a) of the Company Disclosure Schedule, there are no
agreements, understandings or proposed transactions between the Company and any of its officers,
directors, Affiliates, or any Affiliate thereof, or between any Subsidiary of the Company and any
of its officers, directors or Affiliates.

          (b) Section 3.11(b) of the Company Disclosure Schedule sets forth all agreements,
understandings, instruments, contracts, judgments, orders, writs or decrees to which the Company or
any of its Subsidiaries is a party or by which it is bound that involve (i) obligations (contingent
or otherwise) of, or payments to, the Company or any of its Subsidiaries in excess of $100,000,
(ii) the license,

-23-

 

assignment or transfer of any patent, copyright, trade secret or other proprietary right to or
from the Company or any of its Subsidiaries (other than licenses to the Company arising from the
purchase of generally available “off the shelf” or other standard products), (iii) the manufacture,
marketing, sale or distribution of any products of the Company or any of its Subsidiaries in any
jurisdiction, or any restrictions on the Company’s or any of its Subsidiaries’ exclusive rights to
develop, manufacture, assemble, distribute, market and sell its products, (iv) indemnification by
the Company or any of its Subsidiaries with respect to infringements of proprietary rights (other
than indemnification obligations arising from purchase, sale or license agreements entered into in
the ordinary course of business), or (v) any supply agreements.

          (c) The Company has delivered or has caused to be delivered to Parent or counsel to Parent
correct and complete copies of each contract, agreement or other arrangement listed in Section 3.11
of the Company Disclosure Schedule, as such contracts, agreements and arrangements are amended to
date. Each such contract, agreement or other arrangement is a valid, binding and enforceable
obligation of the Company or any of its Subsidiaries, as applicable, and, to the knowledge of the
Company, of the other party or parties thereto, and is in full force and effect. Except as set
forth in Section 3.11(c) of the Company Disclosure Schedule, neither the Company nor any of its
Subsidiaries nor, to the knowledge of the Company, the other party or parties thereto, is in breach
or non-compliance, or, to the knowledge of the Company, is considered to be in breach or
non-compliance by the other party thereto, of any term of any such contract, agreement or other
arrangement. Except as set forth in Section 3.11(c) of the Company Disclosure Schedule, neither
the Company nor any of its Subsidiaries has received notice of any default or threat thereof with
respect to any such contract, agreement or other arrangement. Subject to obtaining any necessary
consents by the other party or parties to any such contract, agreement or other arrangement (as
further set forth in Section 3.11(c) of the Company Disclosure Schedule), no contract, agreement or
other arrangement listed in Section 3.11 of the Company Disclosure Schedule includes or
incorporates any provision the effect of which would be to enlarge or accelerate any obligations of
the Company or any of its Subsidiaries or give additional rights to any other party thereto or will
in any other way be adversely affected by, or terminate or lapse by reason of, the transactions
contemplated by this Agreement or the Related Agreements.

          (d) Neither the Company nor any of its Subsidiaries has (i) declared or paid any dividends or
authorized or made any distribution upon or with respect to any class or series of its capital
stock, (ii) incurred any Indebtedness for money borrowed or any other liabilities individually in
excess of $100,000 or, in the case of Indebtedness or liabilities individually less than $100,000,
in excess of $250,000 in the aggregate, (iii) made any loans or advances to any person, other than
ordinary advances for travel expenses or loans not in excess of $100,000 in the aggregate made and
repaid in full prior to January 1, 2003, or (iv) sold, exchanged or otherwise disposed of any of
its assets or rights, other than the sale of its inventory in the ordinary course of business other
than such sales that in the aggregate have a value of less than $100,000.

          (e) For the purposes of Section 3.11(b), all liabilities, agreements, understandings,
instruments, contracts and proposed transactions involving the same person (including persons the
Company or any of its Subsidiaries has reason to believe are affiliated therewith) shall be
aggregated for the purpose of meeting the individual minimum dollar amounts of such subsections.

     3.12 Related-Party Transactions. No employee, officer, or director of or consultant
to the Company or any of its Subsidiaries, as the case may be, or member of his or her immediate
family is indebted to the Company or any of its Subsidiaries, nor is the Company or any of its
Subsidiaries indebted (or committed to make loans or extend or guarantee credit) to any of them
other than (a) for payment of salary or fees (in the case of consultants) for services rendered,
(b) reimbursement for reasonable expenses incurred on behalf of the Company or any of its
Subsidiaries, and (c) for other standard employee benefits made generally available to all
employees (including stock option agreements outstanding under any stock option plan approved by
the Company Board or the board of directors of any

-24-

 

of the Company’s Subsidiaries, as the case may be). To the knowledge of the Company, none of
such persons has any direct or indirect ownership interest in any firm or corporation with which
the Company or any of its Subsidiaries is affiliated or with which the Company or any of its
Subsidiaries has a business relationship, or any firm or corporation that competes with the Company
or any of its Subsidiaries, except that employees, officers or directors of the Company or any of
its Subsidiaries and members of their immediate families may own stock in publicly-traded companies
that may compete with the Company or any of its Subsidiaries. To the knowledge of the Company, no
member of the immediate family of any officer or director of the Company is directly or indirectly
interested in any material contract with the Company. To the knowledge of the Company, no member
of the immediate family of any officer or director of any Subsidiary of the Company is directly or
indirectly interested in any material contract with such Subsidiary. Except as may be disclosed in
the Financial Statements, neither the Company nor any of its Subsidiaries is a guarantor or
indemnitor of any Indebtedness of any other person.

     3.13 Changes. Except as reflected in the Financial Statements provided to Parent,
since the end of the latest completed fiscal year of the Company, there has not been:

          (a) Any change in the assets, liabilities, financial condition or operating results of the
Company or any of its Subsidiaries from that reflected in the Financial Statements, other than
changes in the ordinary course of business consistent with past practice, none of which
individually or in the aggregate has had or could reasonably be expected to have a Material Adverse
Effect;

          (b) Any resignation or termination of any key officers or employees of the Company or any of
its Subsidiaries;

          (c) Any material change, except in the ordinary course of business consistent with past
practice, in the contingent obligations of the Company or any of its Subsidiaries by way of
guaranty, endorsement, indemnity, warranty or otherwise;

          (d) Any damage, destruction or loss, whether or not covered by insurance, which has had or
could reasonably be expected to have a Material Adverse Effect;

          (e) Any waiver by the Company or any of its Subsidiaries of a material right or of a material
debt owed to it;

          (f) Any direct or indirect loans made by the Company to any stockholder, employee, officer or
director of the Company, or a Subsidiary of the Company to any stockholder, employee, officer or
director of such Subsidiary, other than advances made in the ordinary course of business consistent
with past practice;

          (g) Any material change in any compensation arrangement or agreement with any employee,
officer, director or stockholder of the Company or any of its Subsidiaries, other than in the
ordinary course of business consistent with past practices;

          (h) Any declaration or payment of any dividend or other distribution of the assets of the
Company or any of its Subsidiaries;

          (i) Any labor organization activity;

          (j) Any Indebtedness, obligation or liability incurred, assumed or guaranteed by the Company
or any of its Subsidiaries, except those for immaterial amounts and for current liabilities
incurred in the ordinary course of business consistent with past practice;

          (k) Any sale, assignment, transfer or license of any patents, trademarks, copyrights, trade
secrets or other intangible assets of the Company or any of its Subsidiaries, except for (i)
licenses to use such Intellectual Property granted in connection with the commercial use of the
Company’s products by end-users (but which do not grant rights to manufacture, sell or distribute
products using such Intellectual Property to such persons), (ii) rights to manufacture products
using such Intellectual Property

-25-

 

granted to contract manufacturing partners pursuant to agreements that are terminable upon no
more than ninety (90) days’ notice without penalty and do not grant the other party the right to
market, distribute or sell products including such Intellectual Property and (iii) non-commercial
site licenses granted to clinical investigators who are evaluating the Company products in clinical
trials, which licenses terminate at the conclusion of such trials;

          (l) Any change in any material agreement to which the Company or any of its Subsidiaries is a
party or by which it is bound which has had or should reasonably be expected to have a Material
Adverse Effect; or

          (m) Any other event or condition of any character that, either individually or cumulatively,
has had or could reasonably be expected to have a Material Adverse Effect.

     3.14 Compliance with Laws; Permits. Neither the Company nor any of its Subsidiaries
is in violation of any applicable statute, rule, regulation, order, judgment, decree, writ or
restriction of any domestic or foreign government or any instrumentality or agency thereof in
respect of the conduct of its business or the ownership of its properties which has had or could
reasonably be expected to have a Material Adverse Effect. The Company and each of its Subsidiaries
has all franchises, permits, licenses and any similar authority (the “Permits”) necessary
for the conduct of its business as now being conducted by it. No suspension or cancellation of any
of the Permits is pending or, to the knowledge of the Company, threatened.

     3.15 Environmental, Zoning and Safety Laws. Except as set forth in Section 3.15 of
the Company Disclosure Schedule, (a) neither the activities carried on by the Company or any of its
Subsidiaries at the facilities, offices or properties leased by the Company or any of its
Subsidiaries, as the case may be, nor, to the knowledge of the Company, such facilities, offices or
properties, are in material violation of any Environmental Laws, or any other zoning, health or
safety law or regulation; (b) neither the Company nor any of its Subsidiaries nor, to the knowledge
of the Company, any operator of its past or present properties, is or has been in violation, or
alleged violation, of, or has any liability or threatened liability under, any Environmental Laws;
(c) to the knowledge of the Company, none of the properties currently or formerly owned, leased or
operated by the Company or any of its Subsidiaries (including, without limitation, soils and
surface and ground waters) are contaminated with any Hazardous Substance; (d) neither the Company
nor any of its Subsidiaries is actually, potentially or allegedly liable for any off-site
contamination by Hazardous Substances; (e) to the knowledge of the Company, neither the Company nor
any of its Subsidiaries is actually, potentially or allegedly liable under any Environmental Law
(including, without limitation, pending or threatened liens); (f) the Company and each of its
Subsidiaries has all Environmental Permits necessary for the conduct of its business as now being
conducted by it; (g) the Company and each of its Subsidiaries has always been and is in compliance
with its Environmental Permits; and (h) neither the execution of this Agreement nor the
consummation of the transactions contemplated hereby will require any investigation, remediation or
other action with respect to Hazardous Substances, or any notice to or consent of Governmental
Authorities or third parties, pursuant to any applicable Environmental Law or Environmental Permit.

     3.16 Manufacturing and Marketing Rights. Neither the Company nor any of its
Subsidiaries has granted rights to manufacture, produce, assemble, license, market, or sell its
products to any other person and is not bound by any agreement that affects the Company’s, or any
of its Subsidiaries’, exclusive right to develop, manufacture, assemble, distribute, market or sell
its products.

     3.17 Disclosure. The Company has provided Parent or counsel to Parent with all the
information that Parent has requested for deciding whether to purchase the Purchased Shares and to
execute this Agreement and the Related Agreements. Neither this Agreement (including all the
exhibits and schedules hereto), the Related Agreements, nor any other statements or certificates
made or delivered in connection herewith or therewith, contains any untrue statement of a material
fact or omits to state a material fact relating to the Company necessary to make the statements
herein or therein not misleading in

-26-

 

light of the circumstances under which they were made. Except as set forth in this Agreement,
to the knowledge of the Company, there is no material fact relating to the Company that the Company
or any of its Subsidiaries, as the case may be, has not disclosed to Parent or counsel to Parent
and of which any of its officers, directors or executive employees is aware that could reasonably
be expected to result in a Material Adverse Effect on the Company.

     3.18 Registration or First Offer Rights. Except as set forth in Section 3.18 of the
Company Disclosure Schedule, neither the Company nor any of its Subsidiaries has granted or agreed
to grant any registration rights, including piggyback rights, or any right of first offer to any
person.

     3.19 Insurance. The Company and each of its Subsidiaries has in full force and effect
fire and casualty insurance policies, with coverages, and in the good faith belief of the Company,
sufficient in amount (subject to reasonable deductibles) to allow the Company or such Subsidiary to
replace in full any of its properties that might be damaged or destroyed. The Company and each of
its Subsidiaries has in full force and effect products liability and errors and omissions insurance
in amounts customary for companies similarly situated. Neither the Company nor any of the
Company’s Subsidiaries is in default with respect to its obligations under any insurance policy
maintained by it, and neither the Company nor any of the Company’s Subsidiaries has been denied
insurance coverage.

     3.20 Employee Benefit Plans.

          (a) Identification of Plans. Except as disclosed in Section 3.20(a) of the Company
Disclosure Schedule, neither the Company nor any of its Subsidiaries currently maintains or
contributes to, or has any outstanding liability to or in respect of or obligation under, any
pension, profit-sharing, deferred compensation, bonus, stock option, employment, share appreciation
right, severance, group or individual health, dental, medical, life insurance, survivor benefit, or
similar plan, policy, arrangement or agreement, whether formal or informal, written or oral, for
the benefit of any current or former director, officer or employee of or consultant to the Company
or any of its Subsidiaries, as applicable. Each of the arrangements set forth in Section 3.20(a)
of the Company Disclosure Schedule is herein referred to as an “Employee Benefit Plan”,
except that any such arrangement which is a multi-employer plan shall be treated as an Employee
Benefit Plan only for purposes of Sections 3.20(d)(ii) and (vi) and 3.20(g) below.

          (b) Delivery of Documents. The Company has heretofore delivered to Parent or counsel
to Parent true, correct and complete copies of each Employee Benefit Plan and, with respect to each
such Employee Benefit Plan, true, correct and complete copies of (i) any associated trust,
custodial, insurance or service agreements, (ii) any annual report, actuarial report, or disclosure
materials (including specifically any summary plan descriptions) submitted to any governmental
agency or distributed to participants or beneficiaries thereunder in the current or any of the
three (3) preceding calendar years, and (iii) the most recently received IRS determination letters,
if any, and any governmental advisory opinions, rulings, compliance statements, closing agreements
or similar materials specific to such Employee Benefit Plan.

          (c) Compliance with Terms and Law. Each Employee Benefit Plan is and has heretofore
been maintained and operated in material compliance with the terms of such Employee Benefit Plan
and in material compliance with the requirements prescribed (whether as a matter of substantive law
or as necessary to secure favorable tax treatment) by any and all applicable statutes, governmental
or court orders, or governmental rules or regulations in effect from time to time, including ERISA
and the Code, and applicable to such Employee Benefit Plan. Each Employee Benefit Plan which is
intended to qualify under Section 401(a) of the Code and each trust or other entity intended to
qualify as a “voluntary employee benefit association” within the meaning of Section 501(c)(9) of
the Code and associated with any Employee Benefit Plan is expressly identified as such in Section
3.20(c) of the Company Disclosure Schedule and has been determined to be so qualified by the IRS,
may rely on an opinion letter issued by the IRS with respect to a standardized prototype plan
adopted in accordance with the requirements for such reliance, or has time remaining for
application to the IRS for a determination of the qualified status

-27-

 

of such Employee Benefit Plan and, to the knowledge of the Company, nothing has occurred as to
each which has resulted or is likely to result in the revocation or denial of such determination or
which, to the knowledge of the Company, would not reasonably be expected to be resolved without
such revocation or denial under the compliance resolution programs of the IRS to preserve such
qualification.

          (d) Absence of Certain Events and Arrangements. Except as set forth in Section
3.20(d) of the Company Disclosure Schedule:

               (i) there is no pending or, to the knowledge of the Company, threatened legal action,
proceeding or investigation, other than routine claims for benefits, concerning any Employee
Benefit Plan or, to the knowledge of the Company, any fiduciary or service provider thereof;

               (ii) no liability (contingent or otherwise) to the PBGC or any multi-employer plan has been
incurred by the Company or any of its Affiliates or Subsidiaries (other than insurance premiums
satisfied in due course);

               (iii) no reportable event, or event or condition which presents a material risk of termination
by the PBGC, has occurred with respect to any Employee Benefit Plan, or any retirement plan of an
Affiliate or Subsidiary of the Company, which is subject to Title IV of ERISA;

               (iv) no Employee Benefit Plan nor any party in interest with respect thereof has, to the
knowledge of the Company, engaged in a prohibited transaction which could subject the Company or
any of its Subsidiaries directly or indirectly to material liability under Section 409 or 502(i) of
ERISA or Section 4975 of the Code;

               (v) no Employee Benefit Plan provides welfare benefits subsequent to termination of employment
to employees or their beneficiaries except to the extent required by applicable state laws and
Title I, Part 6 of ERISA;

               (vi) neither the Company nor any of its Subsidiaries has announced its intention to modify or
terminate any Employee Benefit Plan or adopt any arrangement or program which, once established,
would come within the definition of an Employee Benefit Plan, except for amendments required by
law; and

               (vii) neither the Company nor any of its Subsidiaries has undertaken to maintain any Employee
Benefit Plan for any stated period of time and each such Employee Benefit Plan is terminable at the
sole discretion of the sponsor thereof, subject only to such constraints as may be imposed by
applicable law.

          (e) Funding of Certain Plans. With respect to each Employee Benefit Plan for which a
separate fund of assets is or is required to be maintained, full and timely payment has been made
of all amounts required of the Company or any of its Subsidiaries, as the case may be, under the
terms of each such Employee Benefit Plan or applicable law, as applied through the Closing Date,
the consummation of the Merger or a short-form merger, and no accumulated funding deficiency (as
defined in Section 302 of ERISA and Section 412 of the Code), whether or not waived, exists with
respect to any such Employee Benefit Plan. The current value of the assets of each such Employee
Benefit Plan, as of the end of the most recently ended plan year of that Employee Benefit Plan
subject to Article IV of ERISA, equals or exceeds the current value of all benefits liabilities
under that Employee Benefit Plan.

          (f) Effect of Transactions. The execution of this Agreement and the consummation of
the transactions contemplated by this Agreement and the Related Agreements, including upon delivery
of the Merger Election Notice, the Merger, will not, by themselves or in combination in any other
event (regardless of whether that other event has or will occur), result in any payment (whether of
severance pay or otherwise) becoming due from or under any Employee Benefit Plan (including any
employment agreement) to any current or former director, officer or employee of or consultant to
the Company or any of its Subsidiaries or result in the vesting, acceleration of payment or
increases in the amount of any

-28-

 

benefit payable to or in respect of any such current or former director, officer or employee
of or consultant to the Company.

          (g) Multi-employer Plans. No Employee Benefit Plan is a multi-employer plan.

          (h) Definitions. For purposes of this Section, “multi-employer plan”, “party in
interest”, “current value”, “reportable event” and “benefit liability” have the same meaning
assigned such terms under Sections 3, 4043(b) or 4001(a) of ERISA, and “affiliate” means any entity
which under Section 414 of the Code is treated as a single employer with the Company, determined,
however, without regard to this Agreement or the Securities Purchase Agreement.

     3.21 FDA and Regulatory Matters.

          (a) With respect to the Contingent Payment Products and, to the extent applicable, any other
products currently under development by the Company (collectively, the “Products”), (i) (A)
the Company and each of its Subsidiaries has obtained all necessary and applicable approvals,
clearances, authorizations, licenses and registrations required by United States or foreign
governments or government agencies, to permit the design, development, pre-clinical and clinical
testing, manufacture, labeling, sale, distribution and promotion of its Products in jurisdictions
where it currently conducts such activities (the “Activities to Date”) with respect to each
Product (collectively, the “Company Licenses”); (B) the Company and each of its
Subsidiaries, as the case may be, is in compliance in all material respects with all terms and
conditions of each Company License and with all applicable laws pertaining to the Activities to
Date with respect to each Product which is not required to be the subject of a Company License; (C)
the Company and each of its Subsidiaries, as the case may be, is in compliance with all applicable
laws regarding registration, license and/or certification for each site at which a Product is
manufactured or labeled, or from which a Product is sold or distributed by the Company or its
Subsidiaries; and (D) to the extent that any Product has been exported from the United States, the
Company or, as applicable, a Subsidiary of the Company exporting such Product, has exported such
Product in compliance in all material respects with applicable law; (ii) all manufacturing
operations performed by or on behalf of the Company or its Subsidiaries have been and are being
conducted in all material respects in compliance with the Quality Systems Regulations of the FDA
and, to the extent applicable to the Company or any of its Subsidiaries, in all material respects
with counterpart regulations in the European Union and all other countries where compliance is
required; (iii) all non-clinical laboratory studies of Products under development, sponsored by the
Company or any of its Subsidiaries and intended to be used to support regulatory clearance or
approval, have been and are being conducted in compliance in all material respects with the FDA’s
Good Laboratory Practice for Non-Clinical Studies regulations (21 CFR Part 58) in the United States
and, to the extent applicable to the Company or any of its Subsidiaries, counterpart regulations in
the European Union and all other countries; and (iv) the Company and each of its Subsidiaries is in
compliance with all applicable reporting requirements for all Company Licenses or plant
registrations described in clause (i) above, including, but not limited to, applicable adverse
event reporting requirements in the United States and outside of the United States under applicable
law.

          (b) The Company and each of its Subsidiaries is in compliance with all FDA and non-United
States equivalent agencies and similar state and local laws applicable to the maintenance,
compilation and filing of reports, including medical device reports, with regard to the Products.
Section 3.21(b) of the Company Disclosure Schedule sets forth a list of all adverse event reports
related to the Products, including any Medical Device Reports (as defined in 21 CFR 803). Set
forth on Section 3.21(b) of the Company Disclosure Schedule are complaint review and analysis
reports of the Company and each of its Subsidiaries through the date hereof, including information
regarding complaints by product and root cause analysis of closed complaints, which reports are
correct in all material respects.

          (c) Neither the Company nor any of its Subsidiaries has received any written notice or other
written communication from the FDA or any other Governmental Authority (i) contesting the

-29-

 

pre-market clearance or approval of, the uses of or the labeling and promotion of any of the
Products, or (ii) otherwise alleging any material violation of any laws by the Company or any of
its Subsidiaries.

          (d) There have been no recalls, field notifications or seizures ordered or adverse regulatory
actions taken (or, to the knowledge of the Company, threatened) by the FDA or any other
Governmental Authority with respect to any of the Products, including any facilities where any such
Products are produced, processed, packaged or stored and neither the Company nor any of its
Subsidiaries has within the last three (3) years, either voluntarily or at the request of any
Governmental Authority, initiated or participated in a recall of any Product or provided post-sale
warnings regarding any Product.

          (e) The Company and each of its Subsidiaries have conducted all of their clinical trials with
reasonable care and in accordance with all applicable laws and the stated protocols for such
clinical trials.

          (f) All filings with and submissions to the FDA and any corollary entity in any other
jurisdiction made by the Company or any of its Subsidiaries with regard to the Products, whether
oral, written or electronically delivered, were true, accurate and complete as of the date made,
and, to the extent required to be updated, as so updated remain true, accurate and complete in all
material respects as of the date hereof, and do not materially misstate any of the statements or
information included therein, or omit to state a material fact necessary to make the statements
therein not misleading.

     3.22 Brokers; Expenses. No finder, broker, agent or other similar intermediary has
acted for or on behalf of the Company or its stockholders in connection with the negotiation of
this Agreement or the Related Agreements or the consummation of the transactions contemplated
hereby or thereby.

     3.23 Taxes.

          (a) Filing of Tax Returns and Payment of Taxes. The Company has timely filed all Tax
Returns required to be filed by it, each such Tax Return has been prepared in compliance with all
applicable laws and regulations, and all such Tax Returns are true, accurate and complete in all
respects. All Taxes that have become due and payable by the Company have been timely paid, and the
Company is not and will not be liable for any additional Taxes in respect of any Taxable period or
any portion thereof ending on or before the date of the unaudited consolidated financial statements
forming part of the Financial Statements included in the Company Disclosure Schedule in an amount
that exceeds the corresponding reserve therefor separately identified in Section 3.23(a) of the
Company Disclosure Schedule, if any, as reflected in such Financial Statements, and any Taxes of
the Company arising after such date and at or before the Effective Time have been or will be
incurred in the ordinary course of the Company’s business. The Company has delivered to Parent or
counsel to Parent true, correct and complete copies of all Tax Returns with respect to income Taxes
filed by or with respect to it with respect to Taxable periods ended on or after December 31, 2000
(the “Delivered Tax Returns”), and has delivered or made available to Parent or counsel to Parent
all relevant documents and information with respect thereto, including without limitation work
papers, records, examination reports, and statements of deficiencies proposed, assessed against or
agreed to by the Company.

          (b) Deficiencies. No deficiency or adjustment in respect of Taxes has been proposed,
asserted or assessed by any Taxation Authority against the Company. There are no outstanding
refund claims with respect to any Tax or Tax Return of the Company.

          (c) Liens. There are no liens for Taxes (other than current Taxes not yet due and
payable) on any of the assets of the Company.

          (d) Extensions to Statute of Limitations for Assessment of Taxes. The Company has not
consented to extend the time in which any Tax may be assessed or collected by any Taxation
Authority.

-30-

 

          (e) Extensions of the Time for Filing Tax Returns. The Company has not requested or
been granted an extension of the time for filing any Tax Return that has not yet been filed.

          (f) Pending Proceedings. There is no action, suit, Taxation Authority proceeding, or
audit with respect to any Tax now in progress, pending or, to the knowledge of the Company,
threatened against or with respect to the Company.

          (g) No Failures to File Tax Returns. No claim has ever been made by a Taxation
Authority in a jurisdiction where the Company does not pay Tax or file Tax Returns that the Company
is or may be subject to Taxes assessed by such jurisdiction.

          (h) Tax Attributes, Etc. Set forth in Section 3.23(h) of the Company Disclosure
Schedule are the net operating loss, net capital loss, credit, minimum Tax, charitable
contribution, and other Tax carryforwards (by type of carryforward and expiration date, if any) of
the Company. Except as set forth in Section 3.23(h) of the Company Disclosure Schedule or the
Updated Company Disclosure Schedule none of those carryforwards are presently subject to limitation
under Sections 382, 383, or 384 of the Code, or the federal consolidated return regulations, or any
analogous provision of foreign, state, or local Tax law.

          (i) Elections. All elections with respect to Taxes affecting the Company that were
not made in the Delivered Tax Returns are described in Section 3.23(i) of the Company Disclosure
Schedule.

          (j) Membership in Affiliated Groups, Liability for Taxes of Other Persons, Etc. The
Company has never been a member of any affiliated group of corporations (as defined in Section
1504(a) of the Code) or filed or been included in a combined, consolidated or unitary Tax Return.
The Company is neither a party to nor bound by any Tax sharing or allocation agreement. The
Company is not presently liable, nor does the Company have any potential liability, for the Taxes
of another person (i) under Treasury Regulations Section 1.1502-6 (or comparable provision of
state, local or foreign law), (ii) as transferee or successor, or (iii) by contract or indemnity or
otherwise.

          (k) Adjustments under Section 481. The Company will not be required, as a result of a
change in method of accounting for any period ending on or before or including the Closing Date, to
include any adjustment under Section 481(c) of the Code (or any similar or corresponding provision
or requirement under any other Tax law) in Taxable income for any period ending on or after the
Closing Date. The Company will not be required to include any item of income in Taxable income for
any Taxable period (or portion thereof) ending after the Closing Date as a result of any prepaid
amount received on or prior to the Closing Date.

          (l) Withholding Taxes. The Company has timely withheld and timely paid all Taxes
which are required to have been withheld and paid by it in connection with amounts paid or owing to
any employee, independent contractor, creditor or other person.

          (m) Permanent Establishments and Branches Outside the United States. The Company does
not have a permanent establishment in any country with which the United States of America has a
relevant Tax treaty, as defined in such relevant Tax treaty, and does not otherwise operate or
conduct business through any branch in any country other than the United States.

          (n) U.S. Real Property Holding Corporation. The Company is not and has not been a
United States real property holding corporation within the meaning of Code Section 897(c)(2),
during the applicable period specified in Code Section 897(c)(1)(A)(ii).

          (o) Safe Harbor Lease Property. None of the property owned or used by the Company is
subject to a Tax benefit transfer lease executed in accordance with Section 168(f)(8) of the
Internal Revenue Code of 1954, as amended by the Economic Recovery Tax Act of 1981.

-31-

 

          (p) Tax-Exempt Use Property. None of the property owned by the Company is “tax-exempt
use property” within the meaning of Section 168(h) of the Code.

          (q) Security for Tax-Exempt Obligations. None of the assets of the Company directly
or indirectly secures any Indebtedness, the interest on which is tax-exempt under Section 103(a) of
the Code, and the Company is not directly or indirectly an obligor or a guarantor with respect to
any such Indebtedness.

          (r) Section 341(f) Consent. The Company has not filed any consent agreement under
Section 341(f) of the Code (as in effect prior to its repeal by the Jobs and Growth Tax Relief
Reconciliation Act of 2003) or agreed to have Section 341(f)(2) of the Code (as in effect prior to
such repeal) apply to any disposition of a subsection (f) asset (as defined in Section 341(f)(4) of
the Code, prior to such repeal) owned by the Company.

          (s) Parachute Payments, Etc. The Company has not made any payments, is not obligated
to make any payments, and is not a party to any agreement that under certain circumstances could
obligate it to make any payments, that will not be deductible under Code Sections 162(m) or 280G.

          (t) Rulings. There are no outstanding rulings of, or requests for rulings by, any
Taxation Authority addressed to the Company that are, or if issued would be, binding on the
Company.

          (u) Divisive Transactions. The Company has never been either a “distributing
corporation” or a “controlled corporation” in connection with a distribution of stock qualifying
for tax-free treatment, in whole or in part, pursuant to Section 355 of the Code.

          (v) Section 83(b) Elections. To the Company’s knowledge, all persons who have
purchased shares of the Company’s stock that at the time of such purchase were subject to a
substantial risk of forfeiture under Section 83 of the Code have timely filed elections under
Section 83(b) of the Code and any analogous provisions of applicable state and local Tax laws.

     For purposes of this Section 3.23, references to the Company shall be deemed to include the
Company and all of its Subsidiaries.

     3.24 Minute Book. The minute book of the Company made available to Parent or counsel
to Parent contains minutes of all meetings of directors and stockholders since the time of
incorporation and reflects all transactions referred to in such minutes accurately in all material
respects.

     3.25 Employees. The Company has no collective bargaining agreements with any of its
employees. There is no labor union organizing activity pending or, to the Company’s knowledge,
threatened with respect to the Company or any of its Subsidiaries. To the Company’s knowledge, no
employee of the Company, nor any consultant with whom the Company has contracted, is in violation
of any material term of any employment contract, proprietary information agreement or any other
agreement relating to the right of any such individual to be employed by, or to contract with, the
Company because of the nature of the business to be conducted by the Company; and to the Company’s
knowledge, the continued employment by the Company of its present employees, and the performance of
the Company’s contracts with its independent contractors, will not result in any such violation.
The Company has not received any notice alleging that any such violation has occurred. No employee
of the Company has been granted the right to continued employment by the Company or to any material
compensation following termination of employment with the Company. The Company is not aware that
any officer or key employee, or that any group of key employees, intends to terminate their
employment with the Company, nor does the Company have a present intention to terminate the
employment of any officer, key employee or group of key employees.

     3.26 Obligations of Management. Each officer of the Company and its Subsidiaries is
currently devoting one hundred percent (100%) of his or her business time to the conduct of the
business

-32-

 

of the Company. The Company is not aware of any officer or key employee of the Company
planning to work less than full time at the Company in the future.

     3.27 Title to Properties and Assets; Liens, Etc. The Company has good and marketable
title to all of its properties and assets, including the properties and assets reflected in the
most recent balance sheet included in the Financial Statements, and good title to its leasehold
estates, in each case subject to no mortgage, pledge, lien, lease, encumbrance or charge, other
than (a) those resulting from Taxes which have not yet become delinquent, (b) minor liens and
encumbrances which do not materially detract from the value of the property subject thereto or
materially impair the operations of the Company, and (c) those that have otherwise arisen in the
ordinary course of business. All facilities, machinery, equipment, fixtures, vehicles and other
properties owned, leased or used by the Company are in good operating condition and repair and are
reasonably fit and usable for the purposes for which they are being used. The Company is in
compliance with all material terms of each lease to which it is a party or is otherwise bound.

     3.28 Information Supplied. None of the information supplied or to be supplied by the
Company in writing to Parent or counsel to Parent with the intention that such information be
included or incorporated by reference in any registration statement, permit application or proxy
statement in connection with the issuance of Parent Common Stock pursuant to Section 1.8 at the
time such registration statement or permit application is filed or at the time such proxy statement
is mailed to the stockholders of the Company, will contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary in order to make the
statements therein in light of the circumstances under which they were made not misleading.
Notwithstanding the foregoing, the Company makes no representation, warranty or covenant with
respect to any information supplied or required to be supplied by Parent or which is contained in
or omitted from any of the foregoing documents.

ARTICLE 4

REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

     Parent and Merger Sub, jointly and severally, hereby represent and warrant to the Company as
of the Agreement Date, and as of the Closing Date, as follows, subject in each case to such
exceptions as are specifically contemplated by this Agreement. The representations and warranties
contained in Sections 4.6 through 4.8 are made solely in connection with the possible issuance of
shares of Parent Common Stock in connection with the Merger, shall not be deemed to be made for any
other purpose and shall be of no force or effect if such issuance does not occur or for any other
purpose.

     4.1 Organization, Good Standing and Qualification. Parent is a corporation duly
organized, validly existing and in good standing under the laws of the State of Delaware. Merger
Sub is a corporation duly organized, validly existing and in good standing under the laws of the
State of California. Each of Parent and Merger Sub has all requisite corporate power and authority
to own and operate its properties and assets, to execute and deliver this Agreement and the Related
Agreements to which it is a party, to carry out the provisions of this Agreement and those of the
Related Agreements to which it is party, and to perform its obligations under, and carry out the
provisions of, this Agreement and such Related Agreements, and to carry on its business as
presently conducted and as presently proposed to be conducted. Each of Parent and Merger Sub is
duly qualified to transact business and is in good standing in each jurisdiction where such
qualification is required and in which failure to so qualify would have a Material Adverse Effect
on Parent or Merger Sub, as the case may be.

     4.2 Authorization; Binding Obligations; Governmental Consents.

          (a) All corporate actions on the part of Parent and Merger Sub, and their respective officers,
directors and stockholders necessary for the authorization, execution and delivery of this
Agreement and those of the Related Agreements to which they are respectively parties and the

-33-

 

performance of all obligations of Parent and Merger Sub hereunder and thereunder have been
taken; provided, that as of the Agreement Date, the board of directors of Parent has not
authorized the delivery of a Merger Election Notice or the performance of any of its obligations
that arise after delivery of the Merger Election Notice and the board of directors of Scimed Life
Systems, Inc. has not authorized the execution of the Merger Certificate. This Agreement and the
those of the Related Agreements to which they are parties are the valid and legally binding
obligations of Parent and Merger Sub, enforceable against such parties in accordance with their
respective terms, except as such enforcement may be limited by (i) the effect of bankruptcy,
insolvency, reorganization, receivership, conservatorship, arrangement, moratorium or other laws
affecting or relating to the rights of creditors generally, or (ii) the rules governing the
availability of specific performance, injunctive relief or other equitable remedies and general
principles of equity, regardless of whether considered in a proceeding in law or equity.

          (b) No consent, approval, order or authorization of, or registration, qualification,
designation, declaration or filing with, any federal, state or local governmental authority on the
part of Parent or Merger Sub is required in connection with the consummation by Parent or Merger
Sub of the transactions contemplated by this Agreement and those of the Related Agreements to which
it is party, except for (i) the filing of merger documents with the California Secretary of State;
(ii) such consents, approvals, orders authorizations, registrations declarations and filings as may
be required under applicable state and federal securities laws and the securities laws of any
foreign country in connection with the possible issuance of Parent Common Stock in the Merger;
(iii) such filings as may be required under the HSR Act or any applicable state or foreign
anti-takeover and similar laws in connection with the Merger; and (iv) such other consents,
authorizations, filings, approvals and registrations which, if not obtained or made, would not have
a Material Adverse Effect on Parent or Merger Sub and would not prevent, or materially alter or
delay any of the transactions contemplated by this Agreement.

     4.3 Compliance with Other Instruments. The execution, delivery and performance of
this Agreement and the Related Agreements to which it is party, the issuance of Parent Common Stock
and the performance by Parent and Merger Sub of each such agreement in accordance with their
respective terms will not (a) violate the Certificate of Incorporation (or Articles of
Incorporation, as the case may be) or bylaws of Parent or Merger Sub, (b) breach or result in a
violation of any law, rule or regulation applicable to Parent or Merger Sub or the transactions
contemplated by this Agreement and the Related Agreements, or (c) constitute a material breach of
the terms, conditions, provisions of, or constitute a default under, any judgment, order, writ or
decree of any court or arbitrator to which Parent or Merger Sub is a party or any material
mortgage, indenture, agreement, contract or instrument to which Parent or Merger Sub is a party or
by which either is bound, to the extent that such breach or default could reasonably be expected to
prevent Parent from consummating the transactions contemplated hereby or (d) result in the
suspension, revocation, impairment, forfeiture or nonrenewal of any permit, license, authorization,
or approval applicable to the business, operations or any of the assets or properties of Parent or
Merger Sub, to the extent that such breach or default could reasonably be expected to prevent
Parent from consummating the transactions contemplated hereby.

     4.4 Brokers. Parent and Merger Sub have not incurred, nor will they incur, any
liability for brokerage or finders’ fees or agents’ commissions or investment bankers’ fees or any
similar charges in connection with this Agreement or the consummation of the transactions
contemplated hereby.

     4.5 Litigation. There are no actions, suits, proceedings or investigations pending
or, to the knowledge of Parent, currently threatened against Parent, Merger Sub, or their
respective Affiliates or Subsidiaries, or their respective officers or directors, relating to or
affecting the transactions contemplated by this Agreement and the Related Agreements, to the extent
that any such action, suit, proceeding or investigation could reasonably be expected to prevent
Parent from consummating the transactions contemplated hereby.

-34-

 

     4.6 SEC Filings of Parent. Parent has timely filed with the SEC all filings required
to be filed by it under the Securities Act and the Exchange Act and the rules and regulations
promulgated thereunder since January 1, 2003 (the “SEC Filings”). The SEC Filings (i)
complied in all material respects with the requirements of the Securities Act and the Exchange Act
and the rules and regulations promulgated thereunder at the time they were filed (or if amended or
superseded by a filing or other public disclosure prior to the Agreement Date, then on the date of
such filing or other public disclosure) and (ii) did not as of the time they were filed (or if
amended or superseded by a filing or other public disclosure prior to the Agreement Date, then on
the date of such filing or other public disclosure) contain any untrue statement of material fact
or omit to state a material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they were made, not misleading.

     4.7 Information Supplied. None of the information supplied or to be supplied by
Parent or Merger Sub for inclusion or incorporation by reference in any registration statement,
permit application or proxy statement in connection with the issuance of shares of Parent Common
Stock pursuant to Section 1.8 hereof at the time such registration statement or permit application
is filed or at the time such proxy statement is mailed to the Participating Rights Holders, will
contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary in order to make the statements therein in light of the circumstances
under which they were made not misleading. Notwithstanding the foregoing, Parent makes no
representation, warranty or covenant with respect to any information supplied or required to be
supplied by the Company which is contained in or omitted from any of the foregoing documents.

     4.8 Disclosure. Parent has provided the Company with all the information that the
Company has requested for deciding whether to execute this Agreement and the Related Agreements.
Neither this Agreement (including all the exhibits and schedules hereto), the Related Agreements,
nor any other statements or certificates made or delivered in connection herewith or therewith,
contains any untrue statement of a material fact or omits to state a material fact necessary to
make the statements herein or therein not misleading in light of the circumstances under which they
were made.

     4.9 Available Resources. At the times required, if any, pursuant to this Agreement
and the Related Agreements, Parent shall have sufficient funds, debt borrowing capacity or shares
of authorized and unissued capital stock to satisfy its obligations hereunder and thereunder.

ARTICLE 5

CONDUCT OF BUSINESS PENDING THE MERGER

AND RELATED COVENANTS

     5.1 Conduct of Business of the Company. The Company covenants and agrees that, during
the period beginning on the Agreement Date and ending on the termination or expiration of the
Option Period, unless Parent shall otherwise agree in writing, the business of the Company shall be
conducted only in, and the Company shall not take any action except in, the ordinary course of
business and in a manner consistent with past practice; and the Company shall use commercially
reasonable efforts to preserve intact its business organization, to keep available the services of
the current officers and employees of and consultants to the Company, and to preserve the current
relationships of the Company with customers, suppliers and other persons with which the Company has
significant business relations. Without limiting the foregoing, the Company shall not do, or
propose to do, any of the following prior to the expiration or termination of the Option Period
without providing notice of such to a designated representative of Parent (the “Parent
Representative”) and obtaining the prior written consent of Parent. The Parent Representative
shall use commercially reasonable efforts to respond to such request for written consent within
fifteen (15) business days of Parent’s receipt of the Company’s notice. The Parent Representative
shall initially be Doug Godshall, who shall serve until Parent designates another individual upon
written notice to the Company in accordance with Section 10.1 hereof. Each of the

-35-

 

clauses below shall constitute an independent obligation of the Company, not qualified by any
other such clause, and shall be deemed to be cumulative:

          (a) Charter Documents. Cause or permit any amendments to its Restated Articles or
bylaws to the extent it could reasonably be expected to cause a Parent Impairment,
provided, that, for purposes of this Agreement, the amendment of the Restated Articles to
provide that any series or class of capital stock of the Company does not automatically convert
into shares of Company Common Stock immediately prior to the closing of the Merger shall be deemed
to be a Parent Impairment;

          (b) Dividends; Repurchases; Changes in Capital Stock. Except as otherwise
specifically contemplated in this Agreement, (i) declare or pay any dividends on, or make any other
distributions (whether in cash, stock or property) in respect of, any of its capital stock, (ii)
issue or authorize the issuance of any other securities in respect of, in lieu of or in
substitution for shares of its capital stock, or (iii) repurchase or otherwise acquire, directly or
indirectly, any shares of its capital stock (other than pursuant to repurchase rights of the
Company that permit the Company to repurchase securities from the holders thereof at the original
purchase price therefor in connection with the termination of services of such holder as an
employee of or consultant to the Company);

          (c) Stock Option Plans, Warrants, Etc. Accelerate, except with respect to grants
already outstanding pursuant to the existing terms thereof, amend or change the period of
exercisability or vesting of options or other rights granted under the Company Option Plan,
establish any new or additional stock option plan, amend the Company Option Plan, or grant any
options, warrants or other rights to acquire shares of Company Common Stock or Company Preferred
Stock, other than options granted under the Company Option Plan;

          (d) Material Contracts. Enter into any material contract or commitment, or violate,
amend or otherwise modify or waive (other than in the ordinary course of business) any of the terms
of any agreements, understandings, instruments or contracts which are material to the business of
the Company as currently conducted and as proposed to be conducted other than (i) contracts that
are entered into in the ordinary course of business or (ii) contracts which are terminable by the
Company upon notice of ninety (90) days or less without penalty or surviving obligations. For
purposes of this Section 5.1(d), the parties hereto acknowledge that any such actions with respect
to any contract or commitment, or series of related contracts or commitments, having a value in
excess of $250,000 shall not be deemed to be in the ordinary course of business. Without limiting
the foregoing, in no event shall the Company extend, terminate or otherwise amend or modify any of
the terms of the Rutgers Agreements during the Option Period without the consent of BSC. Any
material contact or commitment entered into, or extended, by the Company during the Option Period
shall explicitly provide that the consummation of the transactions contemplated by this Agreement
shall not result in a breach or violation of such contract or otherwise require the payment of any
fees or expenses in connection therewith, or give the other party the right to accelerate any
obligations of the Company thereunder or to cause the termination of such contract.

          (e) Issuance of Securities. Issue, deliver or sell or authorize or propose the
issuance, delivery or sale of, any shares of its capital stock or securities or other instruments
(including notes or other evidences of Indebtedness) convertible into, or subscriptions, rights,
warrants or options to acquire, or other agreements or commitments of any character obligating it
to issue any such shares or other convertible instruments or securities, other than (A) the
Purchased Shares, (B) the Conversion Shares, (C) shares of Company Common Stock issuable upon
exercise of Company Options that are either outstanding as of the Agreement Date or that are
subsequently issued under the Company Option Plan, (D) shares of Company Common Stock issuable upon
exercise of Company Warrants that are outstanding as of the Agreement Date, (E) Company Options, or
(F) other shares, convertible instruments or securities that will automatically, by their express
terms, terminate or convert into shares of Company Common

-36-

 

Stock immediately prior to the consummation of the Merger and the issuance of which will not
otherwise have a Parent Impairment.

          (f) Intellectual Property.

               (i) Sell, license, assign or transfer any Intellectual Property of the Company to any other
person other than Parent, or encumber any Intellectual Property of the Company, other than (A)
licenses to use such Intellectual Property granted in connection with the commercial use of the
Company’s products by end-users (but which do not grant rights to manufacture, sell or distribute
products using such Intellectual Property to such persons), (B) rights to manufacture products
using such Intellectual Property granted to contract manufacturing partners pursuant to agreements
that are terminable upon no more than ninety (90) days’ notice without penalty and do not grant the
other party the right to market, distribute or sell products including such Intellectual Property
and (C) non-commercial site licenses granted to clinical investigators who are evaluating the
Company products in clinical trials, which licenses terminate at the conclusion of such trials; or

               (ii) License, or otherwise acquire, any Intellectual Property not owned by the Company or
Parent from any third party on terms requiring any royalty payments following, or imposing other
obligations on the Company that may survive, the Option Period;

          (g) Marketing or Other Rights. Except with the consent of Parent, such consent not to
be unreasonably withheld, enter into or amend, in any material respect, any agreement pursuant to
which any other party is granted manufacturing, marketing or other development or distribution
rights of any type or scope with respect to any of the Company’s products or technology other than
agreements that (i) are not inconsistent with the terms of the Supply Agreement, (ii) are
terminable no longer than ninety (90) days from delivery of a Merger Election Notice without
requiring any payment by the Company in excess of $250,000 in the aggregate for all such
agreements, and (iii) would not require any payment upon delivery of a Merger Election Notice or
the consummation of the Merger in excess of $250,000 in the aggregate for all such agreements, or
enter into any agreement that would limit the ability of any of the Surviving Corporation, Parent
or any Affiliate of Parent to operate in a specific area of business or specific geographic area
after the closing of the Merger;

          (h) Dispositions; Upstream Obligations. Except for the sale of the Company’s
inventory in the ordinary course of business, sell, lease, license or otherwise dispose of or
encumber any of its properties or assets which are material, individually or in the aggregate,
taken as a whole, or otherwise incur obligations that would become obligations of Parent upon
Parent’s delivery of the Merger Election Notice (which, for purposes of clarity, shall not be
deemed to include obligations that would become obligations of Surviving Corporation);

          (i) Indebtedness. Incur any Indebtedness (other than to Parent) for borrowed money or
guarantee any such Indebtedness or issue or sell any debt securities or guarantee any debt
securities of others;

          (j) Repayment of Indebtedness. Repay in cash or repurchase for cash any Indebtedness
to any Affiliate of the Company, or any Securities representing Indebtedness convertible into
Company Common Stock or Company Preferred Stock other than repayment of Indebtedness owing to
Parent in accordance with the terms thereof;

          (k) Leases. Enter into any operating lease with an annual commitment in excess of
$100,000 or with a duration of more than four (4) years;

          (l) Insurance. Materially reduce the amount of any material insurance coverage
provided by existing insurance policies;

          (m) Termination or Waiver. Terminate or waive any right that has material value to
the Company, other than in the ordinary course of business;

-37-

 

          (n) Employee Benefit Plans; New Hires; Pay Increases. Adopt or amend any employee
benefit plan or arrangement, pay any special bonuses or special remuneration to any employee or
director (other than pre-existing obligations) which in the aggregate exceed 20% of the Company’s
then-current annual aggregate salary obligation, or, except in the ordinary course of business
consistent with past practices, increase the salaries, bonuses or wage rates of its employees;

          (o) Severance Arrangements. Except as specifically described in Section 3.20 of the
Company Disclosure Schedule attached to this Agreement, adopt or approve any severance, bonus or
benefit acceleration arrangements (whether individually or more broadly) that could be triggered
after the consummation of the Merger;

          (p) Lawsuits. Commence a lawsuit other than (i) for the routine collection of bills,
(ii) in such cases where it in good faith determines that failure to commence suit would result in
the material impairment of a valuable aspect of its business, provided, that it consults
with Parent prior to the filing of such a suit, or (iii) with respect to this Agreement or the
Related Agreements;

          (q) Acquisitions. Acquire or agree to acquire by merging or consolidating with, or by
purchasing a substantial portion of the assets of, or by any other manner, any business or any
corporation, partnership, association or other business organization or division thereof which are
material, individually or in the aggregate, to the Company’s business, taken as a whole;

          (r) Taxes. Make or change any election in respect of Taxes, adopt or request
permission of any Taxation Authority to change any accounting method in respect of Taxes, enter
into any closing agreement in respect of Taxes, settle any claim or assessment in respect of Taxes,
surrender or allow to expire any right to claim a refund of Taxes, consent to any extension or
waiver of the limitation period applicable to any claim or assessment in respect of Taxes, or take
(or permit any Subsidiary to take) any such actions with respect to any Subsidiary;

          (s) Notices. Fail to give any notices and other information required to be given to
the employees of the Company, any collective bargaining unit representing any group of employees of
the Company, or any applicable government authority under the Worker Adjustment and Retraining Act
(the WARN Act), the National Labor Relations Act, the Code, the Consolidated Omnibus Reconciliation
Act (COBRA), or other applicable law in connection with the transactions provided for in this
Agreement or the Related Agreements;

          (t) Other Transactions. Merge or consolidate with any entity other than Parent,
Merger Sub or an Affiliate of Parent, or liquidate, dissolve or effect a recapitalization or
reorganization in any form of transaction;

          (u) Confidentiality Agreements. Hire or retain, or continue to retain or employ, any
employee or consultant having access to confidential or proprietary information of the Company
unless such employee or consultant enters into, or has entered into, a proprietary information and
inventions agreement, a confidentiality agreement, or a mutual confidentiality agreement with the
Company in the form of Exhibits D-1, D-2, or D-3 attached hereto,
or amend or otherwise modify, or grant a waiver under, any such confidentiality or proprietary
information agreement with any such person;

          (v) Related Party Transactions. Enter into any transaction with any director,
officer, employee, significant stockholder or family member of or consultant to any such person,
corporation or other entity of which any such person beneficially owns 10% or more of the equity
interests or has 10% or more of the voting power, or Subsidiary or Affiliate of the Company, except
as approved by a majority of the disinterested directors of the Company Board on terms and
conditions which are fair and reasonable to the Company and no less favorable to the Company as
could be obtained from a third party on an arms-length basis;

-38-

 

          (w) Principal Business. Engage in any business other than the Principal Business;

          (x) Other Activities. Knowingly engage in any other activity which could reasonably
be expected to materially impair the ability of Parent, the Merger Sub or the Company to consummate
the Merger; or

          (y) Subsidiaries. Permit any Subsidiary of the Company to take any action from which
the Company would be prohibited pursuant to this Section.

     5.2 Clinical Trials. From time to time and at the reasonable request of Parent, the
Company shall provide Parent with updates concerning the progress of and developments in and
results of the Company’s clinical trials. In addition, the Company shall (a) invite Parent to
participate in all meetings with clinical investigators, (b) make available to Parent copies of all
written communication provided to and from such investigators, and (c) make available to Parent
copies of any interim data and data analysis generated with respect to its clinical trials. At
least thirty (30) days prior to finalizing such protocols or delivering drafts or copies thereof to
institutional review boards or regulatory authorities, selecting such clinical investigators and
engaging in such clinical trials, the Company shall furnish to Parent for its review and comment
and shall consult with Parent regarding, (i) clinical trial protocols, (ii) lists of clinical
investigators, (iii) copies of all forms of clinical investigator contracts, and (iv) patient data
forms for any of its proposed clinical trials. All information obtained by Parent pursuant to this
Section 5.2 shall be kept confidential in accordance with Section 6.15 of the Securities Purchase
Agreement to the extent it constitutes “Confidential Information” thereunder.

     5.3 FDA Approval Matters.

     (a) The Company shall notify Parent of any material communications with the FDA or any
corollary entity in any other jurisdiction, including outside of the United States of America, or
any other Governmental Authority, whether written or oral, as soon as reasonably practicable, but
in no event later than five (5) business days after the receipt of such communication, and within
such same time period, the Company shall provide Parent with copies of any such written
communications and written summaries of any such oral communications.

     (b) From time to time and at the reasonable request of Parent, the Company shall provide
Parent with updates concerning the progress of the Company’s regulatory filings and strategy for
obtaining necessary regulatory approvals to market and sell the products of the Company. The
Company shall furnish to Parent for its review and comment, and shall consult with Parent
regarding, any material regulatory filing prior to finalizing such filings and delivering them to
the relevant regulatory authorities.

     5.4 Payment of Taxes, Etc. The Company shall, and shall cause each of its
Subsidiaries to, timely file all of its Tax Returns as they become due (taking all timely filed
proper extension requests into account), all such Tax Returns to be true, correct and complete, and
the Company shall, and shall cause each of its Subsidiaries to, timely pay and discharge as they
become due and payable all Taxes (other than Taxes contested in good faith by the Company or its
Subsidiaries in appropriate proceedings), assessments and other governmental charges or levies
imposed upon it or its income or any of its property as well as all claims of any kind (including
claims for labor, materials and supplies) that, if unpaid, may by law become a lien or charge upon
its properties.

     5.5 Board Observation Rights. During the Option Period, the Company shall permit two
(2) representatives of Parent, who shall initially be Doug Godshall and Eric Simso, to attend all
meetings of the Company Board in a nonvoting observer capacity and, in this respect, shall give
such representatives copies of all notices, minutes, consents and other materials that the Company
provides to its directors; provided, however, that the Company shall be entitled to
exclude such representatives from access to any material or meeting or portion thereof to the
extent that the Company reasonably believes (a) that such exclusion is necessary to maintain the
attorney-client privilege with respect to any material fact or advice

-39-

 

or (b) that such material or meeting or portion thereof presents a clear conflict between the
Company and Parent relating to the relationship represented by this Agreement and the Related
Agreements, or otherwise. All information obtained by Parent or such representatives pursuant to
this Section 5.5 shall be kept confidential in accordance with Section 6.15 of the Securities
Purchase Agreement to the extent it constitutes “Confidential Information” thereunder.

ARTICLE 6

ADDITIONAL AGREEMENTS

     6.1 Notices; Consents; Filings. From and after the delivery of a Merger Election
Notice, the Company shall use its best efforts, at the Company’s expense, to obtain the consents
described in Section 3.4(b) of the Company Disclosure Schedule. In the event that the Company
shall fail to obtain any third party consent necessary for the consummation of the transactions
contemplated hereby, the Stockholder Representative Committee shall use commercially reasonable
efforts, and take any such actions reasonably requested by Parent, to minimize any adverse effect
upon the Company, the Surviving Corporation and Parent, their respective Subsidiaries, and their
respective businesses resulting, or which could reasonably be expected to result after the
Effective Time, from the failure to obtain such consent.

     6.2 HSR Act. In the event that Parent, the Company or any stockholder of Parent or
the Company reasonably determines that it is required to make a pre-merger notification filing (an
“Antitrust Filing”) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended (the “HSR Act”), or any corresponding law or regulation of any foreign Governmental
Authority (a “Foreign Antitrust Filing”) with respect to the Merger and the other
transactions contemplated hereby, such party shall promptly notify the other parties of such
requirement and thereafter each of the parties will:

          (a) as promptly as is practicable, make its required filings under the HSR Act or any laws
mandating a Foreign Antitrust Filing;

          (b) as promptly as is practicable after receiving any governmental request under the HSR Act
or any corresponding law or regulation of any foreign Governmental Authority for additional
information, documents, or other materials, use its commercially reasonable best efforts to comply
with such request;

          (c) cooperate with the other in connection with resolving any governmental inquiry or
investigation, whether domestic or foreign, relating to their respective HSR Act filings, Foreign
Antitrust Filings, the Merger or any related inquiry or investigation;

          (d) promptly inform the other of any communication with, and any proposed understanding,
agreement, or undertaking with any governmental entity, whether domestic or foreign, relating to
their respective HSR Act filings, Foreign Antitrust Filings, the Merger or any related inquiry or
investigation;

          (e) to the extent reasonably practicable, give the other reasonable advance notice of, and the
opportunity to participate in (directly or through its representatives), any meeting or conference
with any governmental entity, whether domestic or foreign, relating to their respective HSR Act
filings, Foreign Antitrust Filings, the Merger or any related inquiry or investigation; and

          (f) pay any filing fees required to be paid in connection with such filings, if any, under the
HSR Act or in connection with any Foreign Antitrust Filings.

     6.3 Stockholders Meeting. Subject to the fiduciary duties of the Company Board under
applicable law, in addition to the solicitation of stockholder approval required under Section 6.6,
if requested by Parent in writing (a “Meeting Request”) at any time during the Option
Period, the Company shall (a) cause a meeting of the Company Stockholders (a “Stockholders
Meeting”), to be called for purposes of approving, reapproving or ratifying the Merger and this
Agreement, or (b) circulate a solicitation for written consent in lieu of such Stockholders Meeting
for the same purposes. In the event

-40-

 

that Parent delivers a Meeting Request pursuant to this Section 6.3, the Company shall cause a
Stockholders Meeting to be held on such date as may be reasonably requested by Parent and set forth
in the Meeting Request and is consistent with the Company’s bylaws and applicable law, and shall
distribute on a timely basis to all stockholders of the Company any soliciting materials relating
to such meeting (including a Joint Statement in accordance with Section 6.4 below, and any other
information statement, proxy statement or prospectus prepared by Parent and, to the extent such
information statement or proxy statement relates to the Company or the Merger, reasonably approved
by the Company). Subject to the fiduciary duties of the Company Board under applicable law, any
such information statement, proxy statement or prospectus shall be distributed together with a copy
of the recommendation of the Company Board that the Company Stockholders vote “FOR” the approval
and adoption of the Merger and this Agreement. In the event that Parent circulates a solicitation
for written consent in lieu of such Stockholders Meeting, the Company shall distribute to the
Company Stockholders, together with such written consent, any materials that would have been
required to be distributed to the Company Stockholders in connection with a Stockholders Meeting.

     6.4 Information/Proxy Statement. Subject to the fiduciary duties of the Company Board
under applicable law, if requested by Parent at any time in connection with a Stockholders Meeting,
Parent and the Company shall jointly prepare and furnish to the Company Stockholders a written
proxy/information statement (the “Joint Statement”) which shall (a) solicit on behalf of
the Company Board such Company Stockholders’ written consent to the ratification and approval of
this Agreement and the Merger and (b) constitute a disclosure document for the offer and issuance
of the shares of Parent Common Stock that may be received by the Company Stockholders in the
Merger. Each of the Company and Parent shall use their commercially reasonable best efforts to
cause any Joint Statement to comply with all applicable requirements of federal and state
securities laws, and California Law. Each of Parent and the Company hereby (i) consents to the use
of its name and, on behalf of its Subsidiaries and Affiliates, the names of such Subsidiaries and
Affiliates and to the inclusion of financial statements and business information relating to such
party and its Subsidiaries and Affiliates (in each case, to the extent reasonably required by
applicable federal and state securities laws or as otherwise deemed reasonably appropriate by the
Company or Parent) in any Joint Statement, (ii) agrees to provide promptly to the other such
information concerning it and its respective Affiliates, directors, officers and Securityholders as
may be reasonably required or appropriate for inclusion in any Joint Statement, or in any
amendments or supplements thereto, and (iii) agrees to cause its counsel and auditors to cooperate
with the other’s counsel and auditors in the preparation of any Joint Statement. The Company will
promptly advise Parent, and Parent will promptly advise the Company, in writing if, at any time
prior to the adoption and approval of this Agreement and the Merger by the Company Stockholders in
connection with any Stockholders Meeting, either the Company or Parent shall obtain knowledge of
any facts that might make it necessary or appropriate to amend or supplement any Joint Statement in
order to make the statements contained or incorporated by reference therein not misleading or to
comply with applicable law. Any Joint Statement shall, subject to the fiduciary duties of the
Company Board under applicable law, contain the recommendation of the Company Board that the
Company Stockholders approve and adopt this Agreement and the Merger, and the conclusion of the
Company Board that the terms and conditions of the Merger are fair and reasonable and in the best
interests of the Company and the Company Stockholders, and shall include no other recommendations
or statements of the Company Board that are inconsistent with such purpose.

     6.5 Further Assurances.

          (a) Following the delivery of a Merger Election Notice, each of Parent and the Company will:

               (i) use its commercially reasonable best efforts to take, or cause to be taken, all
appropriate action, and to do, or cause to be done, all things necessary, proper or advisable under
applicable laws and regulations to consummate and make effective the Merger and the transactions

-41-

 

contemplated hereby, including using its commercially reasonable best efforts to obtain all
permits, consents, approvals, authorizations, qualifications and orders of governmental authorities
as are necessary for the consummation of the Merger and the other transactions contemplated hereby
and to fulfill the conditions set forth in Article 7; provided, that Parent shall not be
required by Section 6.2 or this Section 6.5(a) to enter into any consent decree, hold separate
orders or other arrangements that would have such an effect or, in any event, any consent decree,
hold separate order or other arrangements that would require Parent or the Company to dispose of
any existing assets of such party, and in the event that Parent elects to abandon its efforts to
obtain approval under the HSR Act in accordance with the terms of this Section 6.5(a), Parent shall
promptly give notice of such abandonment to the Company. In case, at any time after the Effective
Time, any further action is necessary or desirable to carry out the purposes of this Agreement, the
proper officers and directors of each party to this Agreement shall use their commercially
reasonable best efforts to take all such action; and

               (ii) cooperate and use its commercially reasonable best efforts to vigorously contest and
resist any action, including administrative or judicial action, and to have vacated, lifted,
reversed or overturned any decree, judgment, injunction or other order (whether temporary,
preliminary or permanent) that is in effect and that restricts, prevents or prohibits consummation
of the Merger and the other transactions contemplated hereby, including by vigorously pursuing all
available avenues of administrative and judicial appeal.

          (b) From the Agreement Date until the Effective Time, the Company will take all further action
that is necessary or desirable to carry out the purposes of this Agreement, and the proper officers
and directors of the Company shall use their commercially reasonable best efforts to take all such
action and shall refrain from taking any actions which would be contrary to, inconsistent with or
against, or would frustrate the essential purposes of, the transactions contemplated by this
Agreement, if Parent were to deliver a Merger Election Notice.

     6.6 Stockholder Approval. Following the execution of this Agreement, the Company will
promptly solicit and obtain the approval by written consent of the execution and delivery by the
Company of this Agreement, and the consummation of the transactions contemplated hereby, by Company
Stockholders holding the requisite number of shares of each class of the Company’s capital stock
required to approve the execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby (the “Initial Stockholder Approval”). Such solicitation
shall be in the form of the Information Statement of the Company and Parent attached as
Exhibit E hereto, and distributed to the Company Stockholders no later than October
15, 2004. The Company shall take all other action necessary or advisable to secure the approval,
by vote or written consent, of stockholders required by California Law.

     6.7 Registration Statement. In the event that Parent deems it appropriate or
desirable to file a Registration Statement on Form S-3 or Form S-4 with the SEC in connection with
this Agreement and the Merger, then Parent shall prepare, with the full cooperation and assistance
of the Company, such Registration Statement. Parent and the Company shall each use their
commercially reasonable best efforts to cause the Registration Statement to comply with all
applicable requirements of federal and state securities laws. The Company hereby (a) consents to
the use of its name and, on behalf of its Subsidiaries and Affiliates, the names of such
Subsidiaries and Affiliates, and to the inclusion of financial statements and business information
relating to the Company and its Subsidiaries and Affiliates (in each case, to the extent required
by applicable securities laws) in the Registration Statement, (b) agrees to provide promptly to
Parent such information concerning its business and financial statements and affairs, including
with respect to any securities of Parent the Company, its Subsidiaries and Affiliates may be deemed
to own beneficially, as may reasonably be requested by Parent for inclusion in the Registration
Statement, or in any amendments or supplements thereto, and (c) agrees to cause its counsel and
auditors to cooperate with Parent’s counsel and auditors in the preparation of the Registration
Statement. The Company will promptly advise Parent, and Parent will promptly advise the Company,
in each case in

-42-

 

writing, if at any time prior to the Effective Time either the Company or Parent shall obtain
knowledge of any facts that might make it necessary or appropriate to amend or supplement the
Registration Statement in order to make the statements contained or incorporated by reference
therein not misleading or to comply with applicable law.

     6.8 California Permit. In the event that Parent deems it appropriate to seek a permit
from the California Department of Corporations to issue shares of Parent Common Stock in connection
with the Merger pursuant to Section 25142 (or any successor section) of the California Law (a
“California Permit”), then Parent shall prepare, with the full cooperation and assistance
of Company, an application for the California Permit (the “Permit Application”). Parent
and Company shall each use their commercially reasonable best efforts to cause the Permit
Application to comply with all applicable requirements of federal and state securities laws. Each
of Parent and Company hereby (a) consents to the use of its name and, on behalf of its Subsidiaries
and Affiliates, the names of such Subsidiaries and Affiliates and to the inclusion of financial
statements and business information relating to such party and its Subsidiaries and Affiliates (in
each case, to the extent required by applicable securities laws) in the Permit Application, (b)
agrees to provide promptly to the other such information concerning its business and financial
statements and affairs as, in the reasonable judgment of the providing party or its counsel, may be
required or appropriate for inclusion in the Permit Application, or in any amendments or
supplements thereto, and (c) agrees to use commercially reasonable best efforts to cause its
counsel and auditors to cooperate with the other’s counsel and auditors in the preparation of the
Permit Application. The Company will promptly advise Parent, and Parent will promptly advise the
Company, in writing if at any time prior to the Effective Time either Company or Parent shall
obtain knowledge of any facts that might make it necessary or appropriate to amend or supplement
the Permit Application in order to make the statements contained or incorporated by reference
therein not misleading or to comply with applicable law.

     6.9 Notice of Developments. Parent, on the one hand, and the Company, on the other
hand, shall use reasonable efforts to give prompt written notice to the other party of any material
development causing a breach of any of its own representations and warranties in this Agreement or
the Securities Purchase Agreement.

     6.10 Exclusivity.

          (a) From and after the date of this Agreement until the Effective Time or termination of this
Agreement pursuant to Article 8, the Company will not, nor will it authorize or permit any of its
officers, directors, Affiliates or employees or any investment banker, attorney or other advisor or
representative retained by it to, directly or indirectly, (i) solicit, initiate or induce the
making, submission or announcement of any Acquisition Proposal, (ii) participate in any discussions
or negotiations regarding, or furnish to any person any non-public information with respect to, or
take any other action to facilitate any inquiries or the making of any proposal that constitutes or
may reasonably be expected to lead to, any Acquisition Proposal, (iii) engage in discussions with
any person with respect to any Acquisition Proposal, except as to disclose the existence of these
provisions, (iv) endorse or recommend any Acquisition Proposal, or (v) enter into any letter of
intent or similar document or any contract, agreement or commitment contemplating or otherwise
relating to any Acquisition Proposal; provided, however, that prior to the adoption of this
Agreement by the required Company Stockholder vote, this Section 6.10(a) shall not prohibit the
Company from furnishing nonpublic information regarding the Company and its subsidiaries to,
entering into a confidentiality agreement with or entering into discussions with, any person or
group in response to a Superior Proposal or any offer or proposal that the Company Board reasonably
determines in good faith is reasonably likely to lead to a Superior Proposal submitted by such
person or group (and not withdrawn), or the Company Board from recommending that the Company
Stockholders approve a Superior Proposal if (A) neither the Company nor any representative of the
Company or its subsidiaries shall have violated any of the restrictions set forth in this Section
6.10, including, but not limited to, obligations under clause (i) above, (B) the Company Board

-43-

 

concludes in good faith, after consultation with its outside legal counsel, that such action
is required in order for the Company Board to comply with its fiduciary obligations to the Company
Stockholders under California Law, (C) prior to furnishing any such nonpublic information to, or
entering into discussions with, such person or group, the Company gives Parent written notice of
the identity of such person or group and of the Company’s intention to furnish nonpublic
information to, or enter into discussions with, such person or group and the Company receives from
such person or group an executed confidentiality agreement containing customary limitations on the
use and disclosure of all nonpublic written and oral information furnished to such person or group
by or on behalf of the Company, and (D) contemporaneously with furnishing any such nonpublic
information to such person or group, the Company furnishes such nonpublic information to Parent (to
the extent such nonpublic information has not been previously furnished by the Company to Parent);
provided, further, however, that the Company shall not consummate any
transaction(s) contemplated by any Superior Proposal unless and until the Company has first
terminated this Agreement pursuant to Section 8.1(i) hereof. The Company and its subsidiaries
will, and will cause their respective officers, directors, Affiliates, employees, investment
bankers, attorneys and other advisors and representatives to, immediately cease any and all
existing activities, discussions or negotiations with any parties conducted heretofore with respect
to any Acquisition Proposal. Without limiting the foregoing, it is understood that any violation
of the restrictions set forth in the preceding two sentences by any officer, director or employee
of the Company or any of its subsidiaries or any investment banker, attorney or other advisor or
representative of the Company or any of its subsidiaries shall be deemed to be a breach of this
Section 6.10 by the Company.

          (b) In addition to the obligations of the Company set forth in Section 6.10(a), the Company as
promptly as practicable shall advise Parent in writing of any Acquisition Proposal or of any
request for nonpublic information or other inquiry which the Company reasonably believes could lead
to an Acquisition Proposal, the material terms and conditions of such Acquisition Proposal (to the
extent known), and the identity of the person or group making any such request, inquiry or
Acquisition Proposal. The Company agrees to keep Parent informed on a current basis of the status
and details (including any material amendments or proposed amendments) of any such request, inquiry
or Acquisition Proposal.

     6.11 Access to Properties and Information. At all times until the expiration of the
Option Period, the Company will afford to Parent and its authorized representatives, upon
reasonable notice, reasonable access during normal business hours to all properties, books,
records, contracts and documents of the Company as Parent and such authorized representatives may
reasonably request and a complete opportunity to make such investigations as Parent and such
authorized representatives reasonably request, and the Company will furnish or cause to be
furnished to Parent and its authorized representatives all such information with respect to the
affairs and businesses of the Company as they may reasonably request. All information obtained by
Parent pursuant to this Section 6.11 shall be kept confidential in accordance with Section 6.15 of
the Securities Purchase Agreement to the extent it constitutes “Confidential Information”
thereunder. No investigation pursuant to this Section 6.11 shall affect any representation or
warranty in this Agreement or the Related Agreements of any party hereto or thereto or any
condition to the obligations of the parties hereto or thereto.

     6.12 Public Announcements. Prior to the closing of the Merger, Parent shall not,
without having previously informed the Company about the form, content and timing of any such
announcement, issue any press release or otherwise make any public statements with respect to this
Agreement or the transactions contemplated hereby. Nothing herein express or implied shall require
Parent to consult with the Company following the closing of the Merger. The Company and the
Company Stockholders shall not, without the prior written consent of Parent, issue any press
release or otherwise make any public statements with respect to this Agreement or the transactions
contemplated hereby at any time.

     6.13 Certain Tax Matters. The Company agrees to cooperate with Parent and provide any
factual information reasonably requested by Parent that is reasonably necessary for Parent to
determine the limitations, if any, on the Company’s carryforwards under Sections 382, 383, and 384
of the Code as

-44-

 

of the Agreement Date. In furtherance of the foregoing, and without limiting the generality
of the foregoing, the Company agrees that, within sixty (60) days after the Agreement Date, it will
provide to Parent the following information determined as of the Agreement Date: (i) any
information known to the Company regarding the ownership of the equity of the Company from the time
the Company was formed through the Agreement Date (including any capitalization tables, option
tables or redemption tables known to the Company with respect to the equity of the Company showing
the ownership of Company stock and/or options, the dates any such stock and/or options were issued
or transferred, and the prices and (if applicable) strike prices at which any such stock and/or
options were issued), (ii) any information known to the Company regarding any relationships between
and/or among the holders of stock and/or options in the Company, (iii) any valuation-type
spreadsheets, memoranda, offering documents, board of directors’ resolutions, or similar materials
of the Company that have been prepared by or for the Company in connection with any stock
offerings, option issuances, changes in option pricing or redemptions, if any, and (iv) any written
analysis known to the Company that has been conducted regarding whether there is any limitation on
its carryforwards under the foregoing Code sections. For the avoidance of doubt, the parties
acknowledge that the Company shall not have any obligation to either (A) conduct any appraisals in
connection with this Section 6.13 or (B) conduct any analysis regarding whether there are any
limitations on its carryforwards under the foregoing Code sections.

ARTICLE 7

CONDITIONS TO THE MERGER

     7.1 Conditions to the Obligations of Each Party. The obligations of the Company,
Parent and Merger Sub to consummate the Merger are subject to the satisfaction of each of the
following conditions:

          (a) no order, stay, decree, judgment or injunction shall have been entered, issued or enforced
by any court of competent jurisdiction which prohibits consummation of the Merger, and there shall
not be any action taken by any Governmental Authority, or any statute, rule, regulation or order
enacted, entered, enforced or deemed applicable to the Merger, which makes the consummation of the
Merger illegal or substantially deprives Parent, the Company or the Participating Rights Holders of
any of the anticipated benefits of the Merger or the related transactions, taken as a whole;

          (b) all actions by or in respect of or filings with any Governmental Authority required to
permit the consummation of the Merger in accordance with the terms hereof shall have been obtained
(other than those actions or filings which, if not obtained or made prior to the consummation of
the Merger, would not have a Material Adverse Effect on the Company prior to or after the Effective
Time or a Material Adverse Effect on Parent after the Effective Time or be reasonably likely to
subject the Company, Parent, Merger Sub, or any of their respective Subsidiaries or any of their
respective officers or directors to substantial penalties or criminal liability);

          (c) the Initial Stockholder Approval shall have been obtained; and

          (d) Parent shall have delivered to the Company a Merger Election Notice in accordance with
Section 1.1(b) and such Merger Election Notice shall not have been withdrawn or revoked in any
manner by Parent.

     7.2 Conditions to the Obligations of Parent and Merger Sub. The obligations of Parent
and Merger Sub to consummate the Merger are subject to the satisfaction of the following further
conditions (any one of which may be waived in whole or part by Parent in its sole discretion by
giving written notice to the Company in compliance with Section 10.1 hereof):

          (a) (i) the Company shall have performed all of its material obligations hereunder required to
be performed by it at or prior to the Effective Time; and (ii) Parent shall have received a
certificate signed by an executive officer of the Company to the foregoing effect;

-45-

 

          (b) (i) each of the representations and warranties of the Company contained in this Agreement
shall have been true and correct in all material respects at the time originally made (as qualified
by the Company Disclosure Schedule) and shall be true and correct as of the Effective Time (as
qualified by the Updated Company Disclosure Schedule delivered by the Company most recently prior
to the delivery of the Merger Election Notice by Parent); and (ii) the Company shall deliver to
Parent at the Closing a certificate, dated as of the date of the Closing and signed by the
Company’s President or Chief Executive Officer, certifying to that effect;

          (c) each of the officers or employees of the Company responsible for oversight of the (i)
research and development, (ii) operations, (iii) clinical, and (iv) general management functions of
the Company shall have executed and delivered non-competition agreements with Parent in the form
attached hereto as Exhibit F;

          (d) except in the case of such person’s death or permanent disability, the persons identified
by Parent at the time of delivery of a Merger Election Notice shall have executed and delivered an
employment agreement or a consulting agreement with Parent in form and substance satisfactory to
Parent and such person;

          (e) no Material Adverse Effect with respect to the Company’s business shall have occurred or
been discovered by Parent since the date of delivery of the Merger Election Notice;

          (f) no injunction or other decree shall have been issued by any court of competent
jurisdiction prohibiting the sale of the Contingent Payment Products by the Company or Parent on
the basis of any rights held by a third party (including without limitation any rights of any third
party in any Intellectual Property);

          (g) Heller, Ehrman, White & McAuliffe LLP or other legal counsel to the Company approved by
Parent in its sole discretion will have issued a legal opinion in the form attached hereto as
Exhibit G;

          (h) the Company shall have delivered a properly executed statement, dated as of the Closing
Date, in a form reasonably acceptable to Parent conforming to the requirements of Treasury
Regulations Section 1.1445-2(c)(3);

          (i) the Company shall have delivered to Parent and Merger Sub a certificate that (x)
incorporates by reference the representations and warranties set forth in Section 3.2 and sets
forth the information required to be set forth on Section 3.2 of the Company Disclosure Schedule as
of the Effective Time, (y) sets forth a description of all Stockholder Debt to be outstanding
immediately prior to the Effective Time, including the current holder thereof and the maximum
amount required to discharge such Stockholder Debt in full (including any accrued interest,
prepayment fees or costs, and any increases or multiples of the principal amount thereof), and (y)
sets forth a description of all Merger-Triggered Fees, including the persons to whom they are
payable, and the respective maximum amounts thereof (the “Capitalization and Fee
Certificate”), which Capitalization and Fee Certificate shall be deemed to be a representation
and warranty of the Company hereunder;

          (j) the Company shall have obtained the consent or approval of each person whose consent or
approval shall be required in connection with the Merger under all notes, bonds, mortgages,
indentures, contracts, agreements, leases, licenses, permits, franchises and other instruments or
obligations to which it is a party, other than consents or approvals which, if not obtained, would
not have a Parent Impairment either prior to or following the Closing;

          (k) any and all rights, warrants, options or other instruments or rights to purchase shares of
Company Common Stock or Company Preferred Stock (other than Company Options and Company Warrants,
which shall be converted into the right to receive a portion of the Merger Consideration in
accordance with Section 2.1) outstanding immediately prior to the Closing, whether or

-46-

 

not exercisable, whether or not vested, and whether or not performance based, shall have been
exercised or terminated, and, except for the Stockholder Debt set forth on the Capitalization and
Fee Certificate which shall be paid by Parent at the Closing in accordance with Section 1.5(a), all
outstanding convertible notes shall have been cancelled without repayment or converted into capital
stock of the Company;

          (l) if requested by Parent, the Company shall have held a Stockholders Meeting and the Company
Stockholders shall have approved the entrance by the Company into this Agreement and the
consummation of the transactions contemplated hereby, including the Merger; and

          (m) holders of no more than 5.0% of the aggregate outstanding Company Common Stock and Company
Preferred Stock (calculated on an as-converted to Company Common Stock basis) as of the Effective
Time shall have elected to, or continue to have contingent rights to, exercise dissenters’,
appraisal or similar rights under California Law with respect to such shares.

     7.3 Conditions to the Obligations of the Company. The obligations of the Company to
consummate the Merger are subject to the satisfaction of the following further conditions (any one
of which may be waived in whole or part by the Company):

          (a) (i) Parent and Merger Sub shall have performed all of their respective material
obligations hereunder required to be performed by them at or prior to the Effective Time; and (ii)
the Company shall have received a certificate from each of Parent and Merger Sub, each signed by an
executive officer of Parent or Merger Sub, as appropriate, to the foregoing effect;

          (b) each of the representations and warranties of Parent and Merger Sub contained in this
Agreement shall have been true and correct in all material respects at the time made and shall be
true and correct in all material respects as of the Effective Time with the same force and effect
as if such representations and warranties had been made at and as of the Effective Time, except to
the extent that a breach of any such representation or warranty would not result in Parent being
unable to perform its obligations under this Agreement in all material respects; and

          (c) Bingham McCutchen LLP or other legal counsel to Parent and Merger Sub approved by the
Company in its sole discretion will have issued a legal opinion in the form attached hereto as
Exhibit H.

ARTICLE 8

TERMINATION

     8.1 Termination. This Agreement may be terminated and the Merger may be abandoned at
any time prior to the Effective Time, notwithstanding any requisite approval and adoption of this
Agreement and the transactions contemplated hereby by the Company Stockholders:

          (a) by duly authorized mutual written consent executed by each of Parent, Merger Sub and the
Company;

          (b) by Parent, or by the Company, if the Effective Time shall not have occurred before the
ninety-first (91st) day (the “Termination Date”) after the closing date
specified in a Merger Election Notice; provided, however, that (i) in the event
that (A) one or both of Parent and the Company (or any stockholder thereof) are required or deem it
advisable to make an Antitrust Filing under the HSR Act, or under similar foreign statutes or
regulations, or seek any other governmental approvals or authorizations as may be reasonably
necessary in connection with the closing of the Merger, or the payment of the consideration
required to be paid to the Participating Rights Holders in connection with the Merger, including
any filings or notifications as may be reasonably necessary that are to be made with or to the SEC
or under California Law (including any filings necessary to satisfy any of the conditions set forth
in Section 1.8 hereof), the Termination Date shall be delayed, without further action of the
parties, until the tenth (10th) business day after the date on which any applicable
waiting periods thereunder have expired or been terminated or such other approvals and
authorizations are received, or (B) Parent elects to

-47-

 

cause the Company to hold a Stockholders Meeting (or to circulate a written consent in lieu
thereof) pursuant to Section 6.3 hereof, the Termination Date shall also be delayed, without
further action of the parties, until a date no later than ten (10) business days after such
Stockholders Meeting is held or after the written consent of the holders of Securities representing
not less than that amount of the voting power of the issued and outstanding shares of Company
Common Stock and Company Preferred Stock that would be required at such time to approve this
Agreement, the Related Agreements and the Merger pursuant to California Law and the Company’s
Amended and Restated Articles of Incorporation is obtained, and (ii) the right to terminate this
Agreement under this Section 8.1(b) shall not be available to Parent in the event that the failure
of the Effective Time to occur on or before such date arises out of or is related to Parent’s
failure to fulfill any obligation of Parent under this Agreement and the right to terminate this
Agreement under this Section 8.1(b) shall not be available to the Company in the event that the
failure of the Effective Time to occur on or before such date arises out of or is related to the
failure by the Company to fulfill any obligation of Company under this Agreement or the Related
Agreements;

          (c) automatically if there shall be any law that makes consummation of the Merger illegal or
otherwise prohibited or if any court of competent jurisdiction or Governmental Authority shall have
issued an order, decree, ruling or taken any other action restraining, enjoining or otherwise
prohibiting the Merger and such order, decree, ruling or other action shall have become final and
non-appealable;

          (d) by Parent, by giving written notice to the Company at any time prior to the Closing in the
event that the Company has given Parent any notice pursuant to Section 6.9 above, if the breach or
breaches described in such notice would, individually or in the aggregate, render any condition to
the Merger contained in Sections 7.1 or 7.2 hereof impossible of being satisfied;

          (e) by the Company, after delivery of a Merger Election Notice, by giving written notice to
Parent at any time prior to the Closing in the event that Parent has given the Company any notice
pursuant to Section 6.9 above, if the breach or breaches described in such notice would,
individually or in the aggregate, render any condition to the Merger contained in Sections 7.1 or
7.3 hereof impossible of being satisfied;

          (f) automatically, in the event that Parent delivers notice of abandonment of its efforts
under the HSR Act in accordance with Section 6.5(a);

          (g) by Parent, by giving written notice to the Company at any time prior to the delivery of a
Merger Election Notice to the Company;

          (h) automatically, upon expiration or termination of the Option Period without a Merger
Election Notice having been delivered by Parent;

          (i) by the Company, in the event that the Company Board has received a Superior Proposal prior
to the adoption and approval of this Agreement and the transactions contemplated hereby by the
Company Stockholders and adopts a resolution electing to terminate the Agreement under this Section
8.1(i), provided, that any termination under this Section 8.1(i) shall not be effective until the
Company has made payment of the fee and expenses required by Section 8.3; or

          (j) by the Company, (a) upon the institution by or against Parent of insolvency, receivership
or bankruptcy proceedings or any other proceedings for the settlement of its debts, which
proceedings are not abandoned, dismissed or otherwise terminated within thirty (30) days after the
commencement thereof, (b) upon Parent’s making an assignment for the benefit of creditors, or (c)
upon Parent’s dissolution or ceasing to do business.

     8.2 Effect of Termination.

Except as provided in Section 8.1 hereof, in the event of the termination of this Agreement
pursuant to Section 8.1, this Agreement shall forthwith become void, there shall be no liability
under this Agreement

-48-

 

on the part of Parent, Merger Sub or the Company or any of their respective officers, directors, or
stockholders, and all rights and obligations of any party hereto shall cease, except for
liabilities arising from a breach of this Agreement prior to such termination; provided,
that the provisions of this Article 8 and Articles 9 and 10 shall survive the termination of this
Agreement for any reason.

     8.3 Expenses; Termination Fee.

          (a) If the Company terminates this Agreement pursuant to Section 8.1(i), then the Company
shall pay to Parent, within ten (10) business days after request by Parent (accompanied by
reasonably detailed documentation to the extent reasonably requested by the Company) from time to
time, up to $250,000 of Parent’s out-of-pocket expenses and fees actually incurred in connection
with this Agreement and the transactions contemplated hereby (including, without limitation, all
reasonable fees and expenses of counsel, financial advisors, accountants, experts and consultants).

          (b) Notwithstanding anything to the contrary in Section 8.2, if the Company terminates this
Agreement pursuant to Section 8.1(i), then the Company shall pay to Parent concurrent with, and as
a condition to the effectiveness of, such termination (in addition to any expenses payable pursuant
to Section 8.3(a)) a fee in an amount equal to $5,000,000.

ARTICLE 9

INDEMNIFICATION AND SET-OFF RIGHTS

     9.1 Indemnification by Parent and the Surviving Corporation. Subject to the
limitations set forth in Section 9.5 hereof, from and after the Effective Time, Parent and the
Surviving Corporation, jointly and severally, will indemnify, defend and hold harmless each of the
Company Stockholders, the Participating Rights Holders and each of their respective directors,
officers, employees, representatives and other Affiliates, from and against any and all Damages
related to or arising out of or in connection with any breach by Parent or Merger Sub of any
representation, warranty, covenant, agreement, obligation, or undertaking made by Parent or Merger
Sub in this Agreement (including any schedule or exhibit hereto), or any other agreement,
instrument, certificate or other document delivered by or on behalf of Parent or Merger Sub in
connection with this Agreement, the Merger or any of the other transactions contemplated hereby.

     9.2 Indemnification by the Participating Rights Holders; Parent Set-Off Rights.
Subject to the limitations set forth in Sections 9.4 and 9.5 hereof, by virtue of the approval of
the execution and delivery by the Company of this Agreement, from and after the Effective Time,
each of the Company Stockholders and the other Participating Rights Holders (regardless of whether
or not such Participating Rights Holder has actually voted his, her or its Securities in favor of
the execution and delivery by the Company of this Agreement) shall be deemed to have agreed that
Parent, the Surviving Corporation, and each of their respective directors, officers, employees,
representatives and other Affiliates, shall be indemnified, defended and held harmless by the
Company Stockholders and the other Participating Rights Holders from and against, and Parent shall
otherwise be entitled to recover amounts held under the Escrow Agreement and to reduce Contingent
Payments in accordance with Section 1.9(h) in connection with, any and all Damages related to or
arising out of or in connection with:

          (a) any breach by the Company or any Company Stockholder of any representation, warranty,
covenant, agreement, obligation or undertaking made by such party in or pursuant to this Agreement,
or any other agreement, instrument, certificate or other document delivered by or on behalf of the
Company or any Participating Rights Holder in connection with this Agreement, the Merger or any of
the other transactions contemplated hereby, including but not limited to the Related Agreements and
the Capitalization and Fee Certificate;

          (b) any obligation or liability of the Company to any employee, former employee or beneficiary
of any Employee Benefit Plan, including those arising in connection with or by virtue of the

-49-

 

employment up to and including the Closing Date or termination of employment of any such
employee or former employee by the Company prior to the Closing Date (collectively, “Benefit
Claims”);

          (c) any actual or alleged liability of the Company, the Surviving Corporation or any of its
Affiliates for death or injury to person or property as a result of any actual or alleged defect in
any product manufactured or sold by the Company or any of its Affiliates at or prior to the
Effective Time, or any actual or alleged warranty, recall or similar liability for any product sold
by or for the Company at or prior to the Effective Time, or any statutory liability of the Company,
the Surviving Corporation or any of its Affiliates or any liability of the Company, the Surviving
Corporation or any of its Affiliates assessed with respect to any failure to warn arising out of
products sold at or prior to the Effective Time (collectively, “Product Liability Claims”),
but only to the extent such damages exceed any amounts actually received by the Parent or the
Surviving Corporation under product liability insurance policies with respect to such claims;

          (d) any liability of the Company, the Surviving Corporation or any of its Affiliates under any
Environmental Laws relating to any occurrences at or prior to the Effective Time (collectively,
“Environmental Claims”);

          (e) any of the matters described in Section 3.8 of the Company Disclosure Schedule or any
Updated Company Disclosure Schedule (the “Known Claims”);

          (f) any payments made by Parent, the Merger Sub or the Surviving Corporation after the
Effective Time with respect to any Dissenting Shares to the extent that such payments exceed the
portion of the Closing Payment to which the holders of such Dissenting Shares would have been
entitled had such Dissenting Shares not been Dissenting Shares, with any claims made pursuant to
this Section 9.2(f) being referred to hereafter sometimes as the “Appraisal Claims”;

          (g) any costs and expenses incurred after delivery of a Merger Election Notice by the Company
or the Surviving Corporation in connection with the preparation, negotiation, execution and
delivery of this Agreement and the Related Agreements, and the consummation of the transactions
contemplated hereby and thereby (including any fees and expenses of legal counsel, financial
advisors and consultants) and the Merger by the Company or the Participating Rights Holders
(collectively, “Transaction Cost Claims”), but only to the extent that such fees exceed
$100,000 in the aggregate; provided, that such maximum amount shall not be deemed to apply
to any Transaction Expenses that arise out of events occurring after the date hereof that could not
reasonably be anticipated on the date hereof (such as state or federal securities law filings by
Parent, or the filing by a party other than the Company, any shareholder of the Company or any
Affiliate thereof of a claim seeking to enjoin, or otherwise challenging, the closing of such
transactions);

          (h) any claim, allegation or assertion that the development, manufacture, marketing,
distribution or sale of the Contingent Payment Products by Parent or the Surviving Corporation
infringes or violates any Intellectual Property or other proprietary rights of any third party
(collectively “Intellectual Property Claims”); provided, that this
indemnification obligation shall not apply to the extent that such infringement or violation arises
by virtue of modifications or improvements made to such Contingent Payment Products by Parent, the
Surviving Corporation or any Affiliate thereof after the Effective Time, other than any such
modifications or improvements that were specifically contemplated to be made by the Company prior
to the Effective Time, to the extent that such products, absent such modifications or improvements,
would not so infringe or violate.

          (i) (i) any breach of any representation or warranty in Section 3.23 of this Agreement or in
Section 4.23 of the Securities Purchase Agreement (provided, that for this purpose there
shall not be taken into account (x) any entries in Sections 3.23 and 3.10 of the Company Disclosure
Schedule and (y) any entries in any Updated Company Disclosure Schedule that differ from the
Company Disclosure Schedule and that relate to Section 3.23 of this Agreement or Section 4.23 of
the Securities

-50-

 

Purchase Agreement or any covenant in Sections 5.1(r), or 5.4 of this Agreement or in Sections
2.1(b), 3.7, 6.1(r), or 6.4 of the Securities Purchase Agreement, and (ii) to the extent not
duplicative of clause (i), any actual or asserted liability for Taxes of or owed by the Company or
any Subsidiary of the Company in respect of any full or partial Tax period ending on or prior to
the Closing Date (claims for indemnification under this Section 9.2(i) are referred to herein as
“Tax Claims”); provided, that for purposes of applying this Section 9.2(i), Parent
and the Company shall use appropriate methods to allocate liability in respect of any Taxes of the
Company or any Subsidiary of the Company attributable to any Tax period that includes but ends
after the Closing Date (each, a “Straddle Period”), which appropriate methods shall include
the following:

               (A) for any income Taxes or any transactional Taxes, including Taxes based on sales or
revenue, the allocation of Taxes to pre- and post-Closing portions of a Straddle Period shall be
determined using a closing-of-the-books method assuming that the applicable Straddle Period
consists of two Taxable periods, one ending at the close of the Closing Date and one beginning at
the opening of the day after the Closing Date, and

               (B) for any Taxes based on net worth, capital, intangibles, or similar items, and for any real
estate Taxes or other property or tangible asset-based Taxes, the allocation of Taxes to pre- and
post-Closing portions of a Straddle Period shall be determined on a per-diem basis taking into
account the number of days in the Straddle Period through and including the Closing Date and the
number of days in the entire Straddle Period;

          Notwithstanding anything in this Agreement to the contrary, the Stockholder Representative
Committee shall, following its delivery to Parent of an irrevocable written undertaking to pay or
cause the Company Stockholders and Participating Rights Holders to pay, on a joint and several
basis, any resulting Tax liability, have the right (but not obligation) to control, at the sole
cost and expense of the Company Stockholders and Participating Rights Holders, any audit or
determination proceeding by or with any Taxing authority to the extent (and only to the extent) it
relates to a Tax that is subject to indemnity under Section 9.2(i), and to contest, defend against,
resolve and settle any assessment, notice of deficiency or other adjustment or proposes adjustment
of such Taxes; provided, that the Stockholder Representative Committee will not settle or
compromise any claim which gives rise to additional Taxes not subject to the indemnification
obligation under Section 9.2(i) and such written undertaking without the prior written consent of
Parent; provided, further, that Parent shall have the right, but not the
obligation, to participate at its cost and expense in any such audit, determination, or other
proceeding controlled by the Stockholder Representative Committee; and, provided,
further, that, in the event that at any time Parent reasonably determines that the amount
of the contested Tax liability, taken together with all other pending claims for indemnification
under Section 9.2 and prior indemnity payments made under Section 9.2, exceeds the amount of
Escrowed Funds, Parent shall have the right (but not the obligation) to assume control of the
proceeding (and to contest, defend against, resolve, and settle the same) unless the Stockholder
Representative Committee, on behalf of the Company Stockholders and Participating Rights Holders,
(x) delivers an irrevocable written undertaking to indemnify Parent, the Surviving Corporation and
their Affiliates against the entire amount of the contested Tax liability (without regard to the
limitations on liability contained in Section 9.5(b)) and (y) causes such amount to be deposited
into escrow until the applicable proceeding is resolved. The Stockholder Representative Committee
and Parent shall have the right to receive in a timely manner copies of all non-privileged
correspondence, records and relevant documentation and to be timely informed of and to attend all
meetings with Tax authorities relating to any claimed Tax for which an indemnification obligation
could arise under Section 9.2(i).

          (j) any claims made by any Company Stockholder based upon any alleged breach of fiduciary or
other duty by any officer, director or stockholder of the Company in connection with this Agreement
or the transactions contemplated hereby, or any claims by any officer, director or Company

-51-

 

Stockholder to indemnification by the Company or the Surviving Corporation with respect to any
such claims (collectively, “Fiduciary Duty Claims”);

          (k) any claims made by any Participating Rights Holder with respect to any payments made by
Parent to the Stockholder Representative Committee under Section 2.5(e) hereof (the
“Stockholder Representative Claims”); or

          (l) any amounts required to discharge any Stockholder Debt or Merger-Triggered Fees in excess
of the respective amounts therefore set forth on the Capitalization and Fee Certificate

Without limiting the foregoing, in addition to the indemnification obligations of the Participating
Rights Holders set forth herein, Parent’s ability to recover for any Damages under this Section 9.2
shall represent an express contract right to seek recovery under the Escrow Agreement in accordance
with the terms thereof, and to reduce the amount of any Contingent Payment in accordance with
Section 1.9(h), and nothing in this Article 9 shall be deemed to require Parent to obtain
jurisdiction over any Participating Rights Holder, or pursue any process in connection therewith
beyond that expressly required by the terms of the Escrow Agreement or Section 9.3 below. Parent’s
various rights of recovery under this Section 9.2 and Section 1.9(h) are severable and distinct,
provided, that in no event shall Parent be entitled to recover the same Damages more than
once under such sections.

     9.3 Third-Party Claims.

          (a) In the event that any Indemnified Party desires to make a claim against an Indemnifying
Party (which term shall be deemed to include all Indemnifying Parties if more than one) in
connection with any third-party litigation, arbitration, action, suit, proceeding, claim or demand
at any time instituted against or made upon it for which it may seek indemnification hereunder (a
“Third-Party Claim”), the Indemnified Party will promptly notify the Indemnifying Party
(or, if the Indemnifying Party is the Company, the Company Stockholders or the Participating Rights
Holders, the Stockholder Representative Committee), of such Third-Party Claim and of its claims of
indemnification with respect thereto; provided, that failure to promptly give such notice
will not relieve the Indemnifying Party of its indemnification obligations under this Section 9.3,
except to the extent, if any, that the Indemnifying Party has actually been prejudiced thereby.

          (b) The Indemnifying Party will have the right to assume the defense of the Third-Party Claim
with counsel of its choice reasonably satisfactory to the Indemnified Party by written notice to
the Indemnified Party within twenty (20) days after the Indemnifying Party has received notice of
the Third-Party Claim; provided, however, that the Indemnifying Party must conduct
the defense of the Third-Party Claim actively and diligently thereafter in order to preserve its
rights in this regard; and provided, further, that the Indemnified Party may retain
separate co-counsel at its sole cost and expense and participate in the defense of the Third-Party
Claim.

          (c) The Indemnifying Party will not consent to the entry of any judgment or enter into any
settlement with respect to the Third-Party Claim without the prior written consent of the
Indemnified Party (which consent will not be unreasonably withheld or delayed) unless the judgment
or proposed settlement (i) includes an unconditional release of all liability of each Indemnified
Party with respect to such Third-Party Claim, and (ii) involves only the payment of money damages
that are fully covered by the Indemnifying Party (which amounts shall be paid solely pursuant to
Section 9.4 by distribution of amounts to Parent from escrow and/or by set-off from unpaid
Contingent Payments to be made by Parent, to the extent that the amount of such payment is then
determinable as a result of Worldwide Net Sales that have already been made) and does not impose an
injunction or other equitable relief upon the Indemnified Party. So long as the Indemnifying Party
has assumed and is conducting the

-52-

 

defense of the Third-Party Claim in accordance with Section 9.3(b) above, the Indemnified
Party will not consent to the entry of any judgment or enter into any settlement with respect to
the Third-Party Claim without the prior written consent of the Indemnifying Party (which consent
will not be unreasonably conditioned, withheld or delayed by the Indemnifying Party).

          (d) In the event that the Indemnifying Party fails to assume the defense of the Third-Party
Claim in accordance with Section 9.3(b) above, (i) the Indemnified Party may defend against, and
consent to the entry of any judgment or enter in to any settlement with respect to, the Third-Party
Claim in any manner it reasonably may deem appropriate (and the Indemnified Party need not consult
with, or obtain any consent from, the Indemnifying Party in connection therewith), and (ii) the
Indemnifying Party will remain responsible for any Damages the Indemnified Party may suffer as a
result of such Third-Party Claim to the extent, and subject to, the terms and conditions for
indemnification under this Article 9.

          (e) Notwithstanding the foregoing, Parent and the Surviving Corporation shall be responsible
for the prosecution and defense of all Product Liability Claims and any claims relating to the
Intellectual Property of the Company, including any Intellectual Property Claims (collectively, the
“Parent-Handled Claims”). Parent and the Surviving Corporation shall pursue in good faith,
through counsel of their selection, the prosecution or defense of all Parent-Handled Claims until
such time, if any, that Parent shall elect not to pursue indemnification with respect to such
Third-Party Claim. Except to the extent that any such disclosure could cause a waiver of
applicable attorney-client privilege, the Stockholder Representative Committee shall have the right
to monitor the progress of Parent-Handled Claims, to review on a timely basis all pleadings and
other filings related thereto and to discuss with counsel to Parent and the Surviving Corporation
such matters relating to Parent-Handled Claims as may be reasonably appropriate.

          (f) Parent shall, to the extent that Parent and the Surviving Corporation are entitled to
indemnification for Damages pursuant to this Article 9 and it could reasonably be expected
that Parent may recover a substantial portion of the Damages relating to such Parent-Handled Claim
pursuant to this Article 9, (i) provide the Stockholder Representative Committee with
access to appropriate employees of Parent and the Surviving Corporation for the purpose of
discussing matters relating to Parent-Handled Claims as the Stockholder Representative Committee
may from time to time reasonably request, and (ii) permit the Stockholder Representative Committee,
upon its reasonable request, to participate in the process of any settlement or other resolution of
any Parent-Handled Claims pursuant to this Article 9; provided, that Parent shall
be entitled to settle, control, compromise or otherwise dispose of Parent-Handled Claims in its
sole discretion and without obtaining the consent of the Stockholder Representative Committee.

     9.4 Payment of Claims. In the event of any bona fide claim for indemnification
hereunder, the Indemnified Party will advise the Indemnifying Party that is required to provide
indemnification therefor in writing with reasonable specificity of the amount and circumstances
surrounding such claim (the “Indemnification Notice”). With respect to liquidated claims for
Damages, if within thirty (30) days following the Indemnifying Party’s receipt of the
Indemnification Notice, the Indemnifying Party has not contested such claim in writing, the
Indemnifying Party will pay the full amount thereof, subject to the limitations set forth in
Section 9.5 and except as set forth in the following sentence of this Section 9.4, within ten (10)
days after the expiration of such period. In order to satisfy any indemnification obligations of
the Company, the Company Stockholders and the Participating Rights Holders pursuant to this Article
9, Parent and the Surviving Corporation (and each of their respective directors, officers,
employees, representatives and other Affiliates) shall have the right to recover Damages that have
been incurred or may be incurred solely from the Escrowed Funds or as a set-off against any
Contingent Payments otherwise due, which shall be paid first from the Escrowed Funds to the extent
available and then by setting off any remaining such amounts against any Contingent Payments
otherwise due to the Participating Rights Holders pursuant to this Agreement or any indemnity
payments owed by Parent and the Surviving Corporation pursuant to Section 9.1; provided,
that the right of set-off against any

-53-

 

Contingent Payments with respect to any Parent-Handled Claims shall be limited to fifty
percent (50%) of any such Contingent Payment. All such recoveries from Escrowed Funds and offsets
against Contingent Payments or indemnification payments shall be made on a pro rata basis from all
Participating Rights Holders in the same proportions in which they would otherwise be entitled to
receive such Escrowed Funds, Contingent Payments or indemnification payments. Any indemnification
obligations of Parent or Merger Sub pursuant to this Article 9 shall be satisfied, at Parent’s
election (a) in cash, (b) by issuing shares of Parent Common Stock (each share of which shall be
valued for such purpose at the Reference Market Value of Parent Common Stock as of the date of such
issuance), subject to the conditions set forth in Section 1.8(b) above, (c) by setting off against
(i.e. reducing) any indemnification payments Parent is required to make pursuant to Section 9.1 or
(d) through a combination of the methods specified in clauses (a), (b) and (c). The parties agree
that to the greatest extent possible the payment of any indemnity hereunder shall be treated as an
adjustment to the Merger Consideration paid by Parent hereunder for Tax purposes.

     9.5 Limitations of Liability.

          (a) Thresholds. No Indemnifying Party will be required to indemnify an Indemnified
Party hereunder for Damages until such time as the aggregate amount of Damages for which (i)
Parent, the Surviving Corporation, and their respective directors, officers, employees,
representatives, and other Affiliates, on the one hand, or (ii) the Company, the Company
Stockholders, the Participating Rights Holders and their respective directors, officers, employees,
representatives, and other Affiliates, as the case may be, on the other hand, are otherwise
entitled to indemnification pursuant to this Agreement exceeds $250,000 (the “Indemnification
Basket”), at which time the Indemnifying Party shall be obligated to indemnify the Indemnified
Party for the full amount of such Damages (including the amount of the Indemnification Basket) and
subject to limitations of this Article 9. Notwithstanding anything to the contrary in this Section
9.5, the threshold limits imposed by this Section 9.5(a) shall not apply to any Damages arising out
of or in connection with (A) any breach by the Company or any Participating Rights Holders of any
Special Representations, (B) any Special Claims, (C) any Stockholder Representative Claims or (D)
any intentional or willful breaches of this Agreement, or fraud or similar circumstances.

          (b) Maximum Liability. The parties specifically agree that, notwithstanding any
provision of this Agreement to the contrary, the sole source of recovery for any Damages by Parent,
the Surviving Corporation and any of their respective Affiliates shall be out of the Escrowed Funds
and, subject to the limitations set forth herein, as a set-off against any Contingent Payments and
that the maximum aggregate liability of all of the Participating Rights Holders, on the one hand,
and Parent and the Surviving Corporation, on the other hand, for indemnification under this Article
9, except as to any person in the case of intentional or willful breach of this Agreement or fraud
by such person, will not exceed a maximum amount equal to (x) the aggregate amount of the Closing
Payment originally deposited into escrow pursuant to the Escrow Agreement, plus (y) the
amount set-off in accordance with this Agreement against any Contingent Payments calculated in
accordance with Section 1.9, as such maximum amount may increase from time to time in accordance
with this paragraph (b) as such Contingent Payments become due and such set-offs are made;
provided, that, notwithstanding anything to the contrary in this Agreement, the Parent’s
right to recover Damages from set-off from any Contingent Payment with respect to any
Parent-Handled Claims shall not exceed an amount equal to fifty percent (50%) of the amount of such
Contingent Payment calculated in accordance with Section 1.9. Notwithstanding anything to the
contrary herein and for purposes of clarification, except in the case of intentional or willful
breach of this Agreement or fraud by the Company or a Participating Rights Holder, once any amounts
held pursuant to the Escrow Agreement are released to the Participating Rights Holders or a
Contingent Payment has been paid to the Participating Rights Holders, Parent, the Surviving
Corporation and any Affiliate thereof shall have no further claim to such funds or stock, as the
case may be, from the Participating Rights Holders and Company Stockholders.

-54-

 

          (c) Time Limit. All representations and warranties in this Agreement shall survive
the Closing and shall expire on, and no Indemnifying Party will be liable for any Damages hereunder
with respect to a breach of such representations and warranties unless a written claim for
indemnification is given by the Indemnified Party to the Indemnifying Party with respect thereto
prior to, the eighteen (18)-month anniversary of the Effective Time; provided, that the
representations or warranties in Section 3.23 of this Agreement shall survive, and Tax Claims may
be made, until sixty (60) days after the expiration of the applicable statutes of limitations, and
provided, further, that the Special Representations shall survive, and written
claims for indemnification based on such representations may be made, until the date on which the
final Contingent Payment is made.

     9.6 Right to Bring Action; No Contribution. Notwithstanding anything in this Article
9 or elsewhere in this Agreement to the contrary, only the Stockholder Representative Committee
shall have the right, power and authority to commence any action, suit or proceeding, including any
arbitration proceeding, by and on behalf of any or all Participating Rights Holders against Parent
or the Surviving Corporation, or any other Indemnified Party, and in no event shall any
Participating Rights Holder himself, herself or itself have the right to commence any action, suit
or proceeding, including any arbitration proceeding, against Parent or the Surviving Corporation,
or any other Indemnified Party. Each Participating Rights Holder waives, and acknowledges and
agrees that he shall not have and shall not exercise or assert (or attempt to exercise or assert),
any right of contribution, right of indemnity or other right or remedy against Surviving
Corporation in connection with any indemnification obligation or any other liability to which he
may become subject under or in connection with this Agreement.

ARTICLE 10

GENERAL PROVISIONS

     10.1 Notices. All notices, claims and demands hereunder, and all other communications
which are required to be given in writing pursuant to this Agreement, shall be in writing and shall
be given (and shall be deemed to have been duly given upon receipt) by delivery in person or
facsimile (received at the facsimile machine to which it is transmitted prior to 5 p.m., local
time, on a business day for the party to which it is sent, or if received after 5 p.m., local time,
as of the next business day) or by registered or certified mail (postage prepaid, return receipt
requested) to the respective parties at the following addresses (or at such other address for a
party as shall be specified in a notice given in accordance with this Section 10.1):

if to Parent or Merger Sub:

Boston Scientific Corporation

One Boston Scientific Place

Natick, Massachusetts 01760

Attention: Chief Financial Officer

Facsimile: 508-650-8956

with a copy to:

Boston Scientific Corporation

One Boston Scientific Place

Natick, Massachusetts 01760

-55-

 

Attention: Assistant General Counsel

Facsimile: 508-650-8956

if to the Company:

REVA Medical, Inc.

5751 Copley Drive, Suite B

San Diego, CA 92111

Attention: President

Telephone: (858) 430-0720

Facsimile: (858) 430-0729

with a copy to:

Heller Ehrman White & McAuliffe LLP

4350 La Jolla Village Drive, 7th Floor

San Diego, CA 92122

Attention: Michael S. Kagnoff, Esq.

Telephone: (858) 450-8400

Facsimile: (825) 450-8499

and if to the Stockholder Representative Committee:

Robert Stockman

Group Outcome

181 Cherry Valley Road

Princeton, NJ 08540

Facsimile: (609) 683-7524

and:

Brian Dovey

Domain Associates L.L.C.

One Palmer Square, Suite 515

Princeton, NJ 08542

-56-

 

Facsimile: (609) 683-4581

and:

Gordon Nye

Prism Venture Partners

100 Lowder Brook Drive

Suite 2500

Westwood, MA 02090

Facsimile: (781) 302-4040

with a copy to:

Heller Ehrman White & McAuliffe LLP

4350 La Jolla Village Drive, 7th Floor

San Diego, CA 92122

Attention: Michael S. Kagnoff, Esq.

Telephone: (858) 450-8400

Facsimile: (825) 450-8499

     10.2 Certain Definitions. For purposes of this Agreement, the term:

     “Acquisition Proposal” means any bona fide offer or proposal (other than an offer or
proposal by Parent) relating to any Acquisition Transaction.

     “Acquisition Transaction” means (a) any transaction or series of related transactions
other than the transactions contemplated by this Agreement involving the purchase of all or any
significant portion of the capital stock or assets of the Company, (b) any agreement to enter into
a business combination with the Company, (c) any agreement made, other than in the ordinary course
of business, with regard to the Intellectual Property owned or licensed by the Company, and (d) any
other extraordinary business transaction involving the license of all or substantially all of the
Intellectual Property owned or licensed by the Company.

     “Affiliate” shall have the meaning set forth in the Securities Purchase Agreement.

     “Bundled Product” means a Contingent Payment Product and other products that are not
Contingent Payment Products either (a) packaged together for sale or shipment as a single unit or
(b) sold together in a kit.

     “business day” (whether such term is capitalized or not) means any day other than
Saturday, Sunday or a legal holiday that banks located in Boston, Massachusetts are closed for
business.

     “California Law” means the California Corporations Code of the State of California, as
amended.

-57-

 

     “Closing Payment” means the aggregate portion of the Closing Payment Amount allocable
to the Participating Rights Holders pursuant to Section 2.1.

     “Closing Payment Amount” means (a) if the Deposit and the Third Loan have not each
been made by Parent prior to the Effective Time, the amount of (i) $125,000,000 plus (ii)
an amount equal to the lesser of $2,000,000 or the aggregate exercise price of all Company Options
and Company Warrants outstanding and unexercised immediately prior to the Effective Time,
minus (iii) the amount of any Stockholder Debt outstanding immediately prior to the
Effective Time as set forth in the Capitalization and Fee Certificate, and minus (iv) the
amount of any Merger-Triggered Fees as set forth in the Capitalization and Fee Certificate, and (b)
if the Deposit and the Third Loan have each been made by Parent prior to the Effective Time, the
amount of (i) $175,000,000 minus (ii) the amount of the Deposit, minus (iii) the
original principal amount of the Third Loan (disregarding, for this purpose, any repayments or
prepayments of such Third Loan), plus (iv) an amount equal to the lesser of $2,000,000 or
the aggregate exercise price of all Company Options and Company Warrants outstanding and
unexercised immediately prior to the Effective Time, minus (v) the amount of any
Stockholder Debt outstanding immediately prior to the Effective Time as set forth on the
Capitalization and Fee Certificate, and minus (vi) the amount of any Merger-Triggered Fees
set forth on the Capitalization and Fee Certificate; provided, that (x) if the First
Milestone is completed prior to the Closing, then the Closing Payment Amount shall be increased by
an additional $10,000,000, (y) if the Second Milestone is completed prior to the Closing, then the
Closing Payment Amount shall be increased by an additional $10,000,000, such that if both the First
Milestone and the Second Milestone are completed prior to the Closing then the Closing Payment
Amount shall be increased by an aggregate amount of $20,000,000 under the foregoing clause (x) and
this clause (y), and (z) if the Fourth Milestone is completed prior to the Closing, the Closing
Payment Amount shall be increased by an additional $100,000,000, such that if each of the First
Milestone, Second Milestone and Fourth Milestone are completed prior to the Closing, then the
Closing Payment Amount shall be increased by an aggregate amount of $120,000,000 under the
foregoing clauses (x) and (y) and this clause (z).

     “Code” shall have the meaning set forth in the Securities Purchase Agreement.

     “Common Stock” means the Company’s Common Stock, no par value per share.

     “Company Common Stock” means the Common Stock and the Non-Voting Common Stock.

     “Company Incremental Amount” means, with respect to any Contingent Payment Year, the
amount of the excess of the Worldwide Net Sales reported for such Contingent Payment Year
over the greatest amount of Worldwide Net Sales reported for any completed prior Contingent
Payment Year; provided, that if such amount is not greater than zero, then the Company
Incremental Amount shall be deemed to be zero.

     “Company Licensed Intellectual Property” means all Intellectual Property licensed to
the Company or any of its Subsidiaries by any third party, to the extent that such Intellectual
Property is included in Section 3.9(a) of the Updated Company Disclosure Schedule most recently
delivered by the Company to Parent prior to the delivery of the Merger Election Notice by Parent to
the Company (or if none, the Company Disclosure Schedule).

     “Company Owned Intellectual Property” means all Intellectual Property owned by the
Company or any of its Subsidiaries, to the extent that such Intellectual Property is included in
Section 3.9(a) of the Updated Company Disclosure Schedule most recently delivered by the Company to
Parent prior to the delivery of the Merger Election Notice by Parent to the Company (or if none,
the Company Disclosure Schedule).

     “Contingent Payment Amounts” means the Sales Contingent Payment Amounts and the
Milestone Contingent Payment Amounts.

-58-

 

     “Contingent Payment Commencement Date” means, with respect to all Contingent Payment
Products, the first day of the calendar month following the month including the First Commercial
Sale.

     “Contingent Payment Product” means any product developed by the Company prior to the
Effective Time demonstrating a reasonable level of feasibility prior to such time, to the extent
that the manufacture, marketing and sale of such product by Parent or its Affiliates (excluding the
Surviving Corporation) would infringe a valid and enforceable claim of (x) any patent included in
the Company Owned Intellectual Property or Company Licensed Intellectual Property issued at or
prior to the Effective Time, or (y) issued after the Effective Time pursuant to a patent claim
included in any United States patent application included in the Company Owned Intellectual
Property or Company Licensed Intellectual Property which has been filed prior to the Effective
Time; provided, that such product shall be deemed to be a Contingent Payment Product only from and
after the issuance of such patent.

     “Contingent Payment Year” means each successive twelve consecutive calendar month
period beginning with the twelve calendar month period commencing on the Contingent Payment
Commencement Date and ending with the twelve calendar month period including the Contingent Period
Termination Date.

     “Contingent Period Termination Date” means the earliest of (a) the sixth anniversary
of the completion of the Fourth Milestone, (b) the eleventh anniversary of the first commercial
sale of any Contingent Payment Product anywhere in the world and (c) the date on which Parent has
made (or been deemed to have made pursuant to Section 1.7) Contingent Payments based on Contingent
Payment Amounts equal to the Maximum Contingent Amount.

     “Conversion Shares” shall have the meaning set forth in the Securities Purchase
Agreement.

     “Damages” means all damages, losses, costs, and expenses incurred or suffered by a
party with respect to or relating to an event, circumstance or state of facts. Damages shall
specifically include court costs and the reasonable fees and expenses of legal counsel arising out
of or relating to any direct or third-party claims, demands, actions, causes of action, suits,
litigations, arbitrations or liabilities.

     “Degradable Stent Product” means a degradable stent developed by the Company for the
treatment of coronary lesions (a) which is coated with or incorporates paclitaxel, (b) which is six
(6) French guide compatible, (c) which is as flexible as Parent’s most advanced bare metal stent
currently being offered for commercial sale as of the Agreement Date, based on Parent’s internal
standard bench test data, (d) which does not require different procedural techniques or the use of
different accessories than Parent’s most advanced bare metal stent then being offered for
commercial sale and (e) with respect to which the Company prior to the Closing has produced a
functional prototype and data demonstrating a level of feasibility reasonably satisfactory to
Parent.

     “Disqualified Stockholder” means (with respect to any securities of the Company)
Parent, Merger Sub or any Subsidiary of Parent or Merger Sub or any of their respective Affiliates
or any transferees of any such securities of the Company at any time held by any of the foregoing.

     “Dissenting Shares” means shares of Company Common Stock or Company Preferred Stock
that are outstanding immediately prior to the Effective Time of the Merger and which are held by
stockholders who shall have not voted in favor of the Merger or consented thereto in writing and
who shall have exercised dissenters’ rights or rights of appraisal for such shares of Company
Common Stock or Company Preferred Stock in accordance with California Law and who, as of the
Effective Time, have not effectively withdrawn or lost such dissenters’ rights.

     “Environmental Law” means any judgment, decree, order, law license, rule or regulation
pertaining to environmental matters, including those arising under any federal, state or local
statute, regulation, ordinance, order or decree relating to the environment, or any other zoning,
health or safety law or regulation.

-59-

 

     “Environmental Permit” means all material permits, licenses and other authorizations
required under any Environmental Law.

     “ERISA” means the Employee Retirement Income Security Act of 1974, as amended.

     “Escrowed Funds” means the Merger Consideration (whether in cash, shares of Parent
Common Stock, or a combination thereof) delivered to the Escrow Agent pursuant to the provisions of
Section 1.5 hereof to be held and distributed in accordance with the terms of the Escrow Agreement,
less any amounts distributed to the Participating Rights Holders.

     “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder.

     “Expandable Stent Product” means the Company’s balloon expandable nitinol stent (a)
which, for a 6.0 mm nominal stent product size, has a crossing profile that provides for five (5)
French sheath compatibility and (b) with respect to which the Company prior to the Closing has
produced a functional prototype and data demonstrating a level of feasibility reasonably
satisfactory to Parent.

     “FDA” means the United States Food and Drug Administration.

     “FDA Approval” means, with respect to any FDA Submission for a Principal Product,
clearance from the FDA to sell such Principal Product, or, with respect to any 510(k) application,
receipt of a letter from the FDA of substantial equivalence, for the relevant indications without
conditions or with customary conditions that are commercially reasonable.

     “FDA Submission” means a submission to the FDA, with respect to any Principal Product,
of a premarket approval application (PMAA) which, if submitted prior to the Closing Date, the
Company has delivered to Parent for Parent’s review at least thirty (30) calendar days prior to its
submission.

     “Financial Statements” means (a) the consolidated financial statements (including
balance sheet, income statement and statement of cash flows) of the Company as of the end of the
most recently completed fiscal year ending at least 45 days prior to the latest date on which the
representations set forth in Sections 3.5(a), 3.12, 3.13, 3.23, and 3.27 are deemed to be made, and
for the twelve (12)-month period ended on such date, and (b) the consolidated balance sheet and
income statement of the Company as of the end of the most recently completed fiscal quarter ending
at least 30 days prior to the latest date on which the representations set forth in Sections
3.5(a), 3.12, 3.13, 3.23, and 3.27 are deemed to be made, and for the portion of the current fiscal
year ended on the calendar month ending immediately prior to such date, which the Company has made
available to Parent and included in the Company Disclosure Schedule.

     “First Commercial Sale” means the first commercial sale of any Contingent Payment
Product by Parent to an unaffiliated purchaser in the United States following the Effective Time.

     “First Milestone” means the delivery to Parent or Surviving Corporation of a copy of
the FDA Approval for the Company’s embolic material in the United States for the indication of
uterine fibroid embolization, provided that (x) Parent has tested such embolic material in
its bench and animal studies and demonstrated that such material is equal to or superior to
Parent’s Contour SE® embolic material in all material respects, with such testing procedures
completed according to Parent’s protocols and reviewed by the Company, (y) the Company, prior to
the Closing, has produced a functional prototype of such embolic material and data demonstrating a
level of feasibility of the product reasonably satisfactory to Parent, and (z) the manufacture,
marketing and sale of such product by Parent or its Affiliates would infringe a valid and
enforceable claim of (i) any patent included in the Company Owned Intellectual Property or Company
Licensed Intellectual Property issued at or prior to the Effective Time, or (ii) issued after the
Effective Time pursuant to a patent claim included in any United States patent application included
in the Company Owned Intellectual Property or Company Licensed Intellectual Property which has been
filed prior to the Effective Time.

-60-

 

     “First Milestone Amount” means $10,000,000.

     “Fourth Milestone” means the delivery to Parent or Surviving Corporation of FDA
Approval for the Degradable Stent Product in the United States for coronary indications;
provided that the manufacture, marketing and sale of such product by Parent or its
Affiliates (excluding the Surviving Corporation) would infringe a valid and enforceable claim of
enforceable claim of (i) any patent included in the Company Owned Intellectual Property or Company
Licensed Intellectual Property issued at or prior to the Effective Time, or (ii) issued after the
Effective Time pursuant to a patent claim included in any United States patent application included
in the Company Owned Intellectual Property or Company Licensed Intellectual Property which has been
filed prior to the Effective Time.

     “Fourth Milestone Amount” means $100,000,000.

     “fully-diluted basis” means, with respect to the number of shares of Company Common
Stock outstanding as of a particular time, the sum of (a) the aggregate number of shares of Company
Common Stock issued and outstanding at such time, (b) the maximum number of shares of Company
Common Stock issuable at such time upon the exercise of unexercised Company Options, Company
Warrants and other options, warrants or rights to acquire shares of Company Common Stock issued and
outstanding at such time (whether or not fully vested), and upon the conversion of all convertible
notes or other convertible securities outstanding at such time (excluding the Company Preferred
Stock), and (c) the maximum number of shares of Company Common Stock issuable at such time upon the
conversion of the Company Preferred Stock, including any shares of Company Preferred Stock issuable
upon exercise of the options, warrants and other rights described in (b) above.

     “Fully-Diluted Common Stock Number” means the number of shares of Company Common Stock
outstanding on a fully-diluted basis immediately prior to the Effective Time (including Dissenting
Shares, but excluding shares of Company Common Stock and Company Preferred Stock held by the
Company, any Subsidiary of the Company, or any Disqualified Stockholder, other than any shares of
Company Common Stock issued or issuable upon conversion of any shares of Series G-2 Preferred Stock
held by any such entities, which shares shall be included in the Fully-Diluted Common Stock
Number).

     “GAAP” means generally accepted accounting principles consistently applied.

     “Governmental Authority” shall have the meaning set forth in the Securities Purchase
Agreement.

     “Hazardous Substance” means (a) those substances defined in or regulated under the
following federal statutes and their state counterparts and all regulations thereunder: the
Hazardous Materials Transportation Act, the Resource Conservation and Recovery Act, the
Comprehensive Environmental Response, Compensation and Liability Act, the Clean Water Act, the Safe
Drinking Water Act, the Atomic Energy Act, the Federal Insecticide, Fungicide, and Rodenticide Act
and the Clean Air Act; (b) petroleum and petroleum products, including crude oil and any fractions
thereof; (c) natural gas, synthetic gas, and any mixtures thereof; (d) polychlorinated biphenyls,
asbestos and radon; (e) any other contaminant; and (f) any substance, material or waste regulated
by any federal, state, local or foreign Governmental Authority pursuant to any Environmental Laws.

     “Indebtedness” means, as applied to any person, (a) all indebtedness for borrowed
money, whether current or funded, or secured or unsecured, (b) all indebtedness for the deferred
purchase price of property or services represented by a note or other security, (c) all
indebtedness created or arising under any conditional sale or other title retention agreement with
respect to property acquired (even though the rights and remedies of the seller or lender under
such agreement in the event of default are limited to repossession or sale of such property), (d)
all indebtedness secured by a purchase money mortgage or other lien to secure all or part of the
purchase price of property subject to such mortgage or lien, (e) all obligations under leases which
shall have been or must be, in accordance with GAAP, recorded as capital leases in respect of which
such person is liable as lessee, (f) any liability in respect of banker’s acceptances or letters of
credit, and (g) all indebtedness referred to in clauses (a), (b), (c), (d), (e) or (f)

-61-

 

above which is directly or indirectly guaranteed by or which such person has agreed
(contingently or otherwise) to purchase or otherwise acquire or in respect of which it has
otherwise assured a creditor against loss.

     “Indemnified Party” means any person entitled to seek indemnification pursuant to the
provisions of Article 9.

     “Indemnifying Party” means any person against whom indemnification may be sought
pursuant to the provisions of Article 9.

     “Intellectual Property” means intellectual property or proprietary rights of any description
including (a) rights in any patent, patent application (including any provisionals, continuations,
divisions, continuations-in-part, extensions, renewals, reissues, revivals and reexaminations, any
national phase PCT applications, any PCT international applications, and all foreign counterparts),
copyright, industrial design, URL, domain name, trademark, service mark, logo, trade dress or trade
name, (b) related registrations and applications for registration, (c) trade secrets, moral rights
or publicity rights, (d) inventions, discoveries, or improvements, modification, know-how,
technique, methodology, writing, work of authorship, design or data, whether or not patented,
patentable, copyrightable or reduced to practice, including any inventions, discoveries,
improvements, modification, know-how, technique, methodology, writing, work of authorship, design
or data embodied or disclosed in any: (i) computer source codes (human readable format) and object
codes (machine readable format); (ii) specifications; (iii) manufacturing, assembly, test,
installation, service and inspection instructions and procedures; (iv) engineering, programming,
service and maintenance notes and logs; (v) technical, operating and service and maintenance
manuals and data; (vi) hardware reference manuals; and (vii) user documentation, help files or
training materials, and (e) good will related to any of the foregoing.

     “IRS” means the United States Internal Revenue Service.

     “Material Adverse Effect” means with respect to the Company or Parent, as the case may
be, any change or effect that, when taken individually or together with all other adverse changes
or effects, is or is reasonably likely to be materially adverse to the business, results of
operations and financial condition of the Company or Parent, as the case may be, and their
respective Subsidiaries, taken as a whole.

     “Merger Consideration” means the aggregate amount of the Closing Payment and all
Contingent Payments.

     “Merger-Triggered Fees” means any payments that may be required to be made by the
Company or its successors under obligations that are triggered solely as a result of the closing of
the Merger to any third party, including but not limited to any payments required to be made to
Rutgers, The State University of New Jersey under the Rutgers Agreements, as amended from time
after the date hereof (including, without limitation, pursuant to Section 4.5 of the Exclusive
License Agreement, dated as of January 21, 2004, between the Company and Rutgers, The State
University of New Jersey, as amended) and Goldman Sachs.

     “Milestone” means the First Milestone, the Second Milestone and the Fourth Milestone.

     “Milestone Contingent Payment Amounts” means the First Milestone Amount, the Second
Milestone Amount and the Fourth Milestone Amount.

     “Milestone Contingent Payments” means, collectively, the First Milestone Contingent
Payment, the Second Milestone Contingent Payment and the Fourth Milestone Contingent Payment.

     “Non-Voting Common Stock” means the Company’s Non-Voting Common Stock, no par value
per share.

-62-

 

     “Notes” means the convertible promissory notes, if any, executed by the Company and
delivered to Parent in connection with certain loans that may be made by Parent to the Company
pursuant to the Securities Purchase Agreement.

     “Option Expiration Date” shall have the meaning set forth in the Securities Purchase
Agreement.

     “Option Period” shall have the meaning set forth in the Securities Purchase Agreement.

     “Option Period Termination Notice” shall have the meaning set forth in the Securities
Purchase Agreement.

     “Option Price Adjustment Date” shall have the meaning set forth in the Securities
Purchase Agreement.

     “Parent Common Stock” means duly authorized, validly issued, fully paid and
non-assessable shares of the voting common stock, $0.01 par value per share, of Parent.

     “Parent Impairment” means a material impairment of (a) any material rights of Parent
under this Agreement or any of the Related Agreements (including, but not limited to, any action,
event or circumstance that could have the effect of (i) delaying a Merger, (ii) increasing the
Merger Consideration, or (iii) materially increasing the expenses to be incurred by the Company,
Parent or Merger Sub in connection with the consummation of the transactions contemplated by this
Agreement), or (b) the value of the Company to Parent after the Effective Time of the Merger.

     “Participating
Rights Holders” means those persons (other than the holders of
Dissenting Shares, the Company, any Disqualified Stockholder or any Subsidiary of the Company) who,
immediately prior to the Effective Time of the Merger, were holders of shares of Company Common
Stock, Company Preferred Stock, Company Options or Company Warrants and whose interests therein, as
the result of the Merger, are converted into rights to receive a portion of the Closing Payment or
any Contingent Payment.

     “PBGC” means the Pension Benefit Guaranty Corporation.

     “Per Share Common Closing Payment” means the amount equal to the quotient obtained by
dividing (x) the amount of the Closing Payment Amount minus the Preferred Closing Payment
Amount, by (y) the Fully-Diluted Common Stock Number. In no event shall the Per Share Common
Closing Payment be less than zero.

     “Per Share Common Contingent Payment” means, with respect to any Contingent Payment,
the amount equal to the quotient obtained by dividing (x) the applicable Contingent Payment Amount
for such Contingent Payment, by (y) the Fully-Diluted Common Stock Number. In no event shall the
Per Share Common Contingent Payment be less than zero.

     “Per Share Preferred Closing Payment” means, with respect to each share of any series
of Company Preferred Stock (other than any shares of Series G-1 Preferred Stock held by any
Disqualified Stockholder) outstanding immediately prior to the Effective Time, the portion of the
Closing Payment allocable to such share, in preference to any share of Company Common Stock or
other series of Preferred Stock, pursuant to the provisions regarding liquidation preference
contained in the Company’s Restated Articles as in effect immediately prior to the Effective Time.

     “person” means an individual, corporation, partnership, limited partnership, limited liability
company, syndicate, person (including a “person” as defined in Section 13(d)(3) of the Exchange
Act), trust, association or entity or government, political subdivision, agency or instrumentality
of a government.

     “Per Unit Average Selling Price” means, with respect to a Contingent Payment Product,
the amount equal to (x) the total amount of annual Worldwide Net Sales of such Contingent Payment
Product, not including any such Contingent Payment Products that are sold as a Bundled Product,
divided

-63-

 

by (y) the total number of units of such Contingent Payment Products sold during such year, not
including any such Contingent Payment Products that are sold as a Bundled Product.

     “Preferred Closing Payment Amount” means an amount equal to the sum of all Per Share
Preferred Closing Payments for all series of Company Preferred Stock.

     “Principal Business” means the development, manufacturing, marketing and sale of the
Principal Products.

     “Principal Products” means the Degradable Stent Product, the Expandable Stent Product,
and embolic materials.

     “Purchased Shares” shall have the meaning set forth in the Securities Purchase
Agreement.

     “Reference Market Value” means the average closing sale price, as published in the
Eastern Edition of The Wall Street Journal, of a share of Parent Common Stock on the New York Stock
Exchange (or, if shares of Parent Stock are not then listed on the New York Stock Exchange, such
other primary national securities exchange or quotation system on which shares of Parent Common
Stock are listed or traded) for the twenty (20) consecutive trading day period ending three (3)
business days prior to the date on which such Reference Market Value is determined.

     “Related Agreements” means the Securities Purchase Agreement, the Voting Agreement,
the Notes (if issued) and all other agreements entered into in connection therewith.

     “Rutgers Agreements” means that certain Exclusive License Agreement, dated as of
January 21, 2004, between the Company and Rutgers, The State University of New Jersey, as amended
by the Amendment thereto, effective as of October 4, 2004, and that certain Research Agreement,
dated as of July 18, 2002, as amended by Modification No. 2 thereto dated October 12, 2004, between
the Company and Rutgers, The State University of New Jersey.

     “Sales Contingent Payment Amount” means (a) for the first Contingent Payment Year, an
amount equal to one hundred percent (100%) of the total Worldwide Net Sales for the period
beginning on the Closing Date and ending on the last day of such Contingent Payment Year and (b)
for each Contingent Payment Year thereafter until the Contingent Period Termination Date, an amount
equal to one hundred percent (100%) of the Company Incremental Amount for such Contingent Payment
Year; provided, that with respect to the Contingent Payment Year including the Contingent
Period Termination Date, the Sales Contingent Payment Amount for such Contingent Payment Year shall
not include any Worldwide Net Sales reported after the Contingent Period Termination Date.

     “SEC” means the United States Securities and Exchange Commission.

     “Second Milestone” means the delivery to Parent or Surviving Corporation of a copy of
FDA Approval for the Expandable Stent Product in the United States for vascular or biliary
indications; provided, that the manufacture, marketing and sale of such product by Parent
or its Affiliates (excluding the Surviving Corporation) would infringe a valid and enforceable
claim of (i) any patent included in the Company Owned Intellectual Property or Company Licensed
Intellectual Property issued at or prior to the Effective Time, or (ii) issued after the Effective
Time pursuant to a patent claim included in any United States patent application included in the
Company Owned Intellectual Property or Company Licensed Intellectual Property which has been filed
prior to the Effective Time.

     “Second Milestone Amount” means $10,000,000.

     “Securities” means all shares of Company Common Stock and Company Preferred Stock, all
outstanding options, warrants, convertible notes, rights of conversion and other rights to acquire
capital stock of the Company, and all shares issuable upon exercise or conversion of the Company
Preferred Stock, options, warrants, convertible notes, rights of conversion and other rights to
acquire stock of the Company, outstanding from time to time, whether or not then currently vested,
exercisable or convertible.

-64-

 

     “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder.

     “Securityholder” means any holder of Securities.

     “Special Claims” means any Known Claims, Appraisal Claims, Tax Claims, Fiduciary Duty
Claims, Transaction Cost Claims, Intellectual Property Claims and claims relating to a breach of
Special Representations.

     “Special Representations” means any representations or warranties relating to or set
forth in the Capitalization and Fee Certificate or Sections 3.2 and 3.27 of this Agreement.

     “Stockholder Debt” means all Indebtedness of the Company owing to any Company
Stockholders (other than any Disqualified Stockholder) at any time, or representing loans
originally made to the Company by any person who was a Company Stockholder (other than any
Disqualified Stockholder) at the time the loan was made.

     “Stockholder Representative Committee” means the group of individuals appointed to
serve as such under Section 2.5.

     “Subsidiary or Subsidiaries” shall have the meaning set forth in the Securities
Purchase Agreement.

     “Superior Proposal” means an unsolicited, bona fide written offer made by a third
party to consummate any of the following transactions: (a) a merger, consolidation, business
combination, recapitalization, liquidation, dissolution or similar transaction involving the
Company pursuant to which the Company Stockholders immediately preceding such transaction hold less
than fifty percent (50%) of the equity interest in the surviving or resulting entity of such
transaction; (b) a sale or other disposition by the Company of all or substantially all of its
assets, or (c) the acquisition by any person or group (including by way of a tender offer or an
exchange offer or issuance by the Company), directly or indirectly, of beneficial ownership or a
right to acquire beneficial ownership of shares representing in excess of fifty percent (50%) of
the voting power of the then outstanding shares of capital stock of the Company, in each case on
terms that the Company Board determines, in its reasonable judgment (after consultation with a
financial advisor of nationally recognized reputation), to be more favorable to the Company
Stockholders than the terms of the Merger (after taking into account all relevant factors,
including all conditions to the offer, the timing of the transaction contemplated by the offer, the
risk of non-consummation thereof and the need for any required governmental or other consents,
filings or approvals); provided, however, that any such offer shall not be deemed to be a “Superior
Proposal” if any financing required to consummate the transaction contemplated by such offer is not
committed and is not likely in the reasonable judgment of the Company Board to be obtained by such
third party on a timely basis.

     “Tax” or “Taxes” shall have the meaning set forth in the Securities Purchase
Agreement.

     “Taxation Authority” shall have the meaning set forth in the Securities Purchase
Agreement.

     “Tax Return” shall have the meaning set forth in the Securities Purchase Agreement.

     “Third Loan” shall have the meaning set forth in the Securities Purchase Agreement.

     “Third Milestone” means thirty (30) calendar days following the delivery to Parent or
Surviving Corporation of all of the following:

     (a) Evidence that the Company shall have successfully completed a human coronary feasibility
study of the Degradable Stent Product in coronary lesions (the “Degradable Stent Study”).
The Degradable Stent Study shall include at least 50 patients and shall be managed and funded by
the Company. Fifty percent (50%) of the Degradable Stent Products included in the Degradable Stent
Study

-65-

 

shall be coated with paclitaxel and fifty percent (50%) shall not incorporate any compound. The
paclitaxel release rate shall be reasonably approved by Parent.

     (b) All case report forms and data relating to the follow-up of at least six (6) months of
patients enrolled in the Degradable Stent Study. Stent encapsulation shall be confirmed by one
hundred eighty (180) day intravascular ultrasound.

     (c) Evidence that the Company shall have conducted porcine studies of the same Degradable
Stent Products as are included in the Degradable Stent Study, and at least five (5) Degradable
Stent Products in such studies shall each have demonstrated at least 90% loss of mass.

     (d) All case report forms and data for each Degradable Stent Product included in the porcine
studies referred to in paragraph (c) above.

     “Voting Agreement” means that certain Voting Agreement that will be executed and
delivered by the Parent with the Company at the Closing of the Securities Purchase Agreement, a
form of which is attached as Exhibit B thereto.

     “Worldwide Net Sales” means net sales recorded by Parent from the sales of Contingent
Payment Products to unaffiliated third parties, either directly or through one or more Affiliates,
in accordance with GAAP, consistently applied by Parent across all similar product lines, in
connection with the preparation of Parent’s financial statements, as publicly reported.

          (a) The term “Worldwide Net Sales” shall not include revenue received by Parent (or any of its
Affiliates) from transactions with an Affiliate of Parent.

          (b) Whenever any Contingent Payment Product is sold as part of a Bundled Product and all
products in such Bundled Product are sold on a “stand-alone” basis within the particular sales
region of such sale, the “Worldwide Net Sales” for such Contingent Payment Product resulting from
such sale of such Bundled Product shall be the product of (i) the net sales reported by Parent or
its Affiliate, whichever is applicable, for such Bundled Product multiplied by (ii) a
fraction, the numerator of which is the Per Unit Average Selling Price of such Contingent Payment
Product sold within such sales region and the denominator of which is the sum of (x) the numerator
and (y) the aggregate Per Unit Average Selling Prices within such sales region of all other
products included in such Bundled Product.

          (c) Whenever any Contingent Payment Product is sold as part of a Bundled Product, such
Contingent Payment Product is sold on a “stand-alone” basis within the particular sales region of
such sale, and any of the other products included in such Bundled Product are not sold on a
“stand-alone” basis within such sales region, the “Worldwide Net Sales” for such Contingent Payment
Product resulting from such sale of such Bundled Product shall be the product of (i) the net sales
reported by Parent or its Affiliate, whichever is applicable, for such Bundled Product
multiplied by (ii) a fraction, the numerator of which is the Per Unit Average Selling Price
of such Contingent Payment Product sold within such sales region, and the denominator of which is
the sum of (x) the numerator, (y) the aggregate Per Unit Average Selling Prices within such sales
region of all other products included in such Bundled Product that are sold on a “stand-alone”
basis within such sales region, and (z) the fair market prices that Parent would have charged
within such sales region to an unrelated purchaser, on a “stand-alone” basis, for all of the other
products included in such Bundled Product that are not sold on a “stand-alone” basis within such
sales region.

-66-

 

     The following table sets forth certain other defined terms and the Section of the Agreement in
which the meaning of each such term appears:

	 	 	 
	 	 	Section(s)
	“Accountants”
	 	1.9(e)
	“Activities to Date”
	 	3.21(a)
	“Affidavits”
	 	2.2(a)(i)
	“Agreed Contingent Payment Amount”
	 	1.9(d)
	“Agreement”
	 	Preamble
	“Agreement Date”
	 	Preamble
	“Antitrust Filing”
	 	6.2
	“Appraisal Claims”
	 	9.2(f)
	“Appraiser”
	 	1.9(e)
	“Audit Notice”
	 	1.9(b)
	“Benefit Claims”
	 	9.2(b)
	“California Permit”
	 	6.8
	“Capitalization and Fee Certificate”.
	 	7.2(i)
	“Certificates”
	 	2.2(a)(i)
	“Closing”
	 	1.1(c)
	“Closing Date”
	 	1.1(c)
	“Committee Reimbursement Amount”
	 	1.5(c)
	“Company”
	 	Preamble
	“Company Board”
	 	Preamble
	“Company Disclosure Schedule”
	 	1.1(a)
	“Company Licenses”
	 	3.21(a)
	“Company Option”
	 	2.1(c)
	“Company Option Plan”
	 	2.1(c)
	“Company Preferred Stock”
	 	Preamble
	“Company Stockholders”
	 	Preamble
	“Company Securityholders”
	 	1.1(d)
	“Company Warrant”
	 	2.1(d)
	“Contingent Payments”
	 	1.6(a)
	“Contingent Payment Audit”
	 	1.9(b)
	“Contingent Payment Certificate”
	 	1.9(a)
	“Delivered Tax Returns”
	 	3.23(a)
	“Deposit”
	 	1.1(d)
	“Derivative Instruments”
	 	2.2(a)(i)
	“Designated Representative”
	 	2.5(a)

-67-

 

	 	 	 
	 	 	Section(s)
	“Disclosure Schedule Request”
	 	1.1(a)
	“Dispute Notice”
	 	1.9(c)
	“Dispute Period”
	 	1.9(c)
	“Disputed Contingent Payment Amount”.
	 	1.9(d)
	“Effective Time”
	 	1.1(c)
	“Employee Benefit Plan”
	 	3.20(a)
	“Environmental Claims”
	 	9.2(d)
	“Escrow Agent”
	 	1.5(b)
	“Escrow Agreement”
	 	1.5(b)
	“Fiduciary Duty Claims”
	 	9.2(j)
	“First Milestone Contingent Payment”.
	 	1.6(c)
	“Foreign Antitrust Filing”
	 	6.2
	“Fourth Milestone Contingent Payment”
	 	1.6(e)
	“HSR Act”
	 	6.2
	“Indemnification Basket”
	 	9.5(a)
	“Initial Escrow Amount”
	 	1.5(b)
	“Initial Stockholder Approval”
	 	6.6
	“Intellectual Property Claims”
	 	9.2(h)
	“Joint Statement”
	 	6.4
	“Known Claims”
	 	9.2(e)
	“Maximum Contingent Amount”
	 	1.7
	“Meeting Request”
	 	6.3
	“Merger”
	 	Preamble
	“Merger Certificate”
	 	1.1(b)(i)
	“Merger Election Notice”
	 	1.1(b)(i)
	“Merger Sub”
	 	Preamble
	“Option Shares”
	 	2.1(c)
	“Parent”
	 	Preamble
	“Parent-Handled Claims”
	 	9.3(e)
	“Parent Representative”
	 	5.1
	“Permit Application”
	 	6.8
	“Permits”
	 	3.14
	“Product Liability Claims”
	 	9.2(c)

-68-

 

	 	 	 
	 	 	Section(s)
	“Products”
	 	3.21(a)
	“Restated Articles”
	 	Preamble
	“Sales Contingent Payments”
	 	1.6(b)
	“SEC Filings”
	 	4.6
	“Second Milestone Contingent Payment”
	 	1.6(d)
	“Securities Purchase Agreement”
	 	Preamble
	“Series G-1 Preferred Stock”
	 	Preamble
	“SRC Expenses”
	 	2.5(c)
	“Stockholder Representative Claims”
	 	9.2(k)
	“Stockholders Meeting”
	 	6.3
	“Straddle Period”
	 	9.2(i)
	“Surviving Corporation”
	 	Preamble
	“Surviving Corporation Charter”
	 	1.3(a)
	“Tax Claims”
	 	9.2(i)
	“Termination Date”
	 	8.1(b)
	“Third-Party Claim”
	 	9.3(a)
	“Transaction Cost Claims”
	 	9.2(g)
	“Updated Company Disclosure Schedule”
	 	1.1(a)
	“Warrant Shares”
	 	2.1(d)

     10.3 Severability. If any term or other provision of this Agreement is invalid,
illegal or incapable of being enforced by any rule of applicable law, or public policy, all other
conditions and provisions of this Agreement shall nevertheless remain in full force and effect so
long as the economic or legal substance of the Merger is not affected in any manner materially
adverse to any party. Upon such determination that any term or other provision is invalid, illegal
or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties as closely as possible in a mutually
acceptable manner in order that the Merger be consummated as originally contemplated to the fullest
extent possible.

     10.4 Entire Agreement; Assignment. This Agreement, together with the Confidentiality
Agreement and the Related Agreements, constitutes the entire agreement among the parties with
respect to the subject matter hereof and thereof and supersedes all prior agreements and
undertakings, both written and oral, among the parties, or any of them, with respect to the subject
matter hereof and thereof. This Agreement shall not be assigned by operation of law or otherwise,
except that (a) Parent and Merger Sub may assign all or any of their rights and obligations
hereunder to any Affiliate of Parent; provided, that no such assignment to an Affiliate
shall relieve the assigning party of its obligations hereunder, and (b) after the Effective Time,
Parent may assign all of its rights and obligations hereunder to a person that acquires all of the
capital stock, or substantially all of the assets, of the division or business unit of Parent
responsible for the business of the Company; provided, that such person assumes this
Agreement, in writing, and agrees to be bound by and to comply with all of the terms and conditions
hereof.

-69-

 

     10.5 Parties in Interest. This Agreement shall be binding upon and inure solely to
the benefit of each party hereto and nothing in this Agreement, express or implied is intended to
or shall confer upon any other person any right, benefit or remedy of any nature whatsoever under
or by reason of this Agreement.

     10.6 Specific Performance. The parties hereto agree that irreparable damage would
occur in the event that any provision of this Agreement was not performed in accordance with the
terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in
addition to any other remedy at law or equity.

     10.7 Governing Law. This Agreement shall be governed by, and construed in accordance
with the laws of the State of California applicable to contracts executed in and to be performed in
that state.

     10.8 Consent to Jurisdiction.

          (a) EACH OF PARENT, THE COMPANY AND MERGER SUB HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE
JURISDICTION OF THE STATE COURTS OF THE STATE OF NEW YORK AND TO THE JURISDICTION OF THE UNITED
STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK, FOR THE PURPOSE OF ANY ACTION OR
PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND EACH OF PARENT, THE COMPANY AND MERGER
SUB HEREBY IRREVOCABLY AGREES THAT ALL CLAIMS IN RESPECT TO SUCH ACTION OR PROCEEDING MAY BE HEARD
AND DETERMINED EXCLUSIVELY IN ANY NEW YORK STATE OR FEDERAL COURT SITTING IN NEW YORK CITY. EACH
OF PARENT, THE COMPANY AND MERGER SUB AGREES THAT A FINAL JUDGMENT IN ANY ACTION OR, PROCEEDING
SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY
OTHER MANNER PROVIDED BY LAW.

          (b) EACH OF PARENT, THE COMPANY AND MERGER SUB IRREVOCABLY CONSENTS TO THE SERVICE OF THE
SUMMONS AND COMPLAINT AND ANY OTHER PROCESS IN ANY OTHER ACTION OR PROCEEDING RELATING TO THE
TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, ON BEHALF OF ITSELF OR ITS PROPERTY, BY THE PERSONAL
DELIVERY OF COPIES OF SUCH PROCESS TO SUCH PARTY. NOTHING IN THIS SECTION 10.8 SHALL AFFECT THE
RIGHT OF ANY PARTY TO SERVE LEGAL PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.

     10.9 Headings; Interpretation. The descriptive headings contained in this Agreement
are included for convenience of reference only and shall not affect in any way the meaning or
interpretation of this Agreement. Whenever the word “include,” “includes,” or “including” appears
in this Agreement, it shall be deemed in each instance to be followed by the words “without
limitation.”

     10.10 Counterparts. This Agreement may be executed and delivered (including by
facsimile transmission) in one or more counterparts, and by the different parties hereto in
separate counterparts, each of which when executed and delivered shall be deemed to be an original
but all of which taken together shall constitute one and the same agreement.

     10.11 Fees and Expenses. Except as provided in Sections 2.5(e) and 9.2 hereof, all
costs and expenses incurred in connection with this Agreement and the Merger by the Company or the
Participating Rights Holders shall be paid by the Company and the Participating Rights Holders,
respectively. All costs and expenses incurred in connection with this Agreement and the Merger by
Parent or Merger Sub shall be paid by Parent.

     10.12 Amendment. This Agreement may be amended prior to the Effective Time only by an
instrument in writing, duly authorized by the Company Board, and executed by Parent or its
designee, the Merger Sub, the Company and the members of the Stockholder Representative Committee.
This

-70-

 

Agreement may be amended subsequent to the Effective Time only by an instrument in writing
executed by Parent, the Surviving Corporation and the members of the Stockholder Representative
Committee.

     10.13 Waiver. At any time prior to the Effective Time, Parent and the Company may
agree to (a) extend the time for the performance of any obligation or other act of the other
(including, in the case of Parent, the Merger Sub) party hereto, (b) waive any inaccuracy in the
representations and warranties of the other contained herein or in any document delivered pursuant
hereto, and (c) waive compliance by the other, as the case may be, with any agreement or condition
contained herein. Any such extension or waiver shall be valid if set forth in an instrument in
writing signed by the party or parties to be bound thereby.

[The remainder of the page is intentionally left blank.]

-71-

 

     In Witness Whereof, Parent, Merger Sub, the Company and the members of the
Stockholder Representative Committee have duly executed this Agreement and Plan of Merger as an
instrument under seal as of the date first above written.

	 	 	 	 	 
	 	Boston Scientific Corporation

 	 
	 	By:  	/s/ Lawrence C. Best
 	 
	 	 	Name:  	Lawrence C. Best 	 
	 	 	Title:  	Senior Vice President -- Finance & Administration and Chief
Financial Officer 	 
	 
	 	RMI Acquisition Corp.

 	 
	 	By:  	/s/ Lawrence C. Best
 	 
	 	 	Name:  	Lawrence C Best 	 
	 	 	Title:  	President and Chief Financial Officer 	 
	 
	 	` REVA Medical, Inc.

 	 
	 	By:  	/s/ Robert K. Schultz
 	 
	 	 	Name:  	Robert K. Schultz 	 
	 	 	Title:  	President & COO 	 
	 
	 	Stockholder Representative Committee

 	 
	 	/s/ Robert Stockman
 	 
	 	Name: Robert Stockman 	 
	 	 	 
	 	         /s/ Brian Dovey
 	 
	 	Name: Brian Dovey 	 
	 	 	 
	 	         /s/ Gordon Nye
 	 
	 	Name: Gordon Nye 	 
	 	 	 

Signature page to Agreement and Plan of Merger

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]